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ABSTRACT OF DISSERTATION 
 
 
 
 
EVALUATION OF INSULIN-LIKE GROWTH FACTOR-1 AS A THERAPEUTIC 
APPROACH FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY 
 
Traumatic brain injury (TBI) is a prevalent CNS neurodegenerative condition that 
results in lasting neurological dysfunction, including potentially debilitating cognitive 
impairments. Despite the advancements in understanding the complex damage that can 
culminate in cellular dysfunction and loss, no therapeutic treatment has been effective in 
clinical trials, highlighting that new approaches are desperately needed. A therapy that 
limits cell death while simultaneously promoting reparative mechanisms, including post-
traumatic neurogenesis, in the injured brain may have maximum effectiveness in 
improving recovery of function after TBI.  
Insulin-like growth factor-1 (IGF-1) is a potent growth factor that has previously 
been shown to promote recovery of function after TBI, but no studies have evaluated the 
efficacy of IGF-1 to promote cell survival and modulate neurogenesis following brain 
injury. Systemic infusion of IGF-1 resulted in undetectable levels of IGF-1 in the brain, 
but did promote increased cortical activation of Akt, a pro-survival downstream mediator 
of IGF-1 signaling, in mice subjected to controlled cortical impact (CCI), a well-
established model of contusion TBI. However, systemic infusion of IGF-1 did not 
promote recovery of motor function in mice after CCI. A one week central infusion of 
IGF-1 elevated brain levels of IGF-1, increased Akt activation and improved motor and 
cognitive function after CCI. Central infusion of IGF-1 also significantly increased 
immature neuron density at 7 d post-injury for a range of doses and when administered 
with a clinically relevant delayed onset of 6 hr post-injury. To mitigate potential side 
effects of central infusion, an alternative conditional astrocyte-specific IGF-1 
overexpressing mouse model was utilized to evaluate the efficacy of IGF-1 to promote 
post-traumatic neurogenesis. Overexpression of IGF-1 did not protect against acute 
immature neuron loss, but did increase immature neuron density above uninjured levels 
at 10 d post-injury. The increase in immature neuron density appeared to be driven by 
enhanced neuronal differentiation. In wildtype mice, immature neurons exhibited injury-
induced reductions in dendritic arbor complexity following severe CCI, a previously 
unknown pathological phenomenon. Overexpression of IGF-1 in brain-injured mice 
promoted the restoration of dendritic arbor complexity to the dendritic morphology 
observed in uninjured mice. Together, these findings provide strong evidence that 
treatment with IGF-1 promotes the recovery of neurobehavioral function and enhances 
post-traumatic neurogenesis in a mouse model of contusion TBI. 
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Chapter 1: Introduction 
Traumatic Brain Injury Definition and Epidemiology 
Traumatic brain injury (TBI) is defined as an acquired insult following an initial 
external, mechanical trauma that consequently results in damage to the brain (NINDS 
2012). TBI is a leading cause of death and disability in the United States, with an 
estimated 1.7 million cases annually (Summers et al. 2009; Faul M 2010). Stratification 
of reported cases reveals that approximately 250,000 individuals are hospitalized and 
50,000 patients do not survive their TBI each year (Langlois et al. 2006; Corrigan et al. 
2010). Motor vehicle and transportation-related incidences, falls, and violence are the 
leading causes of TBI (Thurman et al. 1999; Langlois et al. 2006). TBI afflicts individuals 
independent of age and gender; however, the highest prevalence is reported in males 
aged 20-30 (Langlois et al. 2006). A recent rise in the incidence of TBIs has also been 
reported in individuals over the age of 65 (Thompson et al. 2006). In the United States, 
the financial burden of TBI, including direct and indirect expenses, in 2000 alone was 
over $76 billion (Finkelstein E 2006; Coronado et al. 2011). 
Considerations for Clinical Classification and Treatment of TBI 
The definition of TBI encompasses an array of pathoanatomical types of injury, 
including contusion, hematoma, sub-arachnoid hemorrhage, and diffuse axonal injury. 
The heterogeneity of TBI is a substantial hurdle for the development of effective 
therapeutic strategies for treatment of TBI. The Glasgow Coma Scale (GCS) and 
neuroimaging, including computed tomography scanning and magnetic resonance 
imaging, of physical damage have been utilized to characterize injury severity, provide 
improved prognosis and define clinical management of TBI (Teasdale and Jennett 1976; 
Marshall et al. 1992; Maas et al. 2005). However, these diagnostic metrics to not provide 
insight into the pathological mechanisms that produce neurological impairments that is 
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necessary for implementation of therapeutic interventions tailored for specific 
pathoanatomical types of TBI (Saatman et al. 2008).  
Despite our increased understanding of TBI and the development of therapeutic 
agents, clinical trials have continued to fail (Maas et al. 2007). Several factors have been 
implicated in contributing to the clinical trial failures, including delayed treatment onset, 
enrollment of patients in clinical trials based on injury severity determined by the GCS, 
and a disconnect between injury heterogeneity and targeted therapeutic intervention 
(Maas et al. 2007; Maas et al. 2008). The staggering number of clinical trial failures 
highlights the need for improved diagnostic tools, such as biomarkers, to improve 
classification parameters in the clinic based on pathoanatomical features and to pair 
treatment strategies tailored to a specific pathoanatomical injury type (Saatman et al. 
2008). In addition, the multitude of pathological processes after TBI may undermine the 
efficacy of therapeutic agents aimed at targeting only a single process of injury. 
However, therapeutic strategies designed to mitigate multiple pathological processes 
may be efficacious for the treatment of TBI (Margulies and Hicks 2009).  
Traumatic Brain Injury Pathology 
 Symptoms of a TBI can manifest as an innocuous headache, mild concussion, 
prolonged coma, or death. Cognitive impairment is the most frequent and debilitating 
functional consequence of TBI (Levin 1998; Lundin et al. 2006). Impairments in both 
motor and cognitive function have been reported for weeks and years after a TBI, with 
approximately 40% of patients developing long-term disabilities after being discharged 
from the hospital (Capruso and Levin 1992; Levin 1998; Lundin et al. 2006; Selassie et 
al. 2008; Jang 2009). Years after sustaining a TBI, patients often report that cognitive 
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impairment contributes greatly to decreased satisfaction with their quality of life (Truelle 
et al. 2010).  
TBI is a complex injury that can be divided into two main sources of damage in 
terms of cellular and histological pathology: 1) initial primary damage that occurs as an 
external mechanical force is transferred to the head and 2) the activation of secondary 
injury cascades (Fig. 1.1). Processes involved in recovery after TBI will be discussed in 
subsequent sections of this chapter.   
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Figure 1.1: Progression of primary and secondary injury mechanisms that can 
occur or become initiated within seconds to days following TBI. Several processes, 
including neurogenesis and hippocampal plasticity, can be targeted by therapeutic 
agents to enhance recovery following TBI.  
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Primary Damage and Types of Injury 
Primary damage occurs as a result of shearing, stretching or compression of 
cells and vasculature with potential concomitant disruption to cellular membrane integrity 
(Maas et al. 1999; Beauchamp et al. 2008). The primary source of injury cannot be 
prevented nor targeted for therapeutic intervention, and subsequently leads to the onset 
of the second source of injury, the activation of secondary injury cascades. 
The types of initial force delivered to the brain can originate from contact with a 
penetrating or nonpenetrating object, rapid acceleration/deceleration, waves of energy 
emanating from a blast, or a combination of these forces (Maas et al. 2008). Focal injury 
is characterized by damage located in a discrete area, while diffuse injury is reflective of 
injury potentially distributed in non-discrete regions throughout the brain (Morales et al. 
2005; Povlishock and Katz 2005; Andriessen et al. 2010). Focal injury is typically 
characterized by the presence of contusions and hematomas while traumatic axonal 
injury and edema are defining hallmarks of diffuse injury (Morales et al. 2005). However, 
this distinction between focal and diffuse injury pathology can become obscured with 
increasing injury severity.   
Secondary Injury 
 Secondary injury is a term used to designate the activation of pathophysiological 
mechanisms following the initial primary damage. The type of brain injury can greatly 
influence the heterogeneity and duration of the secondary injury mechanisms that 
manifest, which synergistically exacerbate injury pathology (McIntosh et al. 1998; Maas 
et al. 1999). Each of the secondary injury mechanisms present and persist with varying 
duration dependent upon injury type and severity. However, secondary injury cascades 
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are the target of therapeutic and surgical intervention (Maas et al. 2005; Beauchamp et 
al. 2008).  
As a consequence of acutely disrupted cellular integrity and loss of ion 
homeostasis, brain injury results in unregulated neurotransmitter release and the 
activation of intracellular proteases, including calpains, within hours of the primary injury 
(Baker et al. 1993; Saatman et al. 1996; Hall et al. 2005). Moreover, high concentrations 
of intracellular calcium and the accumulation of free radicals contribute to mitochondria 
dysfunction (Singh et al. 2006). Structural damage to endothelial tight junctions that 
comprise the blood-brain barrier and the formation of microhemorrhages can both 
contribute to brain edema (Sutton et al. 1993; Baldwin et al. 1996; Maas et al. 1999; 
Greve and Zink 2009). Moreover, damage to the vasculature compromises cerebral 
blood flow resulting in hypoxic-ischemia, impaired delivery of nutrients and, ultimately, 
disrupted metabolic status of cells within the injured tissue (Martin et al. 1997). 
Consequently, the numerous secondary injury mechanisms can overwhelm injured cells 
yielding apoptosis or necrosis depending on the cell type and proximity to the primary 
injury site (Rink et al. 1995; Conti et al. 1998; Fox et al. 1998). Cell loss is progressive as 
dying cells may propagate dysfunction and death of adjacent cells (Conti et al. 1998; 
Pleasant et al. 2011). Secondary axonal degeneration and demyelination can contribute 
to neuronal dysfunction (Meaney et al. 2001; Mac Donald et al. 2007). The 
consequences of the secondary injury mechanisms are not restricted exclusively to 
neurons, but also extend to other cells of the brain. 
Neuronal Support System 
Collectively, the primary damage and various secondary injury cascades disrupt 
neuronal cell function and the neuronal support system, comprised of astrocytes, 
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endothelial cells, microglia and oligodendrocytes, contributing to neuronal cell loss within 
the injured tissue. Glial cells play a critical, but complex role in the response to injury as 
their actions can be both beneficial and detrimental to injured cells. Following TBI, glial 
cells may mitigate or exacerbate the mechanisms of secondary injury depending on the 
proximity to the site of injury and time after injury (Chen and Swanson 2003; Myer et al. 
2006; Sofroniew and Vinters 2010; Graeber and Christie 2012). Each type of glial cell 
including astrocytes, microglia and oligodendrocytes has unique properties that are 
important for normal brain health and responses following injury.  
Resident astrocytes are important in preserving homeostatic conditions in the 
brain through maintenance of fluid and extracellular ion balance, scavenging of free 
radicals, clearance of extracellular glutamate, production of growth factors and 
inflammatory mediators, and supplying nutrients to neighboring cells. Reactive 
astrocytosis is an endogenous response observed in human and experimental TBI, 
characterized by cellular proliferation and hypertrophy, including cytoplasmic 
enlargement, elongation of cellular processes, and increased expression of glial fibrillary 
acidic protein (GFAP) (Baldwin et al. 1996; Ridet et al. 1997; Castejon 1998; Hausmann 
and Betz 2000; Saatman et al. 2006). In the context of CNS trauma, astrocytes can 
contain the products of injury, including cellular debris and cytotoxic cellular contents 
released from dying cells, by formation of a physical barrier referred to as the glial scar 
(Fitch et al. 1999; Myer et al. 2006; Fitch and Silver 2008). Conversely, astrocytes 
produce cytokines that propagate inflammation in the brain and chondroitin sulfate 
proteoglycan, a component of the glial scar, that inhibits regeneration and repair 
mechanisms (Smith et al. 1986; Snow et al. 1990; McKeon et al. 1991; Dong and 
Benveniste 2001).  While astrocytes can be recruited to the site of injury, they are still 
susceptible to mechanisms of injury, including hypoxia and reactive oxygen species that 
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can promote cell death (Giffard et al. 1990; Swanson et al. 1997; Bondarenko and 
Chesler 2001; Zhao et al. 2003). 
Microglial cells, the resident immune cells in the CNS, play a critical role in the 
surveillance of the CNS extracellular environment. Resident microglia or blood-borne 
peripheral macrophages can be recruited to the site of injury after TBI (Holmin et al. 
1995; Soares et al. 1995; Zhang et al. 2006). In the context of injury, microglia can 
become activated to aid in the clearance of cellular debris and the recognition of foreign 
antigens (Giulian et al. 1989; Kreutzberg 1996).  Similar to astrocytes, microglia exhibit a 
dual role after TBI by aiding in the elimination of injury debris, but, conversely, releasing 
cytokines that potentiate the inflammatory response (Morganti-Kossman et al. 1997; 
Morganti-Kossmann et al. 2002; Harting et al. 2008). 
Oligodendrocytes myelinate neurons and facilitate rapid conduction of action 
potentials in the CNS. Diffusion tensor imaging of brain-injured patients revealed 
reduced fractional anisotropy, indicative of white matter track damage, which may be the 
consequence of dysfunction or loss of oligodendrocytes (Levin et al. 2008; Rutgers et al. 
2008). Damage to white matter tracks and loss of oligodendrocytes have been observed 
within days and up to one year following experimental TBI (Pierce et al. 1998; Dixon et 
al. 1999; Bramlett and Dietrich 2002; Lotocki et al. 2011; Flygt et al. 2013). Damage to 
and subsequent loss of oligodendrocytes can impair axonal transmission and propagate 
neuron loss following injury, in part, due to loss of trophic support for ensheathed 
neurons (Povlishock 1992; Conti et al. 1998; Newcomb et al. 1999; Wilkins et al. 2001). 
TBI Models  
Several types of experimental brain injury models have been developed to 
reproduce the continuum of human TBI in order to understand the mechanisms of 
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secondary injury and to develop therapeutic strategies to mitigate the consequences of 
secondary injury cascades. In order to reflect the condition of human TBI, models need 
to collectively reproduce the spectrum of injury severity with fidelity to pathological 
features observed in human TBI. Several of the most frequently utilized and well-
established experimental models of TBI will be discussed. The pathology observed in 
these models can be broken into two general categories that aim to reproduce aspects 
of diffuse or focal injury (Morales et al. 2005; Xiong et al. 2013).  
Diffuse Models 
The fluid percussion injury (FPI) produces an injury by delivering a bolus of fluid 
rapidly onto the dural surface of the brain through a craniotomy in the skull (Dixon et al. 
1987; McIntosh et al. 1989; Hicks et al. 1996; Xiong et al. 2013). Completion of a midline 
craniotomy and fluid pulse over the sagittal suture of the brain (midline FPI) produces 
features of diffuse injury, but increases in the magnitude of injury are associated with the 
manifestation of features of focal injury (Dixon et al. 1987; Hayes et al. 1987; McIntosh 
et al. 1989; Morales et al. 2005). Placement of the craniotomy and fluid pulse over the 
lateral cortex of the brain (lateral FPI) results in a combination of focal contusion injury 
with aspects of diffuse injury spread throughout the contused hemisphere (Cortez et al. 
1989; Hicks et al. 1996). Increases in the injury magnitude for both lateral and midline 
fluid percussion injury are achieved by increasing the fluid pressure pulse introduced 
onto the dural surface of the brain (Dixon et al. 1987). The FPI model is widely used and 
highly characterized for use in rats  (Dixon et al. 1987; McIntosh et al. 1987; Saatman et 
al. 1998), but the model has also been adapted for the utilization of mice (Carbonell et 
al. 1998; Spain et al. 2010).  
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Rodent weight drop models, including the Marmarou, Shohami, and Feeney 
models, produce a brain injury by transferring force generated from a guided weight 
falling at a prescribed height directly onto the intact skull or onto the dura through a 
craniotomy (Feeney et al. 1981; Marmarou et al. 1994; Chen et al. 1996; Xiong et al. 
2013). This model typically results in graded diffuse pathology and development of focal 
injury with increasing heights and weights of the suspended weight (Feeney et al. 1981; 
Tang et al. 1997). 
Focal Models: Controlled Cortical Impact  
The controlled cortical impact (CCI) model is a highly characterized and a widely 
utilized model that produces a predominantly focal injury. Originally developed for use in 
the ferret (Lighthall 1988) and later adapted for rodents (Dixon et al. 1991; Smith et al. 
1995) to reduce the costs associated with therapeutic studies and to facilitate the usage 
of transgenic and knockout animals (Schoch et al. 2012). The model utilizes a computer-
controlled pneumatic cylinder with an affixed impactor tip that transiently impacts the 
brain at a specified velocity and depth (Fig. 1.2) (Lighthall 1988; Dixon et al. 1991). The 
contact force is transferred to the intact dura of the brain by a metal impactor passing 
through a craniotomy in the skull (Dixon et al. 1991). The advantages of the CCI model 
include low mortality rates and control over biomechanical injury parameters including 
the depth of injury, velocity and duration of impact. The CCI model is easily adapted for 
mild, moderate, and severe injuries by changing the depth of impact facilitating graded 
injury responses in altered physiology, histopathology, and behavioral function (Dixon et 
al. 1991; Goodman et al. 1994; Saatman et al. 2006; Mao et al. 2010; Huh et al. 2011). 
Additional parameters of injury, including impactor tip geometry, the velocity of impact, 
and impact dwell time have a profound effect on the developing injury pathology 
(Goodman et al. 1994; Hannay et al. 1999; Mao et al. 2010; Mao et al. 2011; Pleasant et 
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al. 2011). Finite element modeling of CCI parameters suggested that the geometry of the 
impactor tip ranked second to impact depth as an external mechanical parameter 
capable of altering maximal principal strains during a contusion event (Mao et al. 2010). 
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Figure 1.2: Controlled Cortical Impact (CCI) injury in the mouse positioned over 
the somatosensory cortex.  The computer-controlled pneumatic cylinder rapidly 
impacts the intact dura of the brain with a metal impactor tip. The contusion site is 
designated by the red circle.   
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CCI Pathology 
The CCI model produces features of human contusion TBI with a focal injury 
encompassing the spectrum of contusion pathology and regional hematomas (Dixon et 
al. 1991; Xiong et al. 2013). Severe CCI in the rat and mouse produces pervasive 
damage to the white and gray matter, hematoma and cortical cavitation as a result of 
apoptotic and necrotic cell death (Smith et al. 1995; Hall et al. 2005; Saatman et al. 
2006; Pleasant et al. 2011). Concurrent with cortical damage, loss of the subcortical 
white matter at the site of injury occurs within hours and days following injury (Hall et al. 
2005; Saatman et al. 2006; Mac Donald et al. 2007; Pleasant et al. 2011). Compromised 
vascular integrity is evident within minutes and persists for days after injury (Smith et al. 
1995; Baldwin et al. 1996; Baskaya et al. 1997; Saatman et al. 2006; Pleasant et al. 
2011). Consequently, impaired cerebral blood flow can last for hours following contusion 
injury (Bryan et al. 1995; Kochanek et al. 1995). Diffuse axonal injury and axonal 
degeneration are observed within contused tissue and penumbral regions of the cortex 
within hours and days after CCI (Dixon et al. 1991; Hall et al. 2005; Mac Donald et al. 
2007; Pleasant et al. 2011). Regional hippocampal neuron loss occurs in the dentate 
gyrus granular layer and hilus, CA3 and CA1 within hours after injury, the pattern and 
extent of which is highly dependent on injury severity (Anderson et al. 2005; Hall et al. 
2008; Dennis et al. 2009; Pleasant et al. 2011). Neuronal dysfunction and death 
throughout the contused cortex, hippocampus, and penumbral tissue can culminate in 
impaired motor and cognitive function.   
Consistent with the manifestation of neurological impairments in clinical TBI, the 
rodent CCI model of TBI produces impairments in motor and cognitive function (Fox et 
al. 1998; Levin 1998; Saatman et al. 2006). Following CCI, rodents exhibit deficits in 
motor function by 24 hr and can persist for up to two weeks, as evaluated by tasks that 
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require a combination of balance and coordinated movement (Fox et al. 1998; Hannay et 
al. 1999; Nakamura et al. 1999; Whalen et al. 1999; Pleasant et al. 2011). However, rats 
and mice can exhibit spontaneous recovery of motor function over time and, as a result, 
the rate of motor function recovery is utilized to evaluate improvements in motor 
performance (Saatman et al. 2006; Pleasant et al. 2011). 
In addition to motor dysfunction, CCI produces impairments in learning and 
memory after injury. The Morris water maze (MWM) and the novel object recognition 
task (NOR) are two routinely utilized assessments for evaluating cognitive impairment 
after TBI (Smith et al. 1991; Tsenter et al. 2008; Scafidi et al. 2010; Pleasant et al. 2011; 
Prins et al. 2013). MWM is sensitive to graded injury severity with rodents exhibiting 
deficits in spatial memory as early as 2 days post-injury and spatial learning as early as 
7 days following severe CCI (Hamm et al. 1992; Smith et al. 1995; Scheff et al. 1997; 
Fox et al. 1998; Hannay et al. 1999; Saatman et al. 2006). The learning and memory 
deficits observed in rats subjected to CCI persist for weeks to months post-injury (Hamm 
et al. 1992; Dixon et al. 1999). The deficits reported in behavioral tasks evaluating 
cognition after brain injury may reflect hippocampal neuron dysfunction and loss as 
these tasks evaluate aspects of hippocampal-dependent learning and memory (Smith et 
al. 1991; Hamm et al. 1992; Nakamura et al. 1999; Saatman et al. 2006; Pleasant et al. 
2011). The fidelity of CCI to human contusion TBI and the neurobehavioral dysfunction 
that manifests following injury highlights the appropriateness of the CCI model to 
evaluate the efficacy of therapeutic strategies that aim to improve functional recovery 
after TBI.  
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Therapeutic Strategies for TBI  
The research effort in experimental models of TBI has led to a better understanding 
of secondary injury mechanisms and the identification of promising therapeutic targets. 
The complex and diverse nature of the secondary injury mechanisms poses a 
substantial challenge for the treatment of TBI. In the clinical setting, treatment with 
mannitol to reduce brain edema, and surgical decompressive craniectomy to decrease 
intracranial pressure, are two well-established treatment interventions following TBI 
(Muizelaar et al. 1983; Munch et al. 2000). However, these interventions aim to 
attenuate the consequences of secondary injury mechanisms and do not directly target 
the mechanisms of injury.  
Given the failure of clinical trials based on therapeutics targeting a single injury 
mechanism, combinatorial approaches are gaining popularity as a means for targeting 
multiple mechanisms of injury (Margulies and Hicks 2009). While combination therapies 
using two or more drugs have promising potential for treating multiple aspects of brain 
injury, the arduous task of identifying effective combinations and the necessary 
comprehensive pharmacological characterization has tempered initial enthusiasm for 
combination therapy after TBI. Alternatively, individual pleiotropic therapeutic agents that 
target multiple injury mechanisms and promote regenerative processes are promising 
strategies for attenuating the consequences of injury and improving recovery after TBI.  
Recovery and plasticity in the brain after CCI 
 Brain injury initiates numerous pathological responses that perturb cellular 
function and produce damage that can potentiate cell loss and impair brain function. The 
brain possesses several endogenous repair mechanisms, including structural plasticity 
and regeneration, which may help combat damage after injury. However, the magnitude 
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of damage following TBI may overwhelm endogenous systems, and as a result limit the 
ability of the brain to provide meaningful improvement. While CNS glial cells possess the 
ability to proliferate and replenish lost cells, the brain has limited capacity to replenish 
lost neurons. The subgranular zone of the hippocampus and subventricular zone of the 
adult brain participate in ongoing neurogenesis (Zhao et al. 2008), but the extent of new 
neuron generation is incapable of replenishing the number of neurons lost after brain 
injury. Adult neurogenesis and the generation of new neurons in the context of brain 
injury will be discussed in greater detail later in this chapter.  
The developing brain possess several endogenous mechanisms of growth and 
plasticity that aid in the formation of new neurons and new vessels, and structural 
changes, for instance synaptogenesis and neurite outgrowth, that promote the growth 
and development of the brain. Several of the mechanisms that mediate developmental 
growth and plasticity become activated after CCI in the adult hippocampus, including 
angiogenesis, neurogenesis, and synaptogenesis (Scheff et al. 2005; Rola et al. 2006; 
Xiong et al. 2010). However, the re-establishment of these endogenous developmental 
processes is insufficient to promote meaningful recovery, evident by the lasting cognitive 
deficits associated with experimental TBI (Lyeth et al. 1990; Dixon et al. 1991; Hamm et 
al. 1992; Adelson et al. 2000). Therapeutic agents that reduce neurodegeneration and 
acute cell loss as well as promote and enhance endogenous plasticity may prove 
efficacious in mitigating injury-induced damage and promoting recovery after TBI.     
Growth factors are ideal therapeutic candidates to promote acute protective effects 
with concurrent activation of regenerative mechanisms, including neurogenesis, 
angiogenesis, and structural plasticity after TBI. Brain injury stimulates the production of 
many neurotrophic factors including vascular endothelial growth factor (VEGF) 
17 
 
(Chodobski et al. 2003), basic fibroblast growth factor (bFGF) (Logan et al. 1992), brain-
derived growth factor (BDNF) (Truettner et al. 1999), nerve growth factor (NGF) 
(Truettner et al. 1999), (DeKosky et al. 2004) and insulin-like growth factor-1 (IGF-1) 
(Madathil et al. 2010). Several of these studies demonstrate that TBI produces only 
transient increases in growth factor expression and signaling (Truettner et al. 1999; 
Chodobski et al. 2003; Madathil et al. 2010), suggesting that exogenous administration 
of growth factors may be required to promote sustained increases in the levels of growth 
factors after TBI.  
Several studies have demonstrated that therapeutic strategies to boost 
endogenous levels of growth factors, by genetic manipulation or exogenous 
administration, reduce cell loss and attenuate neurobehavioral dysfunction following 
experimental TBI. Reductions in cell loss after experimental TBI have been associated 
with elevations in brain levels of bFGF (Dietrich et al. 1996), NGF (Philips et al. 2001) 
and IGF-1 (Madathil 2013). Moreover, improvements in motor and cognitive function 
after have been reported in studies evaluating the therapeutic efficacy of bFGF 
(McDermott et al. 1997; Sun et al. 2009), NGF (Philips et al. 2001; Mahmood et al. 
2004), VEGF (Thau-Zuchman et al. 2010), BDNF (Mahmood et al. 2004) and IGF-1 
(Saatman et al. 1997; Rubovitch et al. 2010; Madathil 2013) after experimental TBI. The 
improvements in neurobehavioral performance may be the related to improved cell 
survival (Philips et al. 2001; Madathil 2013). Several studies also highlight that improved 
recovery after TBI with supplementation of a growth factor, including bFGF, VEGF, and 
BDNF, may be related to their capability to enhance post-traumatic neurogenesis. Taken 
together, these studies illustrate that growth factors possess protective and regenerative 
properties that may be effective at combating the pathological consequences of TBI. 
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Several properties uniquely inherent to IGF-1 make this growth factor aptly suited for 
treatment after TBI.  
Insulin-like growth factor-1  
Insulin-like growth factor-1 (IGF-1) is a promising therapeutic agent for the 
treatment of TBI as it has been shown to attenuate motor and cognitive dysfunction after 
experimental TBI (Saatman et al. 1997; Rubovitch et al. 2010; Madathil 2013). IGF-1 is a 
potent growth factor that has many important roles in tissues throughout the body. The 
70 amino acid, 7.6 kDa protein is highly conserved between species, including humans 
and rodents, and is closely related in sequence and structure to insulin (Rinderknecht 
and Humbel 1978). IGF-1 is post-translationally processed to produce the mature protein 
comprised of two amino acid chains with 3 disulfide bonds (Narhi et al. 1993). IGF-1 is 
primarily produced in the liver in response to growth hormone binding to its cognate 
receptor. Once released into the blood from the liver, IGF-1 has a circulating half-life of 
10-30 minutes (Guler et al. 1987; Baxter and Martin 1989). IGF-1 elicits effects in 
several target tissues throughout the body. 
Binding of IGF-1 to one of the six high affinity binding proteins (IGFBPs), 
increases the half-life of IGF-1 in systemic circulation by impeding proteolysis and 
decreasing excretion by the kidneys (Duan 2002). All binding proteins possess similar 
structural features and sequence homology; however, decreased homology in cysteine-
free regions highlights the emergence of differential binding affinities and functional roles 
of the individual binding proteins (Clemmons et al. 1993). IGFBP3 in complex with the 
acid-labile subunit is the predominant carrier of IGF-1 in systemic circulation (Guler et al. 
1987). The biological activity and bioavailability of IGF-1 is modulated by the actions of 
the individual binding proteins (Duan 2002).  
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Once present at the target tissue, IGF-1 binds to its cognate receptor, a receptor 
tyrosine kinase (IGFR) (Fig. 1.3). Binding of IGF-1 to the IGFR promotes receptor 
dimerization and autophosphorylation of the intracellular β subunit, and the subsequent 
recruitment of scaffolding and secondary proteins, including, but not limited to, the 
insulin response subunit (IRS) and the growth factor receptor bound protein 2 (Grb2) 
(Laviola et al. 2007; Chitnis et al. 2008). The growth promoting effects of IGF-1 are 
mediated by the activation of PI3K, Akt and ERK/MAPK. Activation of PI3K and Akt in 
vitro leads to increased cell survival, enhanced growth and metabolism, increased 
protein synthesis and the proliferation of new cells (Manning and Cantley 2007). 
Phosphorylation of Akt is a potent anti-apoptotic signal that decreases caspase-9 activity 
and increases Bcl-2 activity within the mitochondria thereby promoting cell survival 
(Manning and Cantley 2007). Similarly, activation of the ERK/MAPK pathway is 
associated with growth and metabolism, cell survival, cellular proliferation, and increased 
gene transcription and translation (Seger and Krebs 1995). Activation of Akt and MAPK 
via IGF-1 also leads to an upregulation in the production and release of IGF-1, which 
can act in an autocrine and paracrine fashion to potentiate IGF-1 signaling in 
neighboring cells (Underwood et al. 1986; Holly and Wass 1989).  
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Figure 1.3: IGF-1 binding to its cognate receptor (IGFR) results in the 
autophosphorylation of the receptor and recruitment of the insulin response 
subunit (IRS) and growth factor receptor bound protein 2 (Grb2). Activation of 
mediators of IGF-1 signaling, including phosphatidylinositol 3-kinase (PI3K) and Ras 
GTPases (Ras) lead to the subsequent activation of Akt and MAPK. Yellow indicates the 
protein is activated by phosphorylation while blue indicates that protein activity is 
regulated by hydrolysis of GTP. 
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 IGF-1 signaling is critical for embryonic and postnatal development. Genetic 
manipulation to reduce the biological activity of IGF-1, including IGF-1 binding protein-1 
overexpression or mutations and homozygous knockout of either IGF-1 or the IGF-1 
receptor during embryonic development, is associated with reduced postnatal viability 
and retardation of brain growth (Baker et al. 1993; Ludwig et al. 1996). Conversely, 
developmental overexpression of IGF-1 does not alter viability, but does increase body 
weight and postnatal brain growth (Carson et al. 1993; Ye et al. 1995; Ye et al. 1995). 
Together, these studies highlight that IGF-1 axis is important for systemic and brain 
growth and development. 
IGF-1 in the Brain 
In addition to important systemic actions, IGF-1 is also critical for normal brain 
development and function throughout life. IGF-1 is mainly expressed in neurons 
throughout the brain (Bondy et al. 1992; Bondy and Lee 1993; D'Ercole et al. 1996), but 
increased astrocytic expression of IGF-1 has been reported after injury to the brain 
(Gluckman et al. 1992; Komoly et al. 1992; Lee et al. 1992; Gehrmann et al. 1994). 
Although IGF-1 may be expressed within a single neuron or astrocyte, autocrine and 
paracrine actions of IGF-1 can promote IGF-1 signaling in neighboring cells. In situ 
hybridization demonstrates that IGF-1 mRNA is present in cells throughout the 
developing brain with high levels of expression in the hippocampus and granular layer of 
the dentate gyrus during postnatal development (Bondy et al. 1992; Bondy and Lee 
1993). While the levels of IGF-1 expression are reduced after development, continued 
postnatal expression has been reported in the cortex, striatum, olfactory bulb, 
cerebellum and hippocampus of the adult brain (Bondy et al. 1992; Bondy and Lee 
1993). 
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IGF-1 receptor (IGF-1R) mRNA is abundantly expressed in the developing neural 
tube with continued widespread postnatal expression in the mature brain, with 
heightened expression in neuron dense regions, such as the granular layer of the 
dentate gyrus, the olfactory bulb and the cerebellar granular layer (Bondy et al. 1992; 
Bondy and Lee 1993). IGFBPs 2, 4, and 5 are the predominant carriers expressed in the 
brain, but low concentrations of IGFBP3 have also been reported (D'Ercole et al. 1996). 
IGF-1R mRNA is observed in the choroid plexus at the CSF-blood-brain barrier and in 
the vasculature throughout the brain parenchyma, which may facilitate IGF-1 
translocation into the brain (Bondy and Lee 1993; Reinhardt and Bondy 1994). While 
IGF-1 is expressed by neurons throughout the brain, IGF-1 is a unique growth factor, in 
that it can cross the blood-brain barrier by receptor-mediated endocytosis (Yu et al. 
2006). The functional roles for brain-derived as compared to liver-derived IGF-1 are still 
debated, but a handful of studies suggest that IGF-1 from the systemic circulation may 
contribute to physiological processes important for cognition and hippocampal plasticity 
(Trejo et al. 2001; Nishijima et al. 2010).  
Consistent with growth-permissive effects during development, IGF-1 is an 
important mediator of growth and survival in the adult brain.  Overexpression of IGF-1 in 
the brain, by glial or neuron-specific promoters, resulted in increased brain growth and 
enhanced numbers and size of neurons, astrocytes and oligodendrocytes (Carson et al. 
1993; Ye et al. 1995; Chrysis et al. 2001; Popken et al. 2004; Ye et al. 2004). The 
observed increases in cell numbers are the result of an IGF-1-mediated enhancement of 
cellular proliferation and reduced apoptosis (Ye et al. 1996; Chrysis et al. 2001). An 
increase in IGF-1 signaling is associated with reduced apoptosis in cultured cells of 
many cell types, including neurons (Russell et al. 1998; Delaney et al. 1999; Takadera et 
al. 1999; Bendall et al. 2007). IGF-1 overexpression also reduces oligodendrocyte 
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apoptosis and promotes remyelination during the weeks following cuprizone-induced 
demyelination (Mason et al. 2000). The well-established growth permissive and anti-
apoptotic properties of IGF-1 are well suited to potentially attenuate the pathological 
consequences of injury and promote functional recovery after TBI.  
IGF-1 and Acute CNS Injury 
IGF-1 has proven to be a promising therapeutic agent for the treatment of acute 
CNS injury, as activation of the IGF-1 signaling cascade is associated with increased cell 
survival and improved recovery. Transplantation of IGF-1-secreting marrow stromal cell 
grafts into the spinal cords or subcortical lesions of rats subjected to either spinal cord 
transection or subcortical axotomy resulted in improved survival of corticospinal neurons, 
but promoted axonal regeneration of only raphespinal and rubrospinal neurons (Hollis et 
al. 2009). Moreover, increased levels of IGF-1 by gene therapy initiated after spinal cord 
transection enhanced Akt activation, reduced apoptosis and neuron loss, and promoted 
recovery of motor function at 1 and 2 weeks following injury (Hung et al. 2007). Taken 
together, these studies demonstrate that prolonged elevations in levels of IGF-1 promote 
the survival of neurons and enhance aspects of regeneration after spinal cord injury.  
In the context of hypoxic-ischemic injury in the brain, several studies have 
demonstrated that IGF-1 is neuroprotective and promotes functional recovery. Central 
administration of IGF-1 by intracerebroventricular injection acutely following hypoxic-
ischemic injury reduced neuron loss and infarct area (Guan et al. 1993; Guan et al. 
2000; Guan et al. 2000; Brywe et al. 2005) and promoted the recovery of somatosensory 
function (Guan et al. 2001). Increased Akt activation and reduced caspase activation 
may underlie the improved neuron survival observed in these studies (Brywe et al. 
2005). Alternative routes of administration, including intranasal (Lin et al. 2009) or topical 
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application of IGF-1 also reduced neuron loss after hypoxic-injury (Wang et al. 2000). 
Intracerebroventricular infusion of IGF-1 for a period of 3 days after ischemic-injury 
resulted in reduced ischemic lesion area by 24 hr that was sustained for 1 week post-
injury (Schabitz et al. 2001). Prolonged elevations in brain IGF-1 by gene therapy, 
initiated after hypoxic-injury, stimulated the formation of new vessels, increased cerebral 
blood flow and enhanced neurogenesis at 8 weeks post-injury (Zhu et al. 2008). These 
studies highlight that treatment of IGF-1 attenuates neuronal loss and enhances 
regenerative processes that may contribute to improved functional recovery observed 
after acute CNS injuries with similarities to TBI.     
IGF-1 and TBI 
Endogenous changes in the IGF-1 axis after Experimental TBI 
Despite the promising results of IGF-1 promoting neuroprotection and recovery in 
CNS injury models, little work has been done to evaluate the therapeutic potential of 
IGF-1 after TBI. Several studies have, however, evaluated changes in the endogenous 
IGF-1 axis after brain injury. In situ hybridization following a weight drop injury showed 
an upregulation of cortical IGFBP2 and IGFBP4 mRNA within 24 hr and a maximal 
increase in IGFBP2 mRNA at 3 days post injury, with no changes in IGFBP 3, 5, or 6 
(Sandberg Nordqvist et al. 1996). IGF-1 mRNA abundance peaked at 3 days post-injury 
at the site of injury, with no change in IGF-1R abundance (Sandberg Nordqvist et al. 
1996). In a rat model of penetrating injury, the number of cortical and hippocampal cells 
positively stained for IGF-1 was increased in the peritraumatic region at 1 week post-
injury (Kazanis et al. 2004). Kazanis et al. (2004) also demonstrated that administration 
of IGF-1 2 hr post-injury reversed acute (4 and 12 hr) injury-induced reductions of BDNF 
and neurotrophin-3 in the injured hippocampus. Mild TBI, in a model of weight drop, 
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resulted in an injury-induced increase in the phosphorylation of the IGF-1R at 24 hr post-
injury, ERK1/2 at 1 hr post-injury, and Akt beginning at 1 hr and persisting for at least 72 
hr post-injury in the hippocampus, which was abolished with treatment of a selective 
IGF-1R inhibitor (AG1024) (Rubovitch et al. 2010). Following moderate CCI, IGF-1 
protein levels were transiently increased in the injured cortex at 1 hr with a subsequent 
increase in Akt phosphorylation at 6 hr post-injury but no alterations in levels of IGF-1R 
after injury (Madathil et al. 2010), illustrating that exogenous administration of IGF-1 is 
required to enhance the strength and duration to promote recovery after CCI.  
Administration of IGF-1 after Experimental TBI 
Only a handful of studies have evaluated the therapeutic efficacy of IGF-1 
administered following TBI. Systemic injections of 4 µg/kg IGF-1 at 24 and 48 hr 
following a mild TBI resulted in improved cognitive performance in a Y-maze task at 7 
days post-injury (Rubovitch et al. 2010). Continuous systemic infusion of 4 mg/kg/d IGF-
1 for a period of 2 weeks in a rat model of moderate lateral fluid percussion injury 
resulted in an attenuation of injury-induced deficits in both motor and cognitive 
impairments (Saatman et al. 1997). While these studies highlight the effectiveness of 
IGF-1 to reduce the neurobehavioral deficits associated with TBI, little is known about 
the mechanisms underlying the neurobehavioral improvements observed after 
experimental TBI.  
IGF-1 Administration after Clinical TBI 
 In a phase II open-label, prospective randomized clinical trial of 33 patients, 
treatment with 0.01 mg/kg/hr recombinant human IGF-1 by intravenous infusion was 
initiated within 72 hr after injury for a period of 14 days in moderate-to-severe brain-
injured patients who presented with GCS scores ranging between 4 and 10 (Hatton et al. 
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1997). Patients treated with IGF-1 exhibited improved metabolic activity and nitrogen 
balance for 2 weeks post-injury, compared to non-treated control patients (Hatton et al. 
1997). No serious or life-threatening events were observed with treatment of IGF-1 in 
brain-injured patients. Moreover, in the same trial, stratification of IGF-1-treated patients 
based on serum concentrations of IGF-1 revealed that patients who achieved a systemic 
circulating IGF-1 concentration of 350 ng/ml or above exhibited improved Glasgow 
Outcome Scale scores at 6 months after injury compared to IGF-1-treated patients that 
did not achieve IGF-1 concentrations above 350 ng/ml (Hatton et al. 1997). A serum 
concentration of 350 ng/mL of IGF-1 is in the upper range of physiological serum 
concentrations of IGF-1, and may be indicative of a threshold concentration for the 
therapeutic efficacy of IGF-1 after TBI. Despite the prolonged infusion, elevated levels of 
IGF-1 were only sustained for an average of 8 d during the IGF-1 treatment regimen 
(Hatton et al. 1997). The inability to maintain serum concentrations of IGF-1 was 
attributed to decreased levels of growth hormone and IGFBP3 during the 14 d infusion of 
IGF-1 (Hatton et al. 1997). These findings suggested that negative feedback of IGF-1 on 
the growth hormone axis resulted in increased IGF-1 clearance as a result of decreased 
levels of IGFBP3, an important protein that increases the half-life of IGF-1 in systemic 
circulation (Guler et al. 1989). Future clinical trials would need to consider co-
administration of growth hormone to maintain binding protein levels and achieve 
sustained increases in IGF-1 for the duration of the treatment regimen (Hatton et al. 
1997).  
In a randomized placebo-controlled trial of 23 patients, treatment with saline or 
intravenous infusion of 0.01 mg/kg/hr recombinant human IGF-1 and daily subcutaneous 
injections of 0.05 mg/kg of recombinant human growth hormone was initiated within 72 
hr following injury for a period of 14 days in moderate-to-severe brain-injured patients 
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that presented with a GCS score ranging between 4 and 10 (Rockich et al. 1999). Co-
administration of IGF-1 and growth hormone resulted in sustained supraphysiological 
circulating concentrations of IGF-1 and increased IGFBP3 levels for the duration of 
treatment (Rockich et al. 1999). These findings suggested that supplementation of 
growth hormone with IGF-1 resulted in increased IGFBP3 expression and was needed 
to achieve sustained concentrations above 350 ng/mL of IGF-1, which was previously 
shown to improve outcome after TBI (Hatton et al. 1997).   
In a randomized, double-blinded placebo-controlled clinical trial of 97 patients, 
treatment of placebo or intravenous infusion of 0.01 mg/kg/hr IGF-1 and daily 
subcutaneous injections of 0.05 mg/kg growth hormone beginning within 72 hr post-
injury for a period of 14 days in moderate-to-severe brain-injured patients presenting 
with a GCS score ranging between 4 and 10 (Hatton et al. 2006). Treatment with IGF-1 
resulted in an increased incidence of hypokalemia, hypocalcaemia, and bacteremia, but 
no significant differences in the majority of safety parameters including infection rates or 
fluid retention (Hatton et al. 2006). These results highlight that treatment with IGF-1 does 
not pose safety concerns in brain-injured patients. Treatment with IGF-1 and growth 
hormone resulted in significantly elevated circulating IGF-1 concentrations above 350 
ng/mL, significantly increased daily serum glucose concentration and significantly higher 
nitrogen balance during the duration of treatment compared to treatment with placebo 
(Hatton et al. 2006). No differences in the Glasgow Outcome Scale scores were 
observed between treatment groups at the cessation of treatment (Hatton et al. 2006). 
This clinical trial for IGF-1 and growth hormone (Hatton et al. 2006) was halted in 
response to reports from a European prospective, randomized clinical trial indicating that 
treatment of growth hormone alone resulted in increased morbidity and mortality from 
complications as a result of infection and septic shock (Takala et al. 1999). Brain-injured 
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patients from placebo and IGF-1 treatment groups exhibited no difference in morbidity 
from infectious complications or sepsis (Hatton et al. 2006). The findings reported by 
Hatton et al. (2006) highlighted that co-administration of IGF-1 and growth hormone was 
effective at achieving sustained IGF-1 concentrations during the dosing period, but 
warranted future work in animal models of TBI to determine effective therapeutic 
strategies to achieve sustained elevations in the levels of IGF-1 without growth hormone 
supplementation. Moreover, the findings from these three clinical trials (Hatton et al. 
1997; Rockich et al. 1999; Hatton et al. 2006) highlight the need for additional work in 
experimental models of TBI to elucidate the IGF-1-mediated mechanisms that may 
underlie the improved recovery observed in brain-injured patients after treatment with 
IGF-1.  
Neurogenesis 
Neurogenesis is the process by which new neurons are generated from neural 
stem cells and progenitor cells. The generation of newborn neurons in the hippocampus 
of the adult human brain was originally demonstrated in postmortem tissue collected 
from cancer patients (Eriksson et al. 1998). This fundamental breakthrough ignited a 
field of study focused on trying to better understand the regenerative capacities and 
plasticity of the adult brain. The subventricular zone and subgranular zone of the 
hippocampus were identified as two regions of the brain that generate newborn neurons 
throughout adulthood (Eriksson et al. 1998; Ming and Song 2011). While the process of 
neurogenesis is similar for development of the immature brain, the remainder of this 
section will discuss the properties of neurogenesis as they pertain to the generation of 
newborn neurons in the hippocampus of the adult brain.  
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Neurogenesis refers to a prescribed complex process, and not a single event 
(Fig. 1.4). In the subgranular zone, asymmetrical division of a radial stem cell can give 
rise to a neural progenitor cell that may begin to express immature neuron-specific 
proteins (e.g. doublecortin, PSA-NCAM) (Ming and Song 2011). Over a period of 2 to 4 
weeks after differentiation, the immature neuron will begin to migrate into the granular 
layer, extend a primary axon into the hilus and ultimately CA-3, develop dendritic 
projections concomitant with synaptogenesis, thereby developing into a mature neuron 
that is functionally integrated into the hippocampal circuitry (Zhao et al. 2006; Deng et al. 
2010; Kempermann et al. 2010; Ming and Song 2011). However, only a portion of the 
immature neurons survive to fully mature and incorporate in the dentate gyrus granular 
layer (Kee et al. 2007; Tashiro et al. 2007; Deng et al. 2009).  
The trisynaptic circuit, critical for learning and memory, is defined by axonal 
projections from the entorhinal cortex synapsing onto the dendrites of neurons in the 
granular layer, including those of newly generated neurons, which in turn project axons 
to CA3 pyramidal neurons, which project onto pyramidal neurons in CA1 (Wojtowicz 
2012). Hippocampal neurogenesis is critical to cognition as several studies that 
specifically deplete immature neurons using methods of targeted ablation demonstrate 
detrimental effects on aspects of contextual and spatial learning and memory (Clelland 
et al. 2009; Deng et al. 2009; Jessberger et al. 2009; Blaiss et al. 2011).  
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Figure 1.4: Hippocampal neurogenesis in the dentate gyrus granular layer. 
Proliferation of radial stem cells and neuronal differentiation of newly proliferated 
neural progenitor cells leads to the generation of immature neurons. As a part of 
the developmental progression into mature granular neurons, immature neurons will 
project axonal and dendritic processes, migrate into the granular layer, and begin to 
functionally integrate into the granular layer. 
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Neurogenesis and TBI 
The subgranular zone of the dentate gyrus shows profound loss of newborn 
neurons after CCI (Rola et al. 2006; Gao et al. 2008; Yu et al. 2008; Zhou et al. 2012). It 
is possible that a reduction in immature neurons contributes to cognitive dysfunction 
after injury, as immature neurons have been shown to be important for hippocampal-
dependent learning and memory (Clelland et al. 2009; Deng et al. 2009; Jessberger et 
al. 2009). Following CCI, indicators of neurodegeneration and necrotic cell death are 
found to colocalize with markers of immature neurons in the granular layer (Gao et al. 
2008; Zhou et al. 2012). Nearly 50% of all immature neurons die within the first 24 hr 
following moderate CCI (Gao et al. 2008), with a slow recovery to sham-injured levels 
over the course of several weeks (Rola et al. 2006; Yu et al. 2008). Prevention of the 
endogenous immature neuron recovery process, by targeted ablation of immature 
neurons during the 4 week after brain injury results in an exacerbation of injury-induced 
deficits in spatial learning and memory at 1 month following CCI (Blaiss et al. 2011). 
Therapeutic strategies targeting enhanced survival and increased generation of 
immature neurons may attenuate the cognitive impairment associated with experimental 
TBI. 
Brain injury elicits a robust increase in cellular proliferation within the subgranular 
zone (Dash et al. 2001; Sun et al. 2005; Rola et al. 2006). Increased numbers of neural 
progenitor cells may contribute to the injury-induced upregulation of neurogenesis and 
the slow recovery of immature neurons within the granular layer of the hippocampus. 
Proliferating cells can be identified by incorporation of bromo-deoxyuridine (BrdU), a 
thymidine analog, into DNA during DNA synthesis (Taupin 2007). Time course 
experiments of BrdU labeling within the granular layer highlight a maximal increase in 
proliferation at 3 days post-injury with sustained proliferation for as long as two weeks 
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after CCI (Dash et al. 2001; Rola et al. 2006). Many of the proliferated cells adopt an 
astrocytic lineage, but a minority of the proliferated cells will differentiate into neurons 
(Rola et al. 2006; Gao and Chen 2013). Treatment with erythropoietin or S100B, a 
calcium binding protein, promoted cellular proliferation over 5 weeks and increased the 
number of newborn neurons within 2 days after experimental TBI (Kleindienst et al. 
2005; Lu et al. 2005). Enhanced post-traumatic neurogenesis and increased immature 
neuron number have been reported in the dentate gyrus granular layer following 
increased BDNF, VEGF, and bFGF in the brain following fluid percussion, weight drop 
and CCI injury (Wu et al. 2008; Sun et al. 2009; Thau-Zuchman et al. 2010; Thau-
Zuchman et al. 2012). These studies highlight that the neurogenic niche of the 
hippocampus is responsive to trophic support after injury, and corroborate the 
hypothesis that treatment with a growth factor can enhance hippocampal neurogenesis 
and immature neuron number following TBI. 
IGF-1 and Neurogenesis 
IGF-1 is an important mediator of brain developmental and adult neurogenesis. 
The well-characterized anti-apoptotic effects of IGF-1 on neurons previously described in 
this chapter extends to cultured pluripotent human embryonic stem cells. Blocking the 
IGF-1 receptor reduced human embryonic stem cell survival within days following 
inhibition of IGF-1 signaling (Bendall et al. 2007). IGF-1 is also a potent promoter of 
cellular proliferation and neuronal differentiation of neural stem cells (Arsenijevic and 
Weiss 1998; Aberg et al. 2000; Brooker et al. 2000; Arsenijevic et al. 2001; Yan et al. 
2006). During maturation, immature neurons will extend dendritic processes and exhibit 
the formation of functional synapses (Zhao et al. 2008). Targeted genetic depletion of 
IGF-1 in the brain is associated with reduced dendritic length and arbor complexity 
during postnatal development (Cheng et al. 2003). However, treatment with IGF-1 on 
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primary organotypic cortical slices cultures resulted in increased branching and lengths 
of dendrites pyramidal neurons (Niblock et al. 2000) and promoted neurite outgrowth in 
dissociated neurons (Torres-Aleman et al. 1989). Collectively, these studies highlight 
that IGF-1 is a potent neurotrophic factor that may promote several aspects of 
neurogenesis, including proliferation and neuronal differentiation, in the hippocampus 
following experimental TBI. 
Specific Aims and Hypothesis of the Dissertation  
TBI is an acquired injury that initiates detrimental secondary injury cascades that 
culminate in cellular dysfunction and death. Clinical trials reveal that therapeutic agents 
aimed at one aspect of injury pathology may not be sufficient in attenuating brain 
damage following TBI. A therapeutic agent that reduces cell death while simultaneously 
promoting regenerative mechanisms in the injured brain might have increased efficacy in 
improving recovery of function after TBI. While previously published data demonstrate 
that IGF-1 is effective at improving recovery after experimental TBI, it is unknown 
whether IGF-1 is capable of protecting against cell death or promoting neurogenesis in 
the traumatically injured brain. Utilizing targeted astrocyte-specific IGF-1 overexpression 
in the brain or clinically relevant strategies to administer IGF-1 into the systemic 
circulation or directly into the brain, this work investigates the recently discovered aspect 
of injury-induced neurogenesis and how this reparative mechanism may be enhanced by 
IGF-1, as enhanced neurogenesis could contribute to improved recovery after TBI. 
The overall hypothesis of this dissertation is that treatment with IGF-1 attenuates 
motor and cognitive impairment and enhances hippocampal neurogenesis in the mouse 
brain following severe CCI. The long-term goal of this work is to provide additional data 
that contributes to a preclinical evaluation of IGF-1 for the treatment of TBI. 
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In chapter 2, we demonstrate that a simple modification to the well-established 
CCI model slows the rate of cortical cell death and hippocampal neurodegeneration after 
severe brain injury. We demonstrate that utilization of a rounded impactor tip reduces 
maximal principal strain compared to a beveled impactor tip in a finite element 
mathematical model of mouse CCI. We demonstrate in vivo that a rounded impactor tip, 
compared to a beveled impactor tip, slows the rate of acute cortical cell loss and reduces 
regional hippocampal neurodegeneration, without modulating other pathological 
consequences of CCI, including blood-brain barrier damage, axonal injury, and 
neurobehavioral dysfunction. In this chapter we provide evidence that CCI with a 
rounded tip is an appropriate model to evaluate the therapeutic efficacy of IGF-1 to 
attenuate hippocampal neurodegeneration and to enhance post-traumatic hippocampal 
neurogenesis. 
In chapter 3, we provide preliminary evidence that systemic infusion of IGF-1, 
compared to infusion of vehicle, promotes the activation of Akt, a downstream mediator 
of IGF-1 signaling, in the contused brain and modestly reduces neurodegeneration in the 
dentate gyrus granular layer.  However, systemic infusion of IGF-1 does not promote the 
survival of hippocampal immature neurons at 3 days post-injury or improve motor 
function over the first week after TBI.  
In chapter 4, we demonstrate that central infusion of IGF-1 attenuates motor and 
cognitive dysfunction associated with severe CCI. Treatment with IGF-1 increases 
hippocampal immature neuron density at 7 d post-injury, even when treatment is 
delayed up to 6 hr after injury. We provide evidence that suggests the observed 
increases in immature neuron density with treatment IGF-1 after TBI is the result of 
enhanced cellular proliferation and enhanced neuronal differentiation in the contused 
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hippocampus. We also observed brain swelling in IGF-1-treated mice that could be 
reduced with decreasing doses of IGF-1 or by alterations to the parameters of central 
infusion.  
In chapter 5, we utilize a conditional astrocyte-specific IGF-1 overexpressing 
transgenic mouse model to evaluate the mechanisms by which IGF-1 enhances post-
traumatic neurogenesis after CCI. We demonstrate that overexpression of IGF-1 does 
not promote the survival of immature neurons at 3 days post-injury. However, 
overexpression of IGF-1 increases immature neuron density at 10 days after severe 
CCI. We demonstrate that this increase in immature neuron number is the product of 
enhanced neuronal differentiation of newly proliferated cells in the injured hippocampus. 
Moreover, we demonstrate for the first time that hippocampal immature neurons exhibit 
reduced dendritic arbor length and complexity at 10 d after severe CCI and provide 
compelling evidence that overexpression of IGF-1 promotes the restoration of immature 
neuron dendritic complexity to that observed in immature neurons of sham-injured mice.   
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Chapter 2: Rate of Neurodegeneration in the Mouse Controlled Cortical Impact 
Model is Influenced by Impactor Tip Shape: Implications for Mechanistic and 
Therapeutic Studies 
This chapter was published in Journal of Neurotrauma. Nov 2011; 28 (11); 2245-62. 
Introduction 
The annual incidence of traumatic brain injury (TBI) is estimated at over 1.5 
million people in the United States alone, with many cases of mild TBI likely unreported.  
Although numerous clinical trials have been conducted for moderate-to-severe TBI, no 
therapeutic intervention has proven effective in improving functional outcome (Narayan 
et al. 2002; Maas et al. 2010).  The difficulty in establishing an effective pharmacological 
treatment approach is thought to be related, in part, to the heterogeneity of TBI (Maas et 
al. 1999; Saatman et al. 2008).  At a cellular level, complexity arises from multiple, 
interacting secondary injury cascades that, over time, amplify primary damage inflicted 
during the traumatic insult.  At a tissue level, TBI is heterogeneous in that it comprises 
multiple pathoanatomical types of injury, such as contusion, diffuse axonal injury and 
hematoma, which likely involve different combinations of primary damage and secondary 
mediators.  To overcome this challenge, treatment approaches tailored to a selected 
pathoanatomical injury type may be utilized in future clinical trials for TBI.  Contusion 
injury is well suited to this targeted therapy approach for several reasons.  Contusion 
represents a common type of TBI which can be diagnosed using standard radiological 
imaging (Marshall et al. 1992; Maas et al. 2005; Alahmadi et al. 2010).  Furthermore, 
animal models of contusion injury are widely used for identification of injury mechanisms 
and the preclinical evaluation of therapeutic interventions.   
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The controlled cortical impact (CCI) model is one of the most commonly used 
models of contusion TBI.  The CCI model utilizes a metal impactor rod to transiently and 
rapidly deform the cortex exposed via a craniotomy.  The model was originally 
developed for use in ferrets (Lighthall 1988), but was subsequently adapted for rats 
(Dixon et al. 1991) and mice (Smith et al. 1995).  The use of CCI brain injury in mice has 
dramatically increased over the past 15 years due to greater reliance on transgenic and 
knockout mice for the study of cellular mechanisms and the cost effectiveness of mice 
for therapeutic testing.  In both mice (Smith et al. 1995; Fox et al. 1998; Hannay et al. 
1999; Hall et al. 2005; Saatman et al. 2006) and rats (Dixon et al. 1991; Hamm et al. 
1992; Sutton et al. 1993; Goodman et al. 1994; Hicks et al. 1997; Scheff et al. 1997), 
experimental CCI reproduces important features of human contusion TBI such as 
neocortical and hippocampal cell loss by necrosis and apoptosis, axonal injury, blood-
brain barrier (BBB) breakdown, and cognitive and motor deficits.  In the process of 
characterizing the CCI model, a number of laboratories have demonstrated that 
changing the depth or velocity of impact or the number of craniotomies influences the 
location and severity of injury (Dixon et al. 1991; Sutton et al. 1993; Goodman et al. 
1994; Meaney et al. 1994; Fox et al. 1998; Hannay et al. 1999; Saatman et al. 2006).  
In contrast, the effects of the shape of the impactor tip on the histopathological or 
behavioral response to CCI brain injury has not been systematically investigated.  
Interestingly, the shape of the impactor tip is frequently not described in the methodology 
of published CCI studies.  The model was originally developed with a rounded tip 
impactor (Lighthall 1988).  However, in mouse CCI studies that do describe the 
impactor, nearly all describe the tip as ‘flat’ or ‘beveled flat’, that is, a flat surface where 
the impactor contacts the exposed brain tissue (Fox et al. 1998; Dennis et al. 2009) 
(Xiong et al. 2005; Thompson et al. 2006; Whalen et al. 2008; Sandhir and Berman 
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2010).  We recently demonstrated that, after impact depth, tip geometry (flat versus 
rounded) was the most important parameter in estimating tissue strains and predicting 
cortical contusion volume in a rat finite element simulation, exceeding the influence of 
impact velocity, tip diameter or number of craniotomies (Mao et al. 2010).  Simulations 
demonstrated that impact with a flat tip resulted in high tissue strains localized at the 
impactor rim, whereas strains produced by impact with a rounded (spherical) tip were 
more radially distributed.   
In our experience, the use of a flat tip impactor frequently resulted in very rapid 
cortical neuron death, extensive cortical hemorrhage and distortion, and sometimes 
even cortical tissue tearing in mice subjected to moderate or severe CCI.  We reasoned 
that by using a hemispheric (rounded) tip, we could decrease tensile/shear strains at the 
edges of the impactor as it penetrated the cortical tissue, resulting in less ablative 
primary cellular damage and a more gradual progression of neuronal death, thereby 
enhancing the fidelity of the model to human closed head contusion injury. 
To test this hypothesis, we utilized a finite element modeling approach to 
visualize and compare the patterns of maximum principal (tensile) strains produced by 
deformation of the mouse cortex with either a flat or rounded tip impactor.  We then 
compared the histological damage and the time course for neocortical contusion 
formation from 1 h to 9 d after a 1.0 mm depth impact with these two tips.  To provide a 
comprehensive evaluation of the effects of modulating the tip shape, we also evaluated 
other important features of CCI brain injury such as regional hippocampal 
neurodegeneration, BBB breakdown, axonal injury, and neurobehavioral deficits.  Our 
data suggest that cortical impact with either a flat or rounded tip impactor results in 
equivalent neocortical cell death at 9 d after injury, similar patterns of BBB breakdown 
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and axonal injury, and equivalent neurobehavioral impairment and recovery.  
Importantly, though, impact with a rounded tip impactor reduced cortical tissue strains at 
the impactor edges, slowed the progression of cortical cell death and reduced the extent 
of acute hippocampal neurodegeneration.  These findings have important implications 
for investigations of cellular mechanisms of damage and testing of therapeutic 
interventions for contusion TBI.   
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Materials and Methods 
Finite Element Mouse Brain Model Development and CCI Simulations 
Considering anatomical similarity between rat and mouse brains, a previously 
developed rat brain finite element model (Mao et al. 2006) was used as the basis to 
generate a finite element mouse brain model.  The geometry used for developing the 
mouse brain model was taken from a comprehensive three-dimensional C57BL/6J 
mouse brain atlas reported by Ma et al. (2005).  Ma and colleagues acquired microscopy 
images from 10 adult male (12-14 weeks, weight range 25-30 g) C57BL/6J mice at a 47 
µm isotropic resolution using a 17.6-T magnetic resonance imaging device (Ma et al. 
2005).  The ‘minimum deformation atlas’, a representation of the average structural 
shape of the 10 mice, was adopted here for developing a mouse brain model.  The 
images were imported to an imaging processing software MIMICS 12 (Materialise, 
Leuven, Belgium) to segment the outer surface of the brain, exterior surfaces of the 
white matter, and ventricles.  The Meshworks 5.0/Morpher (DEP, Troy, MI) was then 
used to morph the exterior meshes of the rat brain model to the outer surface of the 
mouse brain.  After that, the white matter and ventricles were adjusted according to the 
mouse brain anatomy.  The morphed mouse brain model, consisting of the cerebrum, 
cerebellum, corpus callosum, internal and external capsules, lateral ventricles, olfactory 
bulb, brainstem, and part of spinal cord, has a total of 258,428 brick elements with a 
typical spatial resolution of 150 µm (Figure 2.1).  To the best of the authors’ knowledge, 
material properties regarding mouse brain were not reported in the literature.  Therefore, 
the mouse brain material properties were defined based on combined in vitro and in situ 
indentation tests of non-preconditioned adult rat brains reported by Gefen et al. (2003) 
using a linear viscoelastic material law (LS-DYNA Material Type 61).  For the gray 
matter, cerebellum, and brainstem, a short-term shear modulus of 1.72 kPa and a long-
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term shear modulus of 0.51 kPa were assumed.  For the white matter, a short-term 
modulus of 1.2 kPa and a long-term modulus of 0.36 kPa were assumed.  A decay 
constant of 20 ms was assumed for both the white and gray matter.  Additionally, the 
ventricles were assumed to have a short-term modulus of 1 kPa and a long-term 
modulus of 0.3 kPa while the corresponding parameters for the spinal cord were 
assumed to be 3.1 and 0.92 kPa, respectively.  For the membranes, linear elastic 
material properties were assumed with a Young’s modulus of 12.5 MPa for the pia-
arachnoid complex (Jin et al., 2006) and 31.5 MPa for dura (Galford and McElhaney 
1970). 
Two CCI scenarios using a 2.5 mm diameter, flat tip and a 3.0 mm diameter, 
hemispherical (rounded) tip impactor, identical to experimental conditions, were 
simulated.  The hemispherical tip was designed to be slightly larger in diameter to 
partially offset the decrease in tip volume caused by rounding of the tip.  A 4.5 mm 
diameter craniotomy, centered at -2.5 mm Bregma and 2.75 mm lateral to the midline, 
was removed from the mouse skull model.  The impactor compressed the exposed dura 
for up to 1.0 mm at a velocity of 3.51 m/s, the mean value calculated from experimental 
records.  The simulation duration was set as 2 ms and simulation results were plotted at 
every 0.02 ms.   The depth of impact was set at 1.0 mm for both impactors to mimic 
commonly used experimental protocols and control for the variable most critical in 
determining tissue strains in the CCI model (Mao et al. 2010). 
Animals and Surgical Procedures 
Adult male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME), weighing 
22-32 g, were housed in a room with a 14:10 light:dark photoperiod.  Mice were given 
food and water ad libitum.  All animal experiments and procedures were in accordance 
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with the National Institutes of Health Guide for the Care and Use of Laboratory Animals 
and were approved by the University of Kentucky Institutional Animal Care and Use 
Committee.  
Mice were anesthetized using 2.5% isoflurane, their heads were shaved, and 
they were placed in a stereotaxic frame (Kopf, Tujunga, CA) where they were 
maintained on isoflurane delivered by a nose cone.  A midline incision was made to 
expose the skull, and a 4.5 mm craniotomy was made centered at -2.5mm Bregma and 
2.75mm lateral to midline over the left hemisphere.  Mice were subjected to CCI injury at 
a 1.0 mm impact depth and a nominal velocity of 3.5 m/s.  The CCI impactor device 
(TBI-0310 Impactor, Precision Systems and Instrumentation, Fairfax Station, VA) uses a 
computer controlled pneumatically driven piston to rapidly impact the brain.  This system 
has a sensitive mechanism for detecting the cortical surface after which the impactor is 
automatically repositioned for a user determined impact depth.  Mice were randomized 
for injury with either a flat tip or rounded tip impactor (Figure 2.2A).  After injury, a 
cranioplast was placed over the exposed brain.  The mice were sutured and placed on a 
heating pad to maintain normal body temperature until they were fully awake, after which 
they were returned to their home cages.  
Tissue Preparation  
 At 1, 4, 12, or 24 h, or 9 d, (n=5 injured with a flat tip impactor, n=5 injured with a 
rounded tip impactor per time point) mice were anesthetized with 65 mg/kg sodium 
pentobarbital through an intraperitoneal injection.  Mice were then intracardially perfused 
with heparinized saline followed by 10% buffered formalin, and decapitated.  After 24 h 
of fixation in 10% buffered formalin, the brains were removed from the skull, post-fixed 
for 24 h, cryoproteced in 30% sucrose, and quickly frozen in -30°C isopentane.  Coronal 
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40 μm sections were cut using a freezing sliding microtome (Dolby-Jamison, Pottstown, 
PA). 
Cortical Contusion Volume 
 Brain sections selected at 400 µm intervals between 0 and -3.5 mm Bregma 
(Paxinos and Franklin 2001) were stained for Nissl substance using 2.5% Cresyl Violet 
and mounted onto slides.  Existing methods were modified slightly to quantify the 
neocortical area containing surviving neurons (Royo et al. 2006; Saatman et al. 2006).  
Sections were viewed using a light microscope (BH2, Olympus America Inc., Melville, 
NY) equipped with an automated stage and camera.  On a live image, the neocortices of 
the contralateral and ipsilateral hemispheres were separately outlined using a tracing 
tool (Bioquant Life Science version 8.40.20), alternating between 2x and 10x 
magnification to evaluate the boundaries of the neocortex as well as cellular staining and 
morphology.  Only areas containing Nissl-stained cells with presumed neuronal 
morphology were outlined, thereby excluding areas of necrotic tissue.  Contusion area 
was calculated as the difference between contralateral and spared ipsilateral neocortical 
areas.  The contusion volume was obtained using Cavalieri’s principle, integrating over 
the inter-section distance, and is expressed as a percentage of the contralateral 
neocortical volume to control for any potential variation in tissue shrinkage during fixation 
and freezing.  
Regional Hippocampal Neurodegeneration 
 Fluorojade-B staining for degenerating neurons (Schmued et al. 1997) has been 
used to quantify trauma-induced hippocampal neuron death (Anderson et al. 2005; 
Dennis et al. 2009).  Brain sections containing hippocampus were selected every 800µm 
between Bregma levels -1.06 mm and -3.5 mm (Paxinos and Franklin 2001) from mice 
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that survived 1, 4, 12, and 24 h.  After rinsing in Tris-buffered saline (TBS), sections 
were immersed in diaminobenzidine (DAB) (Vector Laboratories, Inc., Burlingame, CA) 
for 5 min to provide a substrate for endogenous peroxidases and eliminate 
autofluorescence from parenchymal hemorrhage.  Sections were then mounted onto 
slides, warmed at 40-45ºC for 30 minutes, and kept at room temperature overnight.  On 
day 2, slides were immersed sequentially in 1% NaOH in 80% EtOH, 70% EtOH, and 
ddH2O.  Sections were placed in a 0.06% potassium permanganate solution for 10 min 
and rinsed in ddH2O, before staining 10 min with 0.0001% Fluorojade-B (Millipore Co., 
Billerica, MA) in 0.1% acetic acid.  Slides were then rinsed in ddH2O, dried on a slide 
warmer at 50°C, immersed in Xylenes (Fisher Scientific, Fair Lawns, NJ), and 
coverslipped in Cytoseal XYL (Richard-Allan Scientific, Kalamazoo, MI).  For 
quantification, Fluorojade-positive neurons were counted separately within the dentate 
gyrus, CA3/CA3c, and CA1 of the ipsilateral hippocampus in three sections centered 
within the impact site. Counting was performed at 20x under a fluorescence microscope 
equipped with an FITC filter (AX80, Olympus America) by an individual blinded to the 
injury conditions of each animal.   
Immunohistochemistry 
Immunoglobulin (IgG)  
Free-floating sections, adjacent to both those used for Nissl and Fluorojade-B 
staining, were used for immunohistochemical analysis of IgG extravasation, indicative of 
BBB breakdown.  Tissue was rinsed in TBS and treated with a 3% H2O2 solution to 
quench endogenous peroxidases before blocking non-specific binding sites with 5% 
normal horse serum (NHS).  Biotinylated donkey anti-mouse IgG antibody (1:1000, 
Jackson Immuno Research) was applied overnight at 4°C.  Negative control sections 
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were incubated in diluent without primary antibody.  On day 2, the tissue was rinsed in 
TBS and incubated in an avidin-biotin complex (AB Elite Kit, Vector Laboratories) and 
reacted with DAB.  
Amyloid Precursor Protein 
Immunohistochemical detection of amyloid precursor protein (APP) accumulation 
in axons is a commonly used marker for acute traumatic axonal injury (Sheriff et al., 
1994; Stone et al., 2000).  Sections were rinsed in TBS and placed in 10M citric acid at 
65ºC for 15 min for antigen retrieval.  Tissue was then washed in TBS, blocked in 5% 
NHS in 0.1% Triton X-100 and incubated overnight at 4°C in 1:500 anti-c-terminal APP 
(Cat # 51-2700, Invitrogen, Carlsbad, CA).  Following incubation in 1:1000 biotinylated 
donkey anti-rabbit IgG secondary antibody, endogenous peroxidases were blocked 
using 0.9% H2O2 in 50% methanol.  Tissue was then rinsed and incubated in avidin-
biotin complex.  Reaction product was visualized using DAB as a substrate. 
Behavioral Testing  
Following CCI injury, mice to be utilized for analysis of tissue damage at 9 d post-
injury (n=5/impactor tip) were subjected to behavior tests at several time points to 
assess their level of motor and cognitive function.  All behavior tests were performed by 
a blinded evaluator.   
Neurological Severity Score  
 A Neurological Severity Score (NSS), adapted from Tsenter et al. (2008), was 
assessed at 1 h and 1, 2 and 7 d.   NSS is a 14-point ordinal scale with 14 representing 
normal motor function.  Mice were scored as they traversed, in sequence, 3, 2, 1, and 
0.5 cm wide Plexiglas beams (60 cm long) and a 0.5 cm diameter wooden rod (60 cm 
long).  The beams and rod were elevated 47 cm above the table top.  Mice were 
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acclimated to walking across the beams and rod 24 h before injury.  Mice were allowed 
up to 30 s to cross the beams and rod during both acclimation and testing.  Each beam 
had a maximum of 3 points; 3 points were given for successfully crossing the beam with 
normal forelimb and hindlimb position, 2 points were given for successfully crossing the 
beam despite either a forelimb or hindlimb hanging from the beam, and 1 point was 
given for crossing the beam despite inverting underneath the beam one or more times.  
If a mouse became inverted on the beam, it was righted and allowed to continue across.  
The mouse scored a 0 if it did not cross the beam in the allotted time or if it fell off the 
beam.  For the wooden rod, there was a maximum of two points.  A mouse received two 
points for successfully crossing the rod and one point was given for crossing despite 
inverting more than three times.  A mouse received a 0 if it did not traverse or fell off of 
the rod. 
Neuroscore  
 Neurological motor function was also assessed at 1, 2, 5 and 7 d post-injury, 
using a 12-point neuroscore evaluation.  The neuroscore test was performed as 
previously described (Scherbel et al. 1999) with slight modifications.  The neuroscore 
evaluation consisted of 3 tests: the grid walk (2 points), forelimb and hindlimb flexion 
tests (3 points each), and lateral pulsion (4 points).  For the grid walk, mice were placed 
upon a wire grate with bars spaced 1.5 cm apart positioned 20 cm above a table.  One 
point was deducted if either a front or hind paw slipped through the grate without 
immediate recovery during 60s of free exploration.  Mice scored a 0 if they had both 
forelimb and hindlimb slips.  In the flexion tests, limb coordination and grip strength were 
evaluated as mice were suspended by their tail over a metal rung cage top and lowered 
to allow them to grasp the cage bars with both forelimbs.  One point was deducted from 
the forelimb score if the mouse had low grip strength, crossed its forelimbs, or had 
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excessive hyperactivity.  For the hindlimb score, abnormal limb extension or toe splaying 
each resulted in a one point deduction, while 3 points were deducted if the mouse curled 
its hindlimb up to its body.  For the lateral pulsion test, mice were pushed 4 times from 
left to right across a ribbed plastic mat at increasing speeds.  Four points were deducted 
for rolling over on the first trial, 3 points for rolling over on the second trial, 2 points for 
rolling over on the third trial, and 1 point for rolling over on the fourth trial.  If the mouse 
did not roll over on any of the 4 trials, it received 4 points.  
Morris Water Maze Cognitive Test  
 Learning ability was evaluated on days 7-9 post-injury using a paradigm similar 
to those widely utilized in models of rodent TBI (Hamm et al. 1992; Saatman et al. 1997; 
Prins and Hovda 2001).  A 1 m diameter Morris water maze (MWM) was filled with 19-
21ºC water containing a non-toxic white paint (Rich Art Co., Northvale, NJ) to hide a 6.3 
cm diameter platform that was submerged 0.5 cm below the surface of the water.  Mice 
were released into the water from one of four different starting points (North, East, 
South, or West quadrant) and their latency to locate the platform (located in the West 
quadrant) using large visual cues placed on the walls outside the tank was recorded.  
Mice were tested in sets of four trials per day over three consecutive days.  If the mouse 
did not find the platform within the allotted 70 s trial time, they were placed onto the 
platform for 5 s, then returned to a heated cage.  Swimming trials were monitored using 
an overhead video camera and tracking software (EZVideo version 5.51DV, Accuscan 
Instruments Inc., Columbus, OH). 
Statistical Analysis  
All data are presented as means and standard deviation.  Contusion volumes 
were compared using a 2-way ANOVA.  Fluorojade-positive cell counts were analyzed 
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using a 2-way ANOVA for each hippocampal subfield.  Morris water maze training 
latencies, neuroscore and NSS motor function tests were analyzed using a repeated 
measures 1-way ANOVA.  In all cases, Neuman-Keuls post-hoc t-tests were performed 
when appropriate.  A value of p < 0.05 was considered statistically significant.    
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Results   
Finite element simulation of cortical impact injury 
CCI brain injury at a 1.0 mm depth of impact was simulated for a flat tip impactor 
and a rounded tip impactor (Figure 2.2A).  Principal strain contours immediately after the 
maximum dural compression was reached are illustrated in Figure 2.2B.  The peak 
maximum principal strains resulting from impact with a flat tip were > 49.5 - 55.0% and 
above.  In contrast, impact with a rounded tip generated lower peak maximum principal 
strains, in the range of 38.5 - 44.0%.  In addition, the largest strains induced by the flat 
tip impactor were highly localized along the impactor rim, while there were no such 
concentrations or ‘edge effects’ observed for the rounded tip impactor (Figure 2.2B).  
The edge effect of the flat tip impactor is also clearly evident in strain profiles illustrating 
the peak maximum principal strain as a function of element location along a lateral to 
medial cortical arc (Figure 2.3), where element no.16 represents the position of the 
center of either the flat tip or rounded tip impactor.  At cortical layers 3 and 5, for 
example, impact with the flat tip induced strains at the impactor rim which were almost 
100% higher than the strains beneath impactor center.  In contrast, the rounded tip 
produced more uniform strain distributions beneath the impactor.  The difference 
between rounded tip and flat tip induced strains was less pronounced at the cortical 
surface (layer 1), where the highest strains were induced due to tissue protrusion 
between the impactor and the edge of the craniotomy.  Strain elevations due to tissue 
protrusion decreased as a function of cortical depth and were essentially eliminated by 
layer 7.  In the hippocampal region, the peak maximum principal strain was 24.8% for 
the rounded tip group and 30.1% for flat tip group.   
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Figure 2.1.  Finite element model of mouse brain and impactor. (A) Isometric view of 
the three-dimensional finite element model of the mouse brain utilized for simulation of 
controlled cortical impact brain injury. (B) Cross-sectional view of the ipsilateral dorsal 
quadrant of the brain model illustrating interior structures, the mesh size and the position 
of the impactor.   
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Figure 2.2.  Effect of impactor shape on brain tissue strains.  (A) Animals received 
cortical impact injury with either a flat tip (left) or rounded tip (right) metal impactor rod.  
(B) The impactor tip shapes were reproduced for the finite element simulations shown 
here, illustrating the maximum principal (tensile) strain contours in a coronal section 
through the impact center at an impact depth of 1.0 mm.  Contours are shown with the 
tip in place (upper maps) and with strains mapped to the undeformed brain (lower 
maps).  The fringe levels indicate the strain levels (0 to 0.5500) represented by colors in 
each contour map.   
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Figure 2.3.  Strain profile as a function of cortical depth and tip geometry.  The 
peak maximum principal strain at any time during the impact is plotted for 31 elements 
along a lateral to medial cortical arc, or cortical layer, in the finite element model.  The 
model consists of 8 cortical layers (see Figure 2.1B), with the cortical surface designated 
as Layer 1, and the deepest layer adjacent to the subcortical white matter designated as 
Layer 8.  Element number 16 corresponds to the center of the impactor and craniotomy.  
Strain peaks labeled ‘A’ correspond to regions of tissue protrusion between the impactor 
and the craniotomy edge.  Strain peaks labeled ‘B’ correspond to the edge effects 
created by the flat tip impactor.   
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Histological damage in Nissl-stained brain sections   
Histological analyses of cortical tissue damage using Nissl staining revealed that 
injury with a flat tip impactor resulted in more pronounced initial tissue disruption and 
more rapid cell death when compared to impact with a rounded tip impactor.  Even 
though cell loss progressed at different rates, neocortical tissue damage was ultimately 
equivalent.  
At 1 h post-injury, brains injured by the flat tip impactor exhibited marked cortical 
swelling associated with extrusion at the craniotomy site (Figure 2.4A).  Hemorrhage and 
neuron loss was observed where cortical tissue strains were predicted to be maximal, at 
the periphery of the impactor.  Hemorrhage was also frequently found at the interface of 
the cortex and the subcortical white matter.  In most animals injured with the flat tip (3 of 
5), hippocampal distortion and hemorrhage were prominent.  In contrast, 1 h after injury 
with a rounded tip impactor, brains exhibited no overt loss of Nissl staining, only mild to 
moderate cortical swelling and minimal hemorrhage, typically along the cortical surface 
(Figure 2.4B).  The ipsilateral hippocampus was not distorted, and no hemorrhage was 
present.   
At 4 h after injury with a flat tip impactor, extensive neocortical cell death 
compromised tissue integrity (Figure 2.4C), and began to result in tissue loss during the 
cutting and mounting procedures.  By 12 h, a cortical cavity or ‘lesion’ was well formed 
(Figure 2.4E).  At 4 and 12 h, hippocampal hemorrhage (6 of 10) and distortion (9 of 10) 
were still prominent.  After injury with a rounded tip impactor, the contused neocortex 
exhibited mild to moderate swelling, mild intraparenchymal hemorrhage, and progressive 
loss of Nissl staining intensity from 4 to 12 h (Figure 2.4D, F).  The subcortical white 
matter tract was intact but exhibited some disruption and hemorrhage.  No hippocampal 
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hemorrhage was observed at 4 or 12 h after injury with a rounded tip impactor, although 
distortion of the hippocampal formation was evident by 12 h.   
By 1 and 9 d postinjury, histological damage in Nissl-stained brain sections from 
mice injured with either a flat and rounded tip impactor appeared much more similar than 
at earlier time points. Both impactors resulted in the formation of a large cortical cavity 
by 1 d, with evidence of intraparenchymal hemorrhage surrounding the cavity (Figures 
2.4G, H).  In both groups, the cortical cavity was lined by reactive glia by 9 d (Figures 
2.4I, J).  As with the flat tip impactor group, the rounded tip impactor produced 
subcortical white matter disconnection and degeneration in nearly all mice (9 of 10) at 1 
and 9 d postinjury.  Delayed hippocampal hemorrhage was noted at 1 d after rounded tip 
impact (3 of 5), while hemorrhage was not typical at 1 d after injury with a flat tip 
impactor and was not observed at 9 d postinjury in either group.    
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Figure 2.4.  Temporal progression of histological damage created by a flat tip 
versus a rounded tip CCI impactor.  Images are shown of the ipsilateral neocortex and 
hippocampus of Nissl-stained coronal sections taken at the epicenter of the impact  at 1 
h (A, B), 4 h (C, D), 12 h (E, F), 24 h (G, H) and 9 d (I, J) after 1.0 mm depth CCI.  Injury 
with a flat tip impactor (A, C, E) created more profound tissue disruption, hemorrhage 
and cell loss within the first 12 h when compared to injury with a rounded tip impactor (B, 
D, F).  By 24 h and 9 d post-injury, tissue damage resulting from the flat tip (G, I) and 
rounded tip (H, J) impactor was similar.  Arrows mark the approximate location of the 
edges of the craniotomy.  Arrowheads note the location of tissue hemorrhage and 
neuron loss, corresponding to the path of the impactor edges, at 1 h after impact.   
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Differences in gross histological responses to injury using a flat tip versus a 
rounded tip impactor (vide supra) were underscored by qualitative analysis of neocortical 
neuron morphology.  As early as 1 h after injury with a flat tip impactor, neocortical Nissl 
staining was diminished in intensity, and scattered cell loss and shrinkage was evident 
through all neocortical layers (Figure 2.5A) when compared to uninjured tissue (Figure 
2.5E). Neurons in the neocortex injured by the rounded tip impactor were pyknotic, but 
normal appearing in size, density, and Nissl intensity (Figure 2.5B). At 4 h after injury 
with a flat tip impactor, neocortical neuronal damage had progressed substantially, with 
few identifiable neurons visible in the contusion site (Figure 2.5C). In the neocortex of 
mice injured with a rounded tip, Nissl-stained cells with neuronal morphology were still 
clearly detectable at 4 h (Figure 2.5D), although pyknosis and loss of Nissl intensity was 
greater than at 1h. The extent of neuronal damage was far less than that induced at 4 h 
by a flat tip impactor (compare Figure 2.5D and 2.5C). Neuronal damage had increased 
by 12 h after impact with a rounded tip (Figure 2.5F), with marked loss of Nissl staining 
comparable to that observed 4 h after injury with the flat tip impactor (Figure 2.5C).   
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Figure 2.5.  Alterations in neocortical neuron morphology as a function of 
impactor tip shape.  Compared to sham injury (E, with black border), cortical injury with 
a flat tip impactor (A) results in more severe neuron shrinkage and loss of neuronal Nissl 
staining at 1 h than injury with a rounded tip impactor (B).  Neuron death is more rapid 
with the flat tip impactor, with nearly complete loss of cells with identifiable neuronal 
morphology by 4 h (C), while morphological damage increases progressively from 4 h 
(D) to 12 h (F) after injury with a rounded tip impactor.  Scale bar represents 100 µm.   
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Quantification of cortical tissue damage 
To quantify cortical damage, the boundaries of the neocortex containing 
morphologically identifiable neurons were outlined ipsilateral and contralateral to the 
impact on Nissl-stained coronal sections. Gross patterns of early neocortical distortion 
and cell death are shown in representative tracings in Figure 2.6A.   Within the swollen 
ipsilateral cortex, two regions of neocortical damage are clearly evident at 1 h after CCI 
with a flat tip impactor, consistent with the regions of acute hemorrhage and neuron loss 
illustrated in Figure 2.4A, and corresponding closely to the regions of high principle 
strains predicted by finite element model simulation (Figure 2.2B, left panels). At 1 h 
after CCI with a rounded tip impactor, neocortical tissue exhibited swelling at the 
craniotomy site, but overt tissue damage was only noted at 4 h.  The volume of 
neocortical tissue damage increased significantly over time (main effect of time, F(4, 38) 
= 52.15, p < 0.00001; Figure 2.6B).  The temporal progression was strongly dependent 
on the tip geometry used to create the injury (interaction of tip and time, F(4, 38) = 11.70, 
p< 0.00001).  At 1 h postinjury, both groups exhibited negative contusion volumes due to 
neocortical swelling and herniation (see also Figures 2.4A, 2.4B and 2.6A).  By 4 h 
postinjury, the amount of cortical damage increased significantly for the group injured 
with the flat tip (p<0.0005 compared to 1 h) but not the rounded tip impactor.  No further 
increase in contusion volume was measured for mice injured using the flat tip impactor, 
suggesting that the majority of neocortical damage occurred by 4 h postinjury.  In 
contrast, mice injured with a rounded tip impactor showed a progressive increase in 
contusion volume from 4 h to 12 h (p < 0.001) and from 12 h to 24 h (p < 0.001).  
Cortical tissue damage was greater with the flat tip impactor than the rounded tip 
impactor at both 4 h (p < 0.0005) and 12 h (p < 0.005), but was equivalent at 24 h and 9 
d.  These data demonstrate CCI injury with a rounded tip impactor resulted in a slower 
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evolution of neocortical cell death over the first 12 h, but ultimately the same volume of 
cortical tissue damage, as compared to injury with a flat tip impactor.   
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Figure 2.6.  Quantification of cortical tissue damage.  (A) Representative tracings of 
the dorsal regions of the ipsilateral and contralateral neocortex containing 
morphologically identifiable neurons at the epicenter of injury 1h after impact with a flat 
tip impactor and 1h and 4h after injury with a rounded tip impact.  Arrows mark the 
location of the craniotomy edges as in Figure 2.3.  (B) The volume of cortical damage 
produced by injury with a flat tip impactor was maximal by 4 h and was unchanged out to 
9 d.  In contrast, cortical injury with a rounded tip impactor led to a more slowly 
developing cortical contusion that increased in size over 24 h, reaching a contusion 
volume equivalent to that of the flat tip impactor group. Square symbols denote flat tip 
impactor group means; diamond symbols denote round tip impactor group means.  Error 
bars represent standard deviations.  (+ p< 0.0005 compared to the previous time point 
for the flat tip impactor group; ** p< 0.001 compared to the previous time point for the 
rounded tip impactor group; # p < 0.005 comparing flat tip and rounded tip impactor 
groups at the same time point).   
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Regional hippocampal neurodegeneration 
Fluorojade staining was used to evaluate acute regional neurodegeneration in 
the hippocampus.  Only a few faintly labeled neurons were observed at 1 h postinjury 
(data not shown).  At 4, 12 and 24 h, Fluorojade-positive neurons were clearly visible in 
both groups of mice after 1.0mm CCI brain injury.  Injury with a flat tip impactor produced 
widespread neurodegeneration in the granule layers and hilus of the dentate gyrus and 
in the CA3 pyramidal layer, with less degeneration in the CA1 pyramidal layer (Figure 
2.7A, C, E).  Neurodegeneration was most prevalent in the dentate gyrus following injury 
with a rounded tip impactor, with fewer Fluorojade-positive neurons in the CA3 pyramidal 
layer and very few, if any, in the CA1 region (Figure 2.7B, D, F).  
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Figure 2.7.   Hippocampal neurodegeneration after controlled cortical impact (CCI) 
with a flat tip (A, C, E) or a rounded tip (B, D, F) impactor.  Fluorojade-B staining of 
sections taken at the impact epicenter illustrate degenerating neurons in the dentate 
gyrus granule layers, dentate hilus, and CA3 and CA1 pyramidal layers at 4 h (A, B), 12 
h (C, D) and 24 h (E, F) after 1.0 mm CCI brain injury.  Scale bar represents 500 µm. 
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Fluorojade-positive neurons were counted in the ipsilateral hippocampus at 4, 12, 
and 24 h postinjury.   In the dentate gyrus, there was no overall effect of tip geometry or 
time, but the interaction between these variables was significant (F(2,24) = 6.15, p< 
0.01; Figure 2.8A).  The flat tip impactor resulted in a initial wave of neurodegeneration 
in the dentate gyrus at 4 h that was reduced by 12 h, although this decrease did not 
reach statistical significance (p = 0.06). The number of Fluorojade-positive dentate gyrus 
neurons increased from 12 h to 24 h after injury with the flat tip impactor (p<0.05).  
Numbers of degenerating dentate gyrus neurons did not change over time for the group 
injured with a rounded tip impactor, and the numbers were not different from the flat tip 
impactor group at any individual time point.  In the CA3/CA3c pyramidal layer, CCI with 
the flat tip impactor resulted in significantly greater neurodegeneration across the first 
24h when compared to the rounded tip impactor (main effect of tip shape, F(1,24) = 
7.30, p < 0.05; Figure 2.8B).  Numbers of Fluorojade-positive cells decreased from 4 h to 
12 h (p < 0.05) and then increased again at 24 h (p < 0.05 compared to 12 h), a 
temporal trend that appeared more pronounced for the flat tip impactor.  Injury with a flat 
tip impactor also produced greater neuron death in the CA1 region than did the rounded 
tip impactor (main effect of tip shape, F(1,24) = 22.90, p < 0.0001; Figure 2.8C), an 
effect that was time dependent (interaction of tip and time, F(2, 24)=4.10,  p < 0.05).  At 
4 h, numbers of Fluorojade-labeled CA1 neurons were more than ten-fold higher after 
injury with a flat tip impactor than with a rounded tip impactor (p < 0.001), and were 
significantly higher than those at 12 h or 24 h for either tip geometry (p < 0.05), 
indicating a very acute wave of CA1 cell death induced only by the flat tip impactor.   
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Figure 2.8.  Quantification of regional hippocampal neurodegeneration as a 
function of impactor tip shape.  Fluorojade-B positive (FJB+) neurons were counted in 
the (A) dentate gyrus, including the granule layers and hilar region, (B) CA3/CA3c 
pyramidal layer, and (C) CA1 pyramidal layer at 4 h, 12 h, and 24 h after brain injury with 
a flat tip impactor (dark grey bars) or rounded tip impactor (light gray bars).  Data are 
shown as means + standard deviation. (+ p < 0.05 compared to the adjacent time point 
for the flat tip impactor group; # p < 0.001 comparing flat tip and rounded tip impactor 
groups at the same time point). 
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Blood-brain barrier (BBB) damage 
Regional patterns of BBB breakdown were comparable after CCI injury using a 
flat tip or rounded tip impactor.  At 1 h, IgG extravasation was localized to the impact site 
spanning neocortical layers I through VI, as well as the subcortical white matter and CA1 
stratum oriens (Figure 2.9A, B).  By 4 h, BBB disruption had extended beyond the 
impact site in the neocortex and encompassed the entire ipsilateral hippocampus at the 
level of the impact epicenter (Figure 2.9C, D).  At 12 and 24 h, in addition to the robust 
IgG immunostaining in the ipsilateral cortex, subcortical white matter and hippocampus, 
faint IgG labeling was observed in the dorsal thalamus and in the contralateral cortex 
and hippocampus near midline.  At 9 d, IgG extravasation was less pronounced than at 
24h.  
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Figure 2.9.  Acute blood-brain barrier damage after severe controlled cortical 
impact using a flat tip impactor (A, C) or a rounded tip impactor (B, D).  The 
location and progression of extravasation of immunoglobulin (IgG) was similar for injury 
with the flat tip and rounded tip impactors, as illustrated at 1 h (A, B) and 4 h (C, D) after 
injury.   
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Traumatic axonal injury 
Traumatic axonal injury was assessed qualitatively using immunohistochemistry 
for APP, a well-established marker of axonal injury.  Impact to the cortex with either a flat 
tip or rounded tip impactor resulted in acute axonal injury throughout cortical and 
subcortical structures in the ipsilateral hemisphere.  There were no overt differences in 
the distribution or time course of axonal injury between the two tip geometries.  From 1 h 
to 24 h post-injury, axonal injury was evident along the edges of the impact site in the 
neocortex, and in the deep neocortex (layer VI) and the subcortical white matter tract 
below the impacted cortex (Figure 2.10A, B).  APP-positive injured axons were also 
observed in the dorsal ipsilateral thalamus (Figure 2.10C, D) and occasionally within the 
hippocampus, most often in the stratum oriens of the CA3 and CA1 regions and along 
the hippocampal fissure.  Qualitatively, the frequency and staining intensity of APP-
positive axons increased from 1 h to 12 h.  No axonal injury was observed in the 
contralateral hemisphere for any of the time points for either tip shape.  
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Figure 2.10.  Traumatic axonal injury induced by injury with either a flat tip (A, C) 
or rounded tip (B, D) impactor.  The spatial patterns of axonal injury, detected using 
immunohistochemistry for amyloid precursor protein, were similar for mice injured with a 
flat tip or rounded tip impactor.  In the neocortex, axonal injury was concentrated around 
the periphery of impact site and in the subjacent white matter and gray matter/white 
matter interface (12 h postinjury shown; A, B).  Axonal injury was also clearly evident in 
subcortical structures such as the hippocampus (not shown) and dorsal thalamus (24 h 
shown; C, D; scale bar represents 200 µm). 
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Motor and cognitive behavioral outcome 
Deficits in coordinated motor function were evaluated using a modified NSS at 1 
h and 1, 2, 5 and 7 d after CCI brain injury.  Tip geometry was not a factor in determining 
the level of initial motor dysfunction or the rate of recovery of function (Figure 2.11A).  
Both groups of brain-injured mice exhibited profound motor deficits using the NSS at 1 h 
post-injury and a significant spontaneous recovery over time (main effect of time, F(4,32) 
= 37.71, p < 0.0001).  Similarly, evaluation of basic motor functions including limb 
flexion, extension and grip strength using a composite neuroscore revealed equivalent 
deficits in mice injured using either a flat tip or rounded tip impactor (Figure 2.11B).  Both 
groups of mice showed notable motor dysfunction at 1 d after CCI, and significant 
recovery of function over time (main effect of time, F(3,24) = 14.26, p < 0.0001).   
As with posttraumatic motor deficits, the use of a flat tip or rounded tip impactor 
did not significantly alter posttraumatic cognitive function assessed in a Morris water 
maze at one week after severe CCI (Figure 2.11C).  Learning latencies were equivalent 
for the two groups, with both achieving significantly lower latencies to the platform on 
days 8 and 9 compared to day 7 (p < 0.0005).   
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Figure 2.11. Effect of impactor tip shape on neurological motor and cognitive 
function of mice subjected to cortical impact injury.  Mice injured with a flat tip 
impactor or a rounded tip impactor exhibited equivalent motor deficits over the first week 
after injury, when measured using (A) a 14-point modified neurological severity score 
(NSS) or (B) a 12-point composite neuroscore. (C) Impactor tip shape also had no 
significant effect on the ability to learn the location of a hidden platform in a Morris water 
maze over a three day testing period. Dark gray bars or square symbols denote flat tip 
impactor group means; light grey bars or diamond symbols denote round tip impactor 
group means.  Error bars represent standard deviations.   
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Discussion 
The CCI model of contusion brain injury is one of the most widely used models of 
TBI in mice.  Mouse models are being increasingly utilized to exploit transgenic and 
knockout technologies for the study of specific proteins or for expression of tissue or cell 
specific reporters.  The low cost and small body weight of mice are also attractive for 
testing therapeutic interventions, especially when large cohorts are needed to perform 
comprehensive dose response studies or test behavioral outcomes.  We have 
demonstrated that in the mouse CCI model the rate of neocortical neurodegeneration is 
highly dependent on the shape of the impactor tip.  A 1.0 mm depth injury with a flat tip 
impactor results in significantly faster cortical neuron death, more pronounced acute 
hemorrhage, and greater initial hippocampal neurodegeneration than injury with a 
rounded tip impactor.  Injury severity, assessed by (a) impact depth and velocity, (b) the 
size of the neocortical contusion at 9 d after injury, (c) the presence or pattern of BBB 
breakdown and axonal injury, and (d) the magnitude of neurobehavioral deficits, was 
equivalent for the two impactors.  These data suggest that rounding the tip of the 
impactor slows the temporal course of the neurovascular damage without reducing or 
eliminating important pathophysiological features of CCI brain injury.  
 A three-dimensional finite element model was utilized to predict tissue strains in 
response to a 1.0 mm 3.5 m/s CCI injury using flat tip or rounded tip impactor.  Maximum 
principal strains were predicted to be substantially higher for the flat tip impactor than for 
the rounded tip impactor.  For the flat tip impactor, tissue strains were predicted to be 
highest around the edge of the impactor as it penetrated the cortical parenchyma.  
Histological damage, including hemorrhage and loss of Nissl stain, was indeed observed 
most frequently at the boundaries of the impactor’s path as early as 1 h after injury with 
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a flat tip impactor (see Figures 2.4 and 2.6).  Interestingly, the strain at which human 
cerebral arteries fail under dynamic elongation ex vivo is estimated to be 0.50, or 50% 
(Monson et al. 2003).  Based on these data, arterial rupture or tearing would be 
predicted along the edges of the path of the flat tip impactor, consistent with the 
presence of hemorrhage in this region.  For the rounded tip impactor, maximum strains 
were predicted to be centered beneath the impactor, more diffusely distributed in the 
deep cortex, consistent with strain contours generated for CCI injury in the rat (Mao et al. 
2010).  One limitation of the current mouse brain model is that the finite element meshes 
were morphed from the previously validated rat brain model with some adjustments 
made on the brain outer surface, ventricles, and white matter.  Gray matter structures 
were assigned the same material properties.  Detailed meshes representing other 
anatomical parts, such as hippocampus or thalamus, and incorporation of region-specific 
material property heterogeneities, are required in the future to improve its biofidelity.  
Testing mouse brains to acquire mouse-specific properties would increase the prediction 
accuracy of the numerical mouse brain model.  Tears within the brain parenchyma 
during impact would necessarily alter the strain pattern in neighboring regions. However, 
micro-tearing of brain tissues or intracranial vasculatures was not addressed in our finite 
element model because a much higher resolution brain model would be needed for 
predicting such injuries.  Unfortunately, a very fine mesh model is computationally 
challenging at present.  Even if such a model existed and were computationally feasible, 
very little is known regarding strain thresholds for individual cellular components within 
the brain.     
 Dynamic strains of 0.10-0.20 (10-20%) or above are sufficient to elicit 
morphological signs of injury or dysfunction in neurons or axons (Bain and Meaney 
2000; Geddes et al. 2003; Cater et al. 2006; Elkin and Morrison 2007).  During focal or 
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diffuse TBI, tissue deformation leads to early compromise of the normal selective barrier 
function of the plasmalemma (Farkas et al. 2006; Whalen et al. 2008), contributing to ion 
dysregulation (Kilinc et al. 2009).  Both enhanced neuronal membrane permeability and 
increases in intracellular free calcium have been shown to be proportional to applied 
strain (LaPlaca et al. 1997; Geddes et al. 2003), suggesting that in regions of highest 
tissue strains, neurons will more likely experience greater and more sustained calcium 
perturbations, which could lead to mitochondrial dysfunction, protease activation and cell 
death.  While trauma-induced membrane permeability increases may be transient under 
some conditions, sustained leakiness results in cell death (LaPlaca et al. 1997; Geddes 
et al. 2003; Geddes et al. 2003; Farkas et al. 2006).  Collectively, these studies are 
consistent with the premise that higher strains generated by a flat tip impactor would be 
associated with more severe membrane permeability alterations and calcium 
dysregulation with less likelihood of recovery, resulting in rapid cell death.  Recent work 
supports a direct correlation between maximum principal strains predicted by finite 
element modeling and the degree of neuronal degeneration in a rat model of CCI brain 
injury (Mao et al. 2010) (Mao et al., 2010a).   
 Quantification of the progression of cell death within the ipsilateral neocortex 
following severe contusion injury with either a flat or rounded tip impactor revealed 
marked differences in the evolution of neocortical damage.  Injury with a flat tip impactor 
produced rapid cell death, with maturation of the neocortical lesion by 4 h, whereas 
impact with a rounded tip resulted in milder initial neocortical damage that progressively 
increased out to 24 h post-injury to a level equivalent to that produced by the flat tip 
impactor.  Although relatively little information is available on the acute time course of 
cortical damage after CCI, our findings are consistent with previous studies using CCI 
with a flat tip impactor in mice.  Using propidium iodide exclusion as an indicator of 
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membrane integrity, Whalen et al. (2008) showed marked increases plasma membrane 
compromise in the cortex at 1 h after 0.6mm, 6 m/s CCI, after which most membrane-
compromised neurons degenerated.  Similarly, Hall and colleagues (Thompson et al. 
2006; Hall et al. 2008) demonstrated that the size of the cortical cavitation (lesion 
volume) is fully developed by 6 h after 1.0 mm, 3.5 m/s CCI.  In the CCI model, the 
amount of neocortical cell death can be altered by changing the depth or velocity of 
impact in the mouse (Fox et al. 1998; Hannay et al. 1999; Saatman et al. 2006) and rat 
(Sutton et al. 1993; Goodman et al. 1994).  However, because these histological 
evaluations were typically carried out days to weeks after the injury, it is unclear to what 
extent velocity or depth of impact affects the rate of cortical neurodegeneration.  Injury 
severity and the rate of cell death may also vary for different injury devices.  Fox et al. 
(1998) use a custom-made CCI device with a flat tip impactor and report no cortical 
cavitation at 7 d after a 1 mm depth, 4.5 m/s injury to C57BL/6 mice.  Nevertheless, a 1 
mm impact at a higher velocity (6 m/s) resulted in neocortical neurodegeneration 
concentrated at the periphery of the flat tip impactor, a pattern consistent with our finite 
element predictions, as described above.    
 In addition to a prominent neocortical contusion, CCI brain injury typically results 
in neuron loss in the hippocampal dentate gyrus and CA3 pyramidal layers (Goodman et 
al. 1994; Smith et al. 1995; Baldwin et al. 1997; Saatman et al. 2006; Hall et al. 2008).  
Although the CA3 subregion is positioned further from the impact than the CA1 region, 
CA3 neurons appear more vulnerable to CCI, perhaps due to greater tissue compliance 
within the CA3 region compared to the CA1 (Elkin et al. 2010).  However, involvement of 
the CA1 pyramidal layer is also often reported as impact depth is increased (Goodman 
et al. 1994; Scheff et al. 1997; Saatman et al. 2006; Whalen et al. 2008).  Quantification 
of degenerating neurons revealed that the rates and extent of neurodegeneration within 
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the hippocampus are altered by the impactor tip geometry.  Injury with a flat tip impactor 
produced a wave of acute neurodegeneration at 4 h, with the largest number of 
degenerating cells in the dentate gyrus, followed by the CA3 and then CA1 regions.  A 
similar acute phase (peak at 1-6 h) and regional distribution of degenerating neurons 
with plasma membrane compromise was reported for mouse CCI with a flat tip impactor 
(Whalen et al. 2008).  In contrast, impact with a rounded tip appeared to produce a more 
consistent progression of hippocampal neurodegeneration across the first 24 h after 
injury, with minimal involvement of the CA1 region.  Early hippocampal 
neurodegeneration may be more extensive following injury with the flat tip impactor as a 
result of larger tissue displacement during impact, with the bulk of the cortical tissue 
being forced downward into the hippocampal structure.  Despite the slightly larger 
diameter of the rounded tip, a much smaller volume of tissue is displaced and some of 
the cortical tissue may be compressed and deformed laterally, reducing the deformation 
of the hippocampus.  Results predicted by the finite element model corroborate this 
assumption.  A peak maximum principal strain of 30.1% was induced using the flat 
impactor while the corresponding value was 24.8% for the rounded impactor.  Despite 
the lower strains that occur in the hippocampus compared to the neocortex with CCI, 
hippocampal neurons in vitro exhibit larger intracellular calcium increases and more cell 
death compared to cortical neurons in response to stretch injury, suggesting an 
enhanced vulnerability to traumatic stimuli (Geddes et al. 2003; Elkin and Morrison 
2007).   
 Blood-brain barrier breakdown is an important aspect of cerebrovascular damage 
in TBI (DeWitt and Prough 2003) that has been reproduced in severe CCI(Smith et al. 
1995; Hicks et al. 1997).  In this study, damage to the BBB was visualized by IgG 
immunoreactivity within the ipsilateral neocortex and hippocampus in patterns similar for 
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both impactor tips.  Extravasation of IgG was localized primarily to the neocortex at 1 h, 
while at 4 h postinjury IgG labeling was also observed in the hippocampus, as previously 
reported (Saatman et al. 2006).  Regional patterns of disruption of the BBB in mice were 
not substantially modulated in the present study by impactor tip geometry, or by severity 
of injury (impact depth) for CCI injury with a rounded tip impactor (Saatman et al. 2006), 
suggesting that the threshold for mechanically stimulated BBB damage may be low and 
compromise of the BBB may be a common pathology across a range of injury severities.  
Our analysis of BBB breakdown is limited in that it was not quantitative, leaving open the 
possibility that the degree of extravasation caused by the two tips may be different.  In 
addition, IgG extravasation yields limited information about the time course of BBB 
disruption.  Further studies with Evan’s blue administered intravascularly at various 
postinjury time intervals could provide more information regarding the time course of 
BBB disruption or recovery for these two injury paradigms.  Nonetheless, our data 
confirm that impact injury with a rounded tip results in neocortical and hippocampal BBB 
damage, reproducing an important aspect of CCI pathology associated with secondary 
injury cascades such as inflammation and oxidative stress.   
 Axons are vulnerable to stretch injury induced by tensile/shear strains within the 
brain tissue.  Traumatic axonal injury results in rapidly altered membrane permeability, 
intracellular calcium imbalances and mitochondrial damage, protease activation and 
disruption in axonal transport (M.F 2009).  Injured axons represent a vital therapeutic 
target in diffuse brain injury, representing the defining pathology in diffuse axonal injury.  
Sparing axonal integrity may also be important in focal brain trauma.  Even in models 
designed to produce focal contusions, such as the CCI model, axonal damage is present 
in several regions outside the contused neocortex, such as the hippocampus and 
thalamus (Lighthall et al. 1990; Dunn-Meynell and Levin 1997; Hall et al. 2005; Hall et al. 
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2008).  Here we show that impact with either a rounded tip or flat tip impactor produced 
axonal injury within the contused neocortex and the underlying hippocampus and 
thalamus.  Although the number of injured axons was not quantified, the onset and 
overall distribution of axonal injury was comparable for the two tip geometries. 
 In preclinical evaluation of therapeutic approaches for TBI, behavioral deficits are 
an especially important outcome measure.  Both motor and cognitive deficits have been 
well described in both rat and mouse models of TBI, utilizing a number of different 
behavioral tasks (Hamm 2001; Fujimoto et al. 2004).  The severity of behavioral 
dysfunction can be altered by changing certain biomechanical aspects of CCI injury, 
such as the depth (Saatman et al. 2006; Yu et al. 2009) or velocity (Fox et al. 1998) of 
impact.  Despite the fact that CCI brain injury with a flat tip impactor resulted in greater 
maximal tissue strains than impact with a rounded tip, motor and cognitive functions of 
brain-injured mice were not grossly influenced by impactor tip geometry, although small 
group sizes may have limited our ability to detect small differences.  Behavior was 
evaluated at several times after injury using a composite neuroscore, neurological 
severity score, and a MWM learning task.  This suggests that slowing the progression of 
cortical cell death through the use of a rounded tip did not compromise the fidelity of the 
behavioral response.  Brain injury-induced neuromotor or cognitive impairments in CCI-
injured mice have been attenuated through various treatment approaches, illustrating the 
influence of secondary injury cascades on posttraumatic behavioral responses (You et 
al. 2008; Clausen et al. 2009; Longhi et al. 2009; Mbye et al. 2009).  Therefore, the use 
of a rounded tip impactor may provide a greater therapeutic window for targeting acute 
cell dysfunction or death without diminishing the power of the CCI model for the 
evaluation of behavioral impairment and recovery. 
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In summary, we have quantitatively and qualitatively investigated the effects of 
impactor tip geometry on predicted tissue strains, histological outcomes and behavioral 
responses following severe lateral CCI brain injury in mice.  Compared to CCI with the 
commonly used flat tip impactor, injury with a rounded tip impactor resulted in more 
uniform maximum principal strains with lower peak magnitudes, reduced acute 
neurovascular disruption, and a slower progression of neocortical cell death.  A more 
gradual evolution of neocortical neuronal death was achieved with a rounded tip CCI 
without altering the size of neocortical contusion at 9 days after injury or substantially 
changing other clinically relevant aspects of this brain injury model such as BBB 
breakdown, axonal injury or neurobehavioral dysfunction.   By slowing the progression of 
neuronal damage, the CCI model may better mimic the evolution of contusive damage in 
human head injury.  Furthermore, lengthening the time between the primary insult and 
the eventual death of the cell is advantageous for mechanistic studies aimed at 
distinguishing the onset, duration and interactions of upstream and downstream events, 
or isolating specific aspects of injury cascades.  Slowing the time course of neuronal 
death also yields a longer therapeutic window, increasing the likelihood that therapeutic 
compounds can be administered using a clinically relevant postinjury paradigm, reach 
therapeutic levels in the CNS and affect the desired targets.  These data suggest that 
along with impact depth and velocity, impactor tip shape is an important determinant of 
acute tissue response to rapid impact brain injury.  Therefore, in studies of acute injury 
mechanisms of contusive TBI or in evaluations of therapeutic interventions targeting 
neuronal death, impactor tip geometry should be carefully considered. 
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Chapter 3: Prolonged Continuous Systemic Infusion of IGF-1 after Severe 
Controlled Cortical Impact 
Introduction  
There are an estimated 1.7 million annual cases of traumatic brain injury (TBI) 
that result predominantly from motor vehicle incidents, falls, and violence (Langlois et al. 
2006; Summers et al. 2009; Faul M 2010). TBI is an acquired condition that can afflict 
individuals independent of age and gender, but the highest prevalence is found in males 
aged 20-30 (Langlois et al. 2006). TBI is characterized by an initial mechanical 
disturbance and the subsequent activation of secondary injury cascades that can 
culminate in cellular dysfunction and death (Lynch and Dawson 1994; Marklund et al. 
2006; Beauchamp et al. 2008). Neurological impairment, including motor and cognitive 
dysfunction, is frequently reported in brain-injured patients (Capruso and Levin 1992; 
Lundin et al. 2006; Selassie et al. 2008; Jang 2009).  
The mouse model of lateral controlled cortical impact (CCI) reliably reproduces 
cortical contusion, selective hippocampal neuron loss, and neurobehavioral deficits 
including motor and cognitive dysfunction (Smith et al. 1995; Saatman et al. 2006; 
Pleasant et al. 2011), recapitulating important features of the pathobiology associated 
with human contusion TBI. CCI is a highly characterized model that is widely utilized for 
preclinical assessment of therapeutic agents for the treatment of TBI.  
The activation of multiple secondary cascades creates a substantial challenge for 
therapeutic agents targeting a single mechanism of the secondary injury cascade after 
TBI (Beauchamp et al. 2008; Margulies and Hicks 2009). Alternatively, a therapeutic 
agent, for example a neurotrophic factor, that targets multiple mechanisms of secondary 
injury and can promote regeneration, may prove efficacious for the treatment of TBI. The 
80 
 
neurotrophic factor insulin-like growth factor-1 (IGF-1) is a highly conserved 7.6 kDa 
protein, predominantly synthesized in the liver, which can cross the blood-brain barrier 
by receptor-mediated endocytosis (Pardridge 1993; Reinhardt and Bondy 1994). IGF-1 
is also synthesized in neurons and astrocytes of the adult rodent brain (Bondy et al. 
1992; Bondy and Lee 1993; Bondy and Cheng 2004). Binding of IGF-1 to its cognate 
receptor, which is highly expressed in the cortex, hippocampus and choroid plexus of the 
adult rodent brain, results in the downstream activation of Akt (Bondy and Lee 1993). 
Increased activation of Akt is linked with increased neuron survival after hypoxic-
ischemic injury and experimental TBI (Noshita et al. 2001; Noshita et al. 2002; Brywe et 
al. 2005). In addition to enhancing neuron survival, IGF-1 also promotes neurogenesis 
by enhancing proliferation and neuronal differentiation of newly proliferated cells in the 
hippocampus (Arsenijevic and Weiss 1998; Aberg et al. 2000; Brooker et al. 2000; 
Arsenijevic et al. 2001; Trejo et al. 2001; Yan et al. 2006). The neuroprotective and 
neurogenic effects of IGF-1 make it a promising therapeutic agent for the treatment of 
TBI.  
Only a handful of studies have evaluated the therapeutic efficacy of IGF-1 in the 
context of TBI. Systemic administration of IGF-1 attenuates deficits in spatial memory in 
mice subjected to a mild brain injury (Rubovitch et al. 2010) and attenuates motor and 
cognitive dysfunction in rats subjected to moderate TBI (Saatman et al. 1997). Previous 
work from our lab also demonstrated that conditional astrocyte-specific overexpression 
of IGF-1 attenuates motor and cognitive dysfunction and reduces hippocampal 
neurodegeneration in CA-3 and the dentate gyrus granular layer at 3 d after severe CCI 
(Madathil 2013). In a phase II clinical trial, brain-injured patients that received IGF-1 by 
intravenous infusion demonstrated improved nitrogen balance and, in a subset of 
patients in which serum IGF-1 concentrations were maintained above 350 ng/ml for 1 
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week, improved outcome at 6 months (Hatton et al. 1997). Only one of these studies 
(Madathil 2013) demonstrated elevated brain levels of IGF-1 and showed that increased 
neuron survival may underlie the observed recovery of neurobehavioral function with 
IGF-1 after TBI. Taken together, these studies suggest that IGF-1 is a viable and 
promising treatment for TBI, and highlight the need for additional preclinical studies to 
evaluate if systemically infused IGF-1 is neuroprotective and contributes to behavioral 
improvement in mice subjected to contusion TBI.  
A dose of 4 mg/kg/d IGF-1 was selected based on a previous study that 
demonstrated this dose improved motor and cognitive function in moderately brain-
injured rats (Saatman et al. 1997). We sought to evaluate if treatment with IGF-1 
improved recovery in motor function during the first week following CCI using the same 
dose that provided behavioral benefit in a rodent contusion TBI model.  We will expand 
on previous work by quantifying levels of IGF-1 in the serum and brain, confirming IGF-1 
signaling in the brain, and determining if treatment with IGF-1 protects against acute cell 
loss. 
In light of the previous observation that overexpression of IGF-1 reduced 
hippocampal neurodegeneration at 3 d following severe CCI, we sought to evaluate if 
systemic infusion of IGF-1 reduced cortical tissue damage and attenuated regional 
hippocampal neurodegeneration at 3 d following severe CCI. Hippocampal 
neurodegeneration is observed in the dentate gyrus granular layer, CA3 and CA1 at 2 
and 3 d following CCI (Anderson et al. 2005; Hall et al. 2005; Saatman et al. 2006; Hall 
et al. 2008; Cai et al. 2012; Zhou et al. 2012). Within the hippocampus, neuronal 
differentiation of progenitor cells in the subgranular zone give rise to new neurons. 
Newborn neurons are generated throughout adulthood in the dentate gyrus subgranular 
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zone of the hippocampus (Eriksson et al. 1998; Zhao et al. 2008). A reduction in the 
number of immature neurons in the hippocampus is associated with reductions in spatial 
learning and memory, suggesting that newborn neurons are critical for cognition 
(Clelland et al. 2009; Deng et al. 2009; Jessberger et al. 2009). Following CCI, the 
number of hippocampal immature neurons is markedly reduced in the dentate gyrus 
granular layer within 3 d of injury (Rola et al. 2006; Gao et al. 2008). We postulated that 
reduced hippocampal neurodegeneration in the granular layer may be indicative of 
enhanced immature neuron survival.  
The data presented in this chapter provides preliminary evidence that prolonged 
continuous systemic infusion of 4 mg/kg/d IGF-1 does not promote improved recovery of 
motor function after severe CCI in mice. Although hIGF-1 could not be detected in the 
brains of treated mice, systemic infusion of IGF-1 enhanced Akt activation in the 
contused brain at 7 d post-injury. However, treatment with IGF-1 showed little efficacy in 
reducing hippocampal neurodegeneration and did not attenuate loss of immature 
neurons at 3 d following CCI.  
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Materials and Methods 
Animals 
 8-12 wk old C57BL/6 male mice utilized for this study were purchased from 
Jackson Laboratories (Bar Harbor, ME). All protocols were approved by the University of 
Kentucky’s Institutional Animal Care and Use Committee in accordance with established 
guidelines from the Guide for the Care and Use of Laboratory Animals from the National 
Institutes of Health. Animals were housed 5 mice per cage in the University of Kentucky 
Medical Center animal vivarium with a 14:10 hr light:dark photoperiod and were provided 
food and water ad libitum; however, food intake was not monitored in the mice utilized in 
this study. 
Controlled Cortical Impact and Minipump Implantation 
The CCI injury was performed as previously described (Madathil et al. 2010; 
Pleasant et al. 2011). Mice were anesthetized with 3% isoflurane to prepare the scalp for 
surgery and for placement in the stereotaxic frame (David Kopf Instruments, CA). 
Anesthesia was maintained with 3% isoflurane via a nose cone for the duration of the 
surgical procedure. A midline incision was created and the skin reflected to expose the 
skull. A 5 mm craniotomy was performed midway between bregma and lambda lateral to 
the sagittal suture over the left hemisphere of the brain. Animals were randomly 
assigned to receive either sham or CCI injury. Sham-injured mice received anesthesia 
and only a craniotomy. In brain-injured mice, the CCI injury was induced using a 
computer-controlled pneumatically driven piston that rapidly impacted the intact dura of 
the brain at 1 mm depth with a velocity of 3.5 m/s using a 3 mm diameter rounded 
impactor tip (TBI-0310 Impactor, Precision Systems and Instrumentation, VA). In the 7 d 
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cohort, mice were subjected to sham injury (n=3/treatment group) or CCI (n=5/treatment 
group) and euthanized at 7 d post-injury for analysis of brain tissue by western blot and 
ELISA. In the 3 d cohort, mice were subjected to CCI (n=5/treatment group) and 
euthanized at 3 d post-injury for histological assessment. Following injury, a small 
circular disk of dental acrylic was adhered to the skull over the craniotomy site and the 
scalp was sutured. At 15 minutes after injury, a small incision was made in the back to 
facilitate subcutaneous implantation of a primed Alzet osmotic minipump (model 1003D 
or 1007D) for the delivery of 4 mg/kg/d recombinant human IGF-1 (hIGF-1; National 
Hormone and Peptide Program, CA) or vehicle (pH 7.4, 100mM acetic acid diluted in 
USP grade PBS) over a period of 3 or 7 d, to provide infusion of hIGF-1 or vehicle until 
the animal was euthanized. Following osmotic minipump implantation, mice were placed 
on a heating pad to maintain normal body temperature. Once ambulatory, the mice were 
returned to their home cage.   
Motor Function Assessment 
 A previously described modified neurological severity score (NSS) (Pleasant et 
al. 2011) task was used to evaluate motor dysfunction at 3 hr, 1, 3, 5, and 7d post-injury. 
At 1 d prior to injury, mice were acclimated to each of four Plexiglas beams of varying 
widths (3, 2, 1, 0.5 cm) and a 0.5 cm diameter wooden rod.  The beams and rod were 60 
cm in length and elevated 47 cm above the table top. Mice were allowed 30 seconds to 
traverse the beams and rod during the periods of acclimation and testing. Each beam 
was assigned a maximum of three points and the rod two points. Three points were 
given for successful crossing of the beam with normal position and utilization of the 
forelimb and hindlimb. Two points were given for successful crossing of the beam 
despite either a forelimb or hindlimb hanging from the beam, and one point was given for 
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crossing the beam despite inverting below the beam one or more times. The mouse was 
righted and allowed to continue across the beam if it became inverted on the beam. A 
score of zero was given if the mouse did not cross in the 30 second time or fell off the 
beam. For the wooden rod, two points was given for successful crossing of the beam in 
the allotted time. A score of one was given for crossing despite inverting greater than 
three times. A score of zero was given if the mouse did not traverse in the allotted time 
or fell off the rod.  
Tissue Collection and Preparation 
At 1 d post-injury, 25 µL of blood was collected from the saphenous vein of mice 
from the 7 d cohort. Blood was collected in an eppendorf tube and allowed to coagulate 
for 30 minutes at room temperature. Collected blood was centrifuged at 4500g for 10 
minutes to separate the serum. Isolated serum was stored at -80°C.  
In the 7 d cohort, mice received an overdose of Fatal-plus (65 mg/kg sodium 
pentobarbital). Blood was collected transcardially with a 22G needle connected to a 1 
mL syringe. To concentrate collection of cortical tissue on the injury site, 3 mm of the 
rostral brain was blocked, and the remaining cortical regions of each hemisphere were 
rapidly dissected and stored in separate tubes at -80°C. Cortical tissue from the injured 
hemisphere was homogenized by wand sonicator in cold lysis buffer (1% triton X-100, 
20 mM Tris-HCl, 150 mM NaCl, 5 mM EGTA, 10 mM EDTA, 10% glycerol, and a cocktail 
of proteinase inhibitors (Roche, IN)) and centrifuged for 30 minutes at 4°C at a speed of 
10,000xg. The supernatants were collected and utilized for analysis. Protein 
concentrations were determined using a BCA assay kit (Pierce Biotechnology, IL). The 
prepared cortical samples were utilized for western blot and ELISA analysis.  
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In the 3 d cohort, mice received an overdose of Fatal-plus (65 mg/kg sodium 
pentobarbital). Mice were transcardially perfused with heparinized saline to clear blood 
from the vasculature. The mice were perfusion fixed using 10% neutral buffered 
formalin. The mice were decapitated and the heads placed in 10% neutral buffered 
formalin for 24 hr. The brains were carefully removed from the head and placed in 10% 
neutral buffered formalin for an additional 24 hr. Brains were placed in 30% sucrose for 
24 hr for cryoprotection prior to freezing in -30°C isopentanes cooled on dry ice. Brains 
were cut into 40 µm coronal sections on a freezing sliding microtome (Microm, Dolbey-
Jamison, PA) at -20°C (Physitemp, NJ).  
Quantification of Human IGF-1 by ELISA 
Concentrations of hIGF-1 were quantified using a highly specific human IGF-1 
ELISA with a sensitivity range of 16 ng/mL to 1137 ng/mL (Immunodiagnostic Systems, 
kit #AC-27F1). The ELISA kit was used in accordance with the kit’s instructions. Serum 
and brain samples were pretreated to dissociate IGF-1 from IGF-1 binding proteins. 
Human IGF-1 standards (16-1137 ng/mL) and pretreated samples were pipetted in 
duplicate into a 96 well plate coated with an antibody specific to hIGF-1. Absorbance of 
each well was measured using a microplate reader (Tecan, NC) at the 450 nm and 540 
nm wavelengths. The absorbance at 540 nm was subtracted from the 450 absorbance to 
account for the background of each well. 
Western Blot 
Western blot analyses were performed as previously described (Madathil et al. 
2010). Electrophoresis was completed using either 20 µg (neurofilament NF68) or 30 µg 
(phosphorylated Akt) of protein supernatant from the injured cortex on a 3-8% Tris-HCl 
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gel running at 150V. After transfer onto nitrocellulose membranes, the membranes were 
blocked for 1 hr in 5% dry milk dissolved in 0.1% Tween 20 diluted in TBS, and 
incubated overnight with either the primary antibody for p-Akt ser473 (rabbit monoclonal, 
1:2000, Cell Signaling Technology, MA), or for NF68 (NR4,  mouse monoclonal, 1:1000, 
Sigma, MO).  Secondary antibodies used were directly conjugated with an infrared dye 
(1:10000 IRDye800CW, Rockland, PA). Membranes were imaged and optical densities 
(OD) were quantified on the Li-Cor Odyssey Infrared Imaging System (Li-Cor 
Biosciences, NE). After p-Akt or NF68 development, the membranes were reprobed for 
actin using a primary antibody for anti-β-actin (mouse monoclonal 1:5000, Calbiochem 
Inc, CA) and a secondary antibody for anti-mouse IgM conjugated to an infrared dye 
(1:10000, Rockland). For quantification, the OD of each p-Akt or NF68 band was 
normalized to its respective actin OD.  
Cresyl Violet and Fluorojade-B Staining 
A parallel set of 40 µm-thick coronal sections (n=10-12/mouse), spaced 400 µm 
apart, were mounted and air-dried on gelatin-coated slides. The slides were hydrated in 
graded ethanol solutions, rinsed in water, stained with 0.5% cresyl violet (Acros 
Organics, NJ), dehydrated through graded ethanol solutions, and cleared in xylenes 
(Fisher Scientific, NJ) prior to mounting with Permount (Fisher Scientific). Three 40 µm-
thick brain sections, 400 µm apart, centered on the injury epicenter, were stained with 
Fluorojade-B (FJB; Millipore Co, MA) to visualize acute hippocampal neurodegeneration 
after injury, as previously described (Pleasant et al. 2011). 
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Immunohistochemistry 
Three 40 µm-thick coronal brain sections, spaced 400 µm apart,  centered on the 
injury epicenter, were stained with doublecortin (DCx) to label immature neurons, using 
standard free floating immunohistochemistry staining protocols, as previously described 
(Cai et al 2012). A primary antibody for DCx (rabbit polyclonal, 1:500, Abcam, MA) and a 
secondary antibody for anti-rabbit IgG directly conjugated to Alexa Fluor® 488 (donkey 
polyclonal, 1:1000, Jackson ImmunoResearch, PA) were utilized to visualize immature 
neurons in the granular layer. Sections were rinsed in TBS and treated with 5% normal 
horse serum with 0.1% Triton-X-100 in TBS for 30 minutes to block nonspecific binding 
sites. The DCx antibody was diluted in blocking solution and the tissue incubated 
overnight at 4°C.  The following day, tissue was rinsed with TBS and incubated with the 
secondary antibody diluted in blocking solution for 1 hr.  Tissue was rinsed with TBS, 
incubated with Hoechst stain (1:10,000, Invitrogen, CA) for 1.5 minutes to label cell 
nuclei and rinsed with TBS. Labeled sections were mounted on gelatin-coated slides, 
coverslipped with Fluoromount (Southern Biotech, AL), and stored at 4°C. 
Image Acquisition and Quantification 
Images of cresyl violet, FJB, and DCx staining were acquired using an AX80 
Olympus microscope (PA). Quantification for FJB and DCx was performed in the upper 
and lower blades of the ipsilateral dentate gyrus granular layer of each section. The 
dentate gyrus granular layer was utilized as an anatomical boundary and served as the 
region of interest for quantification. FJB and DCx positive cells were quantified within 
three sections centered around the injury core, as previously described for the 
quantification of degenerating neurons in the hippocampus (Pleasant et al. 2011). All 
positively labeled cells were manually counted through all focal planes within the 
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granular layer (FJB and DCx), CA3 (FJB) and CA1 (FJB) at 40 x magnification on an 
epifluorescent microscope (Olympus BX51) equipped with a FITC filter (41001, Chroma 
Technology, VT). All quantification was performed by an investigator blinded to the 
treatment and injury conditions of each animal. The DCx cell quantification is expressed 
as a cellular density (cells/mm3) and reflects the summation of positively labeled cells 
counted in the subgranular, inner, and outer granular layers. The Hoechst-stained 
dentate gyrus granular layer was imaged (Olympus, AX80) and area measured using 
ImagePro (MediaCybernetics, MD). The thickness of each section was measured, in 
microns, using an epifluorescent scope (Olympus BX51) equipped with a stereology 
stage. Measurements of granular layer area and thickness were used to calculate the 
granular volume of each section in which quantification was completed.  
Statistical Analysis 
 All data are presented as mean + standard error of the mean (SEM). Analyses of 
hIGF-1 ELISA data and western blot data were performed by one-way analysis of 
variance (ANOVA) and when applicable, the Newman-Keuls post-hoc t-test was used for 
individual comparisons. Cellular counts (FJB and DCx) were analyzed by region using 
Student’s t-tests. Neurological severity score data was analyzed by a repeated 
measures one-way ANOVA. Statistical tests were completed using Statistica (Statsoft 
Inc, OK). A p value less than 0.05 was considered significant for all tests.  
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Results  
 To quantify the levels of hIGF-1 in the brain following systemic infusion of IGF-1, 
we measured the human isoform of IGF-1 in serum collected at 1 and 7 d post-injury 
using a highly-sensitive human-specific ELISA kit. Human IGF-1 was not detected in the 
serum of mice infused with vehicle. Systemic infusion of 4 mg/kg/d hIGF-1 for a period of 
7 d resulted in sustained elevated levels of hIGF-1 in sham-injured and brain-injured 
mice during the infusion period (Fig. 3.1A). The serum concentrations of hIGF-1 in 
sham-injured mice were not significantly different from those measured in brain-injured 
mice. In order to verify that systemically delivered IGF-1 reached the brain, we quantified 
the levels of hIGF-1 in the brain at 7 d post-injury using the same ELISA kit. Human IGF-
1 was not detected in cortical samples from IGF-1-infused sham-injured and brain-
injured mice suggesting that the levels of hIGF-1 in the brain may be lower than the 
detection limits of the ELISA assay.   
As an alternate means of verifying that IGF-1 administered subcutaneously 
reached the brain, we evaluated Akt activation, a downstream mediator of IGF-1 
signaling, as a surrogate measure of hIGF-1 activity in the brain. Western blot analysis 
at 7 d post-injury revealed that brain-injured vehicle-treated mice exhibited a 21% 
increase in cortical Akt activation compared to sham-injured vehicle-treated mice, but 
this did not reach statistical significance (Fig. 3.1B). Brain-injured IGF-1-treated mice 
exhibited a significant 57% increase in cortical Akt activation compared to brain-injured 
vehicle-treated mice (p<0.05; Fig. 3.1B). Infusion of IGF-1 in sham-injured mice resulted 
in only a 38% increase in cortical Akt activation compared to vehicle-treated sham-
injured mice, but this was not statistically significant. These findings highlight that 
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systemic infusion of IGF-1 produced greater Akt activation in the injured brain compared 
to the sham-injured brain. 
To evaluate if systemic infusion of IGF-1 attenuated cortical cell loss after CCI, 
we quantified cortical abundance for neurofilament 68 (NF68), a cytoskeletal protein 
expressed exclusively in neurons, by western blot as an indicator of neuroprotection. 
Brain injury resulted in a 36% decrease in NF68 abundance vehicle-treated mice 
compared to vehicle-treated sham-injured mice, but this was not statistically significant 
(ANOVA p=0.39; Fig. 3.1C). Brain-injured mice treated with hIGF-1 exhibited only a 12% 
decrease in NF68 abundance compared to sham-injured mice treated with hIGF-1, but 
the groups were not significantly different from each other. We were unable to detect a 
brain-injury induced loss of NF68 following severe CCI. Taken together, these data 
demonstrate that systemic infusion of 4 mg/kg hIGF-1 increased systemic circulating 
levels of hIGF-1 and promoted activation of the pro-survival protein Akt at 7 d following 
severe CCI.  
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Figure 3.1: Systemic infusion of human insulin-like growth factor-1 (hIGF-1) for a 
period of 7 d promotes cortical activation of Akt, but does not reduce cortical 
neuron cytoskeletal protein loss after severe controlled cortical impact (CCI). (A) 
Levels of human IGF-1 in the systemic circulation were equivalent on days 1 and 7 of 
the subcutaneous infusion in sham and brain-injured mice, as quantified by human-
specific ELISA. Human IGF-1 was not detected in mice treated with vehicle. (B) 
Systemic infusion of IGF-1 in brain-injured mice significantly enhanced phosphorylation 
of cortical Akt (*p<0.05 compared to all other groups). (C) Brain injury resulted in only a 
modest reduction in abundance of NF68, a neuron-specific cytoskeletal protein, in 
vehicle-treated mice. Treatment with IGF-1 did not significantly alter NF68 abundance 
compared to treatment with vehicle after sham injury or CCI. (n=3 sham-
injured/treatment and n=5 brain-injured/treatment group). 
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 We evaluated if IGF-1 attenuated motor dysfunction in mice after severe CCI 
using a dose of 4 mg/kg/d IGF-1, which was previously reported to improve motor 
function in moderately brain-injured rats (Saatman et al. 1997). Sham-injured mice 
exhibited no significant change in motor function during the 7 d of testing, independent of 
treatment  group (main ANOVA p<0.05, main time effect p<0.05, interaction p<0.05; Fig. 
3.2A). Brain-injured mice, treated with either hIGF-1 or vehicle, showed significant 
impairment in motor function at 3 hr, 1 and 3 d post-injury as compared to their 
respective sham-injured mice (p<0.05, Fig. 3.2A). Systemic infusion of IGF-1 in brain-
injured mice did not result in improved motor function compared to brain-injured mice 
infused with vehicle (p=0.16, Fig. 3.2A). A subsequent follow-up study that evaluated 
acute motor function for 2 d following CCI showed that brain injured mice showed 
significant improvement over time (main time effect p<0.01), but there was no significant 
difference in motor function between mice treated with vehicle or IGF-1 (Fig. 3.2B). This 
data suggest that IGF-1 infusion does improve motor function in mice following severe 
CCI.  
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Figure 3.2: Systemic infusion of human insulin-like growth factor-1 (hIGF-1) did 
not improve recovery of motor function following severe controlled cortical 
impact (CCI). (A) Brain injury produced significant motor dysfunction, as assessed by 
the neurological severity score, at 3 hr, 1 and 3 d post-injury, independent of treatment 
(p<0.001, compared to sham-injury). Treatment with IGF-1 over 7 days did not improve 
recovery of motor function during the week following severe CCI as compared to 
treatment with vehicle. (n=3 sham-injured/treatment group and n=5 brain-
injured/treatment group). (B) Treatment with IGF-1 over 3 days after CCI, in a second 
cohort of mice, did not improve motor function compared to vehicle treatment. 
(n=5/treatment group).  
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 Histological assessment of cell loss by cresyl violet staining revealed that severe 
CCI produced cortical cavitation and loss of subcortical white matter in vehicle-treated 
mice at 3 d post-injury (Fig. 3.3A). Infusion of IGF-1 did not appear to reduce the extent 
of cortical damage or subcortical white matter loss at 3 d following severe CCI. 
Hippocampal neurodegeneration was evaluated at 3 d following CCI, as both 
neurodegeneration and immature neuron loss can be observed at this time within the 
contused hippocampus (Rola et al. 2006; Zhou et al. 2012). Fluorojade-B was utilized to 
quantify the numbers of degenerating neurons in CA-1, CA-3 and in the dentate gyrus at 
3 d after CCI. Representative images show Fluorojade-B positive cells within the 
granular layer of the contused hemisphere (Fig. 3.3B). The abundance of degenerating 
neurons did not appear to differ between mice treated with IGF-1 or vehicle after CCI 
(Fig. 3.3B). Regional quantification of Fluorojade-B positive cells in the injured 
hippocampus indicated that treatment with IGF-1 reduced the total number of 
degenerating neurons by 21% compared to treatment with vehicle, but this did not reach 
statistical significance (p=0.13; Fig. 3.3C, inset). Regional assessment of the numbers of 
Fluorojade-B positive cells in the granular layer and CA3 and CA1 pyramidal layers 
revealed that the greatest number of degenerating neurons were located in the granular 
layer (Fig. 3.3C).  The dentate gyrus granular layer was also the region with the greatest 
reduction in the number of Fluorojade-B positive cells following treatment with IGF-1, 
with a 25% decrease compared to vehicle treatment; however, this decrease was not 
statistically significant (p=0.08; Fig. 3.3C).   
Because immature neurons within the SGZ of the dentate gyrus have been 
reported to be most vulnerable to TBI, immature neuron density was quantified in the 
injured granular layer at 3 d post-injury to evaluate if IGF-1 promoted the survival of this 
particular subpopulation of cells. Qualitative and quantitative analysis indicated that 
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treatment of IGF-1 did not increase the density of immature neurons in the injured 
granular layer at 3 d following severe CCI (Fig. 3.4D, E). 
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Figure 3.3: Systemic infusion of human insulin-like growth factor-1 (hIGF-1) does 
not reduce tissue damage or regional cell loss at 3 d following severe controlled 
cortical impact (CCI). (A) Cortical cavitation and subcortical white matter damage were 
comparable in vehicle-treated and IGF-1-treated mice at 3d after severe CCI. Scale bar 
represents 500 µm. (B) Representative images of CCI-induced hippocampal 
neurodegeneration as detected by Fluorojade-B staining in the dentate gyrus granular 
layer (DG). Scale bar represents 50 µm. (C) Quantification of Fluorojade-B positive cells 
in the DG granular layer and CA3 and CA1 pyramidal layers. Inset shows the summation 
of numbers of degenerating neurons within all three regions. (D, E) Representative 
images of doublecortin (DCx) immunostaining (D) and quantification of immature neuron 
density in the injured granular layer of the dentate gyrus after injury (E). Scale bar 
represents 100 µm. (n=5 brain-injured/treatment group). Granular layer (GL) and Hilus 
(H). 
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Discussion  
 In this chapter, we demonstrated that systemic infusion of 4 mg/kg/d hIGF-1 for a 
period of 7 d resulted in sustained elevated levels of hIGF-1 in the serum. Levels of 
hIGF-1 were not detectable in the brain, but we found that systemic infusion of hIGF-1 
promoted the activation of Akt in the contused brain. We were unable to detect an injury-
induced loss in the abundance of cortical NF68 at 7 d following CCI. We also 
demonstrated that continuous systemic infusion of hIGF-1 did not significantly reduce 
acute hippocampal neurodegeneration or increase hippocampal immature neuron 
density at 3 d post-injury.  
 The short 10-30 minute half-life of IGF-1 (Baxter and Martin 1989; Guler et al. 
1989) poses a substantial obstacle for achieving sustained elevations of IGF-1 in 
systemic circulation after a systemic bolus injection of IGF-1. We demonstrated that 
prolonged continuous systemic infusion of IGF-1 established and sustained elevated 
serum levels of IGF-1 for the duration of the infusion. Findings from a phase II clinical 
trial showed that IGF-1-treated brain-injured patients who achieved systemic 
concentrations of IGF-1 above 350 ng/mL exhibited improved metabolic health and 
improved outcome (Hatton et al. 1997). Quantification of hIGF-1 in the current study 
revealed that prolonged systemic infusion produced sustained concentrations of at least 
150 ng/mL of hIGF-1 during the infusion period. Endogenous physiological levels of IGF-
1 in naïve C57/BL6 mice are reported to be approximately 250 ng/mL (Yuan R 2013), 
suggesting that summation of exogenous hIGF-1 and endogenous IGF-1 may have 
achieved the therapeutic concentration of 350 ng/mL IGF-1 in systemic circulation for the 
duration of the infusion. However, we did not measure endogenous levels of IGF-1 in the 
current study. Additional work will need to be completed to understand if exogenous 
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administration of 4 mg/kg/d of IGF-1 for a period of 7 d modulated the production of 
endogenous IGF-1 or resulted in a down regulation of IGF binding protein 3 as was 
observed in the phase II clinical trial for TBI (Hatton et al. 1997). Similar to the findings 
reported after intravenous infusion of IGF-1 in brain-injured patients (Hatton et al. 1997), 
we have shown that prolonged subcutaneous infusion of hIGF-1 resulted in sustained 
elevations in IGF-1 for 7 d following infusion. 
Large proteins, including growth factors, do not normally gain access to the brain 
parenchyma due to exclusion by the intact blood-brain barrier. Blood-brain barrier 
breakdown, as observed after severe CCI (Baldwin et al. 1996), should greatly facilitate 
growth factor delivery to the brain following severe contusive TBI. Breakdown of the 
blood-brain barrier after severe CCI is biphasic as a first phase occurs between 5 
minutes and 3 hours and a second phase is observed in the injured hippocampus 
between 1 and 2 d following severe CCI (Baldwin et al. 1996). However, growth factor 
based treatment strategies may require prolonged delivery to stimulate regenerative or 
reparative effects in the injured brain, including include periods of time after the blood-
brain barrier is repaired, thereby limiting the movement of growth factors into the brain. 
Moreover, damage to the blood-brain barrier may be less pronounced and shorter in 
duration after mild and diffuse brain injuries, limiting the utility of many growth factors for 
treatment of these types of injuries.  However, IGF-1 is known to be transported across 
the intact blood-brain barrier by receptor-mediated endocytosis (Pardridge 1993; 
Reinhardt and Bondy 1994). The ability of IGF-1 to cross the intact blood-brain barrier 
affords clinical applicability of IGF-1 across the spectrum of injury severity of TBI.  
Despite prolonged elevation in the serum levels of hIGF-1, exogenous IGF-1 was 
undetectable in the brains of uninjured or injured mice. The undetectable levels of 
exogenous IGF-1 in the brain could suggest that IGF-1 did not gain enter the brain; 
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however, we showed that treatment with IGF-1 increased activation of Akt, a 
downstream mediator of IGF-1 signaling. This finding suggests that low levels of 
exogenous IGF-1 entered the brain at 7 d post-injury, a time when the blood-brain 
barrier has resealed (Baldwin et al. 1996). It is possible that we would have detected 
exogenous IGF-1 in the injured brain during periods of compromised blood-brain barrier 
integrity, including the first 3 hours and between 1 and 2 following CCI. Alternative 
methods of detection and quantification, i.e. radiolabeled IGF-1 and high performance 
liquid chromatography/mass spectroscopy, may afford increased sensitivity to quantify 
lower levels of hIGF-1 in the brain. Additional work is also needed to define the temporal 
prolife of changes in the levels of exogenous IGF-1 in the serum and brain after 
prolonged infusion and in the context of brain injury.   
 Although exogenous IGF-1 was not detectable in the cortex of mice subjected to 
sham injury or severe CCI, systemic infusion of IGF-1 enhanced cortical activation of Akt 
following severe CCI, suggesting that exogenous IGF-1 entered the brain and promoted 
the activation of IGF-1 signaling. Binding of IGF-1 to its cognate receptor promotes the 
activation of Akt, a potent pro-survival and anti-apoptotic signal that blunts caspase-3 
and 9 and NF-kB cell death-promoting actions (Fukunaga and Kawano 2003; Brywe et 
al. 2005). Enhanced Akt activity is associated with improved neuron survival while, 
conversely, blunted Akt phosphorylation increases neuron susceptibility to death in the 
context of CNS injury (Noshita et al. 2001; Noshita et al. 2002). Experimental TBI results 
in an acute increase in downstream mediators of endogenous IGF-1 signaling, including 
Akt activation, but these elevations are not sustained after CCI (Zhang et al. 2006; 
Madathil et al. 2010). We demonstrate that brain injury did not increase Akt activation in 
vehicle-treated mice at 7 d post-injury. Treatment of IGF-1 resulted in a small increase in 
Akt activation in sham-injured mice; however, treatment of IGF-1 resulted in a robust 
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significant increase in Akt phosphorylation in brain-injured mice. Enhanced activation of 
Akt following CCI corroborates our hypothesis that systemic infusion of IGF-1 increases 
brain levels of IGF-1 and that breakdown of the blood-brain barrier may facilitate 
increased exposure of circulating IGF-1 in the contused brain parenchyma. Additional 
experiments need to determine if systemic infusion of IGF-1 after CCI results in 
widespread activation of Akt throughout the contused hemisphere, including the 
hippocampus. The levels of phosphorylated Akt need to be quantified in the injured 
hippocampus to determine if lower levels of Akt activation accompany limited reductions 
in neurodegeneration in the hippocampus at 3 d following severe CCI.  While this study 
demonstrates enhanced Akt activation at 7 d post-injury, additional studies also need to 
evaluate the acute time course of Akt phosphorylation following the initiation of 
systemically infused IGF-1. These studies will provide valuable insight into the kinetic 
prolife of IGF-1-mediated Akt activation in the contused cortex acutely following CCI.  
Systemic administration of IGF-1 accelerates recovery of motor function and 
reduces cognitive impairments in rodent models of mild and moderate TBI (Saatman et 
al. 1997; Rubovitch et al. 2010). Previous work from our lab demonstrated that repeated 
systemic injections of 1 mg/kg hIGF-1 significantly improved motor function beginning 5 
days after the initiation of IGF-1 treatment in rats subjected to moderate fluid percussion 
injury (Saatman et al. 1997). Moreover, systemic infusion of 4 mg/kg/d hIGF-1, the same 
dose utilized in our current study, was previous shown to significantly improve motor 
function at 2 weeks post-injury in moderately brain injured rats (Saatman et al. 1997). In 
our current study, systemic infusion of 4 mg/kg/d IGF-1 did not attenuate motor 
impairment during the week following severe CCI. The findings reported by Saatman et 
al. (1997), suggested that prolonged treatment with IGF-1 may promote delayed 
recovery of motor function beginning nearly 1 week post-injury. In our current study, 
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brain-injured mice exhibited spontaneous recovery of motor function, and did not exhibit 
motor impairments after 3 d post-injury. Future studies may need to incorporate 
additional behavioral tasks that are more sensitive at detecting motor dysfunction in mice 
after brain injury. Alternatively, we may need to incorporate more sensitive assessments 
of neurobehavioral function, including cognition, as a recent study by Rubovitch et al. 
(2010) demonstrated that IGF-1 significantly improved performance in a Y maze 
cognitive task in mice subjected to mild weight drop brain injury. Future studies will need 
to incorporate assessments of motor and cognition function to evaluate the efficacy of 
IGF-1 to attenuate neurobehavioral dysfunction after severe CCI. 
Treatment with IGF-1 reduces apoptosis and enhances cell survival in a variety 
of in vitro and in vivo models of CNS injury (Russell et al. 1998; Brywe et al. 2005; Zhu 
et al. 2008; Hollis et al. 2009).  Administration of IGF-1 following hypoxic-ischemic injury 
produces improvements in neurobehavioral function that are concomitant with reduced 
apoptosis and survival of neurons (Guan et al. 2001; Brywe et al. 2005; Lin et al. 2009). 
The CCI model of experimental TBI is a reproducible and well-characterized model that 
produces regional neurodegeneration and loss of cortical and hippocampal neurons 
following contusion (Smith et al. 1995; Anderson et al. 2005; Saatman et al. 2006; 
Pleasant et al. 2011). In the current study, cresyl violet staining revealed that severe CCI 
produced cortical cavitation and subcortical white matter loss in vehicle-treated mice at 3 
d post-injury. Continuous systemic infusion of IGF-1 did not appear to reduce cortical 
tissue damage or loss of the subcortical white matter. Following CCI, acute cleavage 
and sustained cortical breakdown of neurofilament 68, expressed exclusively in neurons, 
is observed within 3 hr and sustained for at least 2 weeks post-injury and is indicative of 
pathological proteolysis associated with neuronal death (Posmantur et al. 1994). 
Quantification of NF68 in the cortex of vehicle-treated mice after CCI revealed a small, 
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but non-significant reduction in the abundance of intact NF68 compared to vehicle-
treated mice after sham injury, highlighting that we were unable to detect injury-induced 
loss using a well-established indicator of cortical cell loss. Moreover, at 3 d post-injury 
we observed cortical cavitation consistent with severe CCI, suggesting that our inability 
to detect a reduction in NF68 abundance after CCI may be reflective of the small group 
sizes. Similar to our findings for the quantification of hippocampal neurodegeneration, a 
power analysis revealed that 7 animals are required to achieve statistical significance. 
We observed an apparent increase in NF68 abundance in brain-injured mice treated 
with IGF-1 compared to brain-injured mice treated with vehicle, but our observations 
from the cresyl violet staining suggests that IGF-1 may not significantly attenuate cortical 
cell loss. Future studies, using appropriately sized groups, need to demonstrate that 
severe CCI produces significant reductions in NF68 abundance in order to subsequently 
evaluate the efficacy of systemically infused IGF-1 to attenuate reductions in cortical 
NF68 abundance after brain injury.  
Of the few studies that have evaluated the efficacy of IGF-1 to improve 
neurobehavioral function in the context of brain injury (Saatman et al. 1997; Rubovitch et 
al. 2010), only one study has evaluated if IGF-1-mediated neuroprotection contributes to 
the improved neurobehavioral performance after TBI (Madathil 2013). Previous work 
from our lab has demonstrated that conditional astrocyte-specific overexpression of IGF-
1 in the injured mouse brain reduces neurodegeneration in the dentate gyrus, but not 
CA3 at 3 d following severe CCI (Madathil 2013). In the current study, quantification of 
regional hippocampal neurodegeneration revealed that systemic infusion of IGF-1 
resulted in a small, but non-significant reduction in the number of degenerating neurons 
in the granular layer. We did not observe a notable reduction in the number of 
degenerating neurons in CA3, similar to findings previously reported from our lab in IGF-
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1 overexpressing mice subjected to severe CCI (Madathil 2013). Our study utilized 5 
brain-injured mice per treatment group. A power analysis using the data acquired from 
the quantification of degenerating neurons in the granular layer at 3 d post-injury 
indicated that 9 mice are required in each treatment group to achieve statistical 
significance. The results of this power analysis are reasonable considering the IGF-1 
overexpressing mouse study reported a significant reduction in the number of 
degenerating neurons in the granular layer with 8 brain-injured mice per genotype group 
(Madathil 2013). Quantification of hippocampal neurodegeneration by Fluorojade-B at a 
single time point provides only an assessment of neurodegeneration at that moment 
after brain injury and does not provide insight into a possible modulation of the temporal 
progression of neurodegeneration. Future studies may need to evaluate hippocampal 
neurodegeneration and neuron survival at multiple time points, including hours and days 
after severe CCI to determine if IGF-1 modulates the time course of neurodegeneration 
after injury. Our findings warrant future studies, using appropriately sized groups, to 
evaluate the efficacy of systemically infused IGF-1 to attenuate hippocampal 
neurodegeneration following severe CCI. 
Indicators of hippocampal neurodegeneration, including Fluoro-jade-B, are 
observed within the granular layer of the dentate gyrus in the days following CCI (Gao et 
al. 2008; Hall et al. 2008; Cai et al. 2012; Zhou et al. 2012). Fluorojade-B has been 
shown to colocalize with doublecortin, a marker of immature neurons, in the subgranular 
zone at 24 hr following moderate CCI. Several studies highlight that immature neurons 
are selectively vulnerable to CCI, and consequently, the density of immature neurons is 
greatly reduced by 3 d post-injury (Rola et al. 2006; Gao et al. 2008; Yu et al. 2008). We 
postulated that reductions in hippocampal neurodegeneration in the granular layer may 
be indicative of improved immature neuron survival. In the current study, we 
105 
 
demonstrate that systemic infusion of IGF-1 did not reduce hippocampal immature 
neuron loss in the granular layer after CCI. This suggests that IGF-1 may not promote 
the acute survival of immature neuron at 3 d post-injury. Additional work is needed to 
identify if Fluorojade-B colocalizes predominantly with markers of immature or mature 
neurons in the context of severe CCI. Subsequent to the acute loss of immature 
neurons, there is a recovery of immature neurons in the weeks following CCI (Rola et al. 
2006; Yu et al. 2008). Considering IGF-1 has been shown to promote neurogenesis by 
increasing cellular proliferation and enhancing neuronal differentiation (Arsenijevic and 
Weiss 1998; Aberg et al. 2000; Brooker et al. 2000; Arsenijevic et al. 2001), future 
studies will evaluate the efficacy of IGF-1 to promote post-traumatic neurogenesis in the 
hippocampus following severe CCI.  
The modest neuroprotective effects of IGF-1 observed in quantification of 
hippocampal neurodegeneration, immature neuron density, and cytoskeletal protein 
levels in cortical neurons after prolonged systemic infusion may be related to delayed 
increases in levels of IGF-1 in the contused brain. We have previously demonstrated 
that vascular compromise occurs within 1 hr in the cortex and between 1 and 4 hr in the 
hippocampus following severe CCI with a rounded tip (Pleasant et al. 2011). Guan et al. 
(2000) demonstrated that delayed central administration of IGF-1 for 2 hr, but not 6 hr 
protected against cortical cell loss in rats subjected to hypoxic-ischemic injury. It is 
possible that delayed elevations in brain levels of IGF-1 reduce the acute 
neuroprotective capacity of IGF-1. As mentioned previously, additional studies to 
evaluate the acute prolife of IGF-1 signaling after systemic administration will provide 
valuable information about the capacity of IGF-1 to promote neuron survival. The 
efficacy of IGF-1-mediated mechanisms of plasticity, including enhancement of post-
traumatic neurogenesis, may not be dependent upon acute accumulations of IGF-1 in 
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the injured brain. Future studies will investigate if IGF-1 enhances post-traumatic 
neurogenesis to accelerate recovery of immature neurons lost after brain-injury.   
The dose of 4 mg/kg/d IGF-1 was selected to evaluate the efficacy of IGF-1 to 
attenuate neurobehavioral impairment and hippocampal neuron loss following severe 
CCI in the mouse. Previously, this dose significantly enhanced recovery of motor 
function and significantly improved learning and memory in the Morris water maze task 
at 2 weeks post-injury in rats subjected to moderate TBI (Saatman et al. 1997). 
Moreover, this dose promoted regeneration and recovery of function after sciatic nerve 
crush injury (Contreras et al. 1995). While the largely negative effects observed with 
infusion of 4 mg/kg/d hIGF-1 might argue for testing higher doses, systemic infusion of 
doses higher than 4 mg/kg/d hIGF-1 should be avoided as continuous infusion of 8 
mg/kg/d hIGF-1 produced undesirable side effects including prolonged hypoglycemia, 
weight loss and increased mortality in brain-injured rats (Saatman et al. 1997). 
Moreover, prolonged hypometabolism occurs within hours of experimental TBI, and 
potentiation of metabolic depression in the brain by high levels of circulating IGF-1 could 
exacerbate injury pathology (Yoshino et al. 1991; Dietrich et al. 1994). Because systemic 
administration of exogenous IGF-1 at 4mg/kg/d appeared to result in very low brain 
levels of IGF-1, in Chapter 4 central infusion of hIGF-1 will be utilized to accelerate and 
maximize delivery of IGF-1 to the contused brain, in an effort to attenuate motor and 
cognitive impairments, and increase immature neuron density after severe CCI. 
 In this chapter, we have demonstrated that prolonged systemic infusion of IGF-1 
enhanced a pro-survival signaling cascade in the injured brain, but did not reduce 
cytoskeletal protein loss in cortical neurons and hippocampal neurodegeneration. IGF-1 
did not improve recovery of motor function in mice subjected to severe CCI. The work 
presented in this chapter demonstrates that additional preclinical work is required to 
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identify the appropriate administration paradigm and to more comprehensively evaluate 
acute and long-term efficacy of IGF-1 to promote recovery after TBI.  
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Chapter 4: Central Infusion of IGF-1 Improves Neurobehavioral Function and 
Increases Immature Neuron Density following Controlled Cortical Impact 
Introduction 
 In Chapter 3, we evaluated the efficacy of systemic administration of recombinant 
human IGF-1 (hIGF-1), using a dose previously shown to improve functional outcome in 
a rat model of TBI (Saatman et al. 1997), to promote recovery of motor dysfunction and 
reduce hippocampal neuron loss after CCI in mice. We found that the dose of 4 mg/kg/d 
resulted in undetectable levels of hIGF-1 in the brain, but increased activation of Akt in 
the cortex suggesting that brain levels of IGF-1 were elevated following systemic 
administration of IGF-1. Systemic administration of hIGF-1 over a period of 3 or 7 d post-
injury did not improve recovery of motor function. We also demonstrated that systemic 
administration of hIGF-1 for 3 d was not sufficient to reduce the cortical contusion size, 
hippocampal neurodegeneration or loss of hippocampal immature neurons after severe 
CCI. 
 Therefore, we postulated that central infusion of hIGF-1 into the lateral ventricle 
would elevate levels of IGF-1 in the brain acutely after injury, above the levels achieved 
with systemic infusion, and minimize potential side effects associated with using doses 
higher than 4 mg/kg/d for systemic administration of IGF-1. Central administration of 
IGF-1 has been utilized as a treatment strategy in models of CNS neurodegeneration. 
Central infusion of IGF-1 reduced the loss of Purkinje cells and inferior olive neurons and 
reduced motor coordination impairments associated with cerebellar ataxia (Fernandez et 
al. 1998; Tolbert and Clark 2003). IGF-1 also promoted improved spatial memory 
following kainic acid-induced cognitive impairment in mice (Bluthe et al. 2005). 
Moreover, intracerebroventricular infusion of IGF-1 reduced striatal lesion volume 
following injections of quinolinate in a rat model of Huntington’s disease (Escartin et al. 
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2004). Intracerebroventricular injections or prolonged infusion of IGF-1 has also been 
shown to reduce infarct areas and promote the survival of neurons (Guan et al. 1993; 
Guan et al. 2000; Brywe et al. 2005; Zhu et al. 2008; Selvamani and Sohrabji 2010) and 
improve neurological function after hypoxic-ischemic injury (Guan et al. 2001; Schabitz 
et al. 2001). Collectively, these studies highlight that administration of IGF-1 directly into 
the brain has therapeutic efficacy in promoting neurobehavioral recovery in models of 
neuronal degeneration and CNS acute injury. However, the therapeutic efficacy of 
centrally infused IGF-1 to attenuate neurobehavioral impairment has not been evaluated 
in the context of TBI. 
 Intracerebroventricular administration has been utilized to evaluate the 
effectiveness of multiple neuroprotective compounds (Fink et al. 1999; Wang et al. 2012) 
and anti-inflammatory agents (Toulmond and Rothwell 1995; Jones et al. 2005; 
Marklund et al. 2005; Byrnes et al. 2012) after experimental TBI. Intracerebroventricular 
administration of neurotrophic or neurotrophic-like factors, including S100B, vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF), and basic fibroblast 
growth factor (bFGF), has also been utilized to evaluate improvements in 
neurobehavioral function or alterations in post-traumatic neurogenesis following 
experimental TBI (Kleindienst et al. 2005; Sun et al. 2009; Sun et al. 2010; Thau-
Zuchman et al. 2010; Thau-Zuchman et al. 2012). Central infusion of therapeutic agents 
represents a clinically relevant route of administration for severe brain-injured patients 
requiring intracranial pressure shunts or decompressive craniotomies. Ideally therapeutic 
agents demonstrating efficacy after central administration also need to be evaluated 
using systemic administration in order to translate their application to TBIs of reduced 
severity that do not necessitate an opening of the skull or dura. In this regard, IGF-1 is a 
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unique therapeutic agent as systemic administration is a viable route of administration 
after TBI, as described in Chapter 2.  
 Hippocampal immature neurons are selectively vulnerable to brain injury with 
marked progressive immature neuron loss within hours and days following CCI (Rola et 
al. 2006; Gao et al. 2008). Brain injury also initiates an endogenous self-renewal process 
that promotes the slow recovery of immature neurons via increased proliferation of 
progenitor cells in the subgranular zone of the dentate gyrus granular layer (Dash et al. 
2001; Chirumamilla et al. 2002; Rola et al. 2006). The majority of newly proliferated cells 
will become glial cells after CCI, but a minority of the proliferated cells will adopt a 
neuronal phenotype after injury (Rola et al. 2006; Gao and Chen 2013). Immature 
neurons generated after injury have been shown to integrate anatomically into the 
granular layer and project to CA-3 (Emery et al. 2005; Sun et al. 2007) and express 
synaptic markers at 10 weeks post injury in rats subjected to moderate fluid percussion 
injury (Sun et al. 2007). However, only a portion of the newly generated immature 
neurons will survive to develop into mature granular neurons and integrate into the 
hippocampus (Sun et al. 2005; Sun et al. 2007). Central infusion of bFGF or VEGF has 
been shown to promote post-traumatic proliferation and increase the generation of 
newborn neurons without altering neuronal differentiation (Sun et al. 2009; Thau-
Zuchman et al. 2010; Thau-Zuchman et al. 2012). While the efficacy of IGF-1 to promote 
neurogenesis after TBI has not been evaluated, several studies demonstrate that 
administration of IGF-1 increases neurogenesis by promoting cellular proliferation and 
neuronal differentiation (Arsenijevic and Weiss 1998; Aberg et al. 2000; Brooker et al. 
2000; Arsenijevic et al. 2001; Trejo et al. 2001).  
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In this chapter we evaluate the efficacy of intracerebroventricular infusion of IGF-
1 to improve motor and cognitive function during the first week following severe CCI in 
mice. In Chapter 3, we showed that IGF-1 did not appear to promote the survival of 
immature neurons at 3 d following CCI. In the current study, we assess immature neuron 
density at 7 d post-injury, a time point at which the rate of new neurons being born is 
increased in the injured hippocampus, to evaluate the efficacy of IGF-1 to increase 
immature neuron density after CCI.  
112 
 
Materials and Methods 
Animals 
All experimental protocols were approved by the University of Kentucky 
Institutional Animal Care and Use Committee in accordance with the established 
guidelines from the Guide for the Care and Use of Laboratory Animals from the National 
Institutes of Health. Animals were housed 5 mice per cage in the University of Kentucky 
Medical Center animal vivarium with a 14:10 hr light:dark photoperiod and provided food 
and water ad libitum, but food consumption was not monitored in the mice utilized for 
this study. Adult male C57/BL6 mice aged 8-10 weeks, weighing 25-30 g, were utilized 
for all experiments.  
Controlled Cortical Impact and Central Infusion of Human IGF-1 
Mice were anesthetized using 3% isoflurane for preparation of the scalp and 
placement in the stereotaxic frame (David Kopf Instruments, CA) and anesthesia was 
maintained via nose cone for the duration of the surgery. An incision was made on the 
midline of the scalp to expose the skull. A 5 mm craniotomy was completed midway 
between bregma and lambda, lateral to the sagittal suture on the left hemisphere of the 
skull with the dura left intact. Sham-injured animals received anesthesia and only a 
craniotomy. CCI injury was performed with a computer-controlled pneumatically driven 
piston to rapidly and transiently (500 msec) impact the exposed dura of the brain (TBI-
0310 Impactor, Precision Systems and Instrumentation, VA). The CCI injury was 
produced by a 1 mm impact depth at a velocity of 3.5 m/s using a 3 mm diameter 
rounded impactor tip. Animals were randomly assigned to either sham injury or brain 
injury and treatment with either vehicle or recombinant human IGF-1 (hIGF-1) in each of 
the studies detailed below.  
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Central Infusion of IGF-1 
While the mouse was anesthetized, a cannula was placed in the lateral ventricle 
at 15 minutes following sham injury or CCI through a burr hole (AP -0.5 mm bregma, ML 
-1.0 mm, DV -3.0 mm; Paxinos and Franklin 2001) in the hemisphere contralateral to the 
site of injury. The cannula (brain infusion kit 3, Alzet, CA) was attached to an osmotic 
minipump (model 1007D, 1002, or 1004, Alzet, CA) for continuous 
intracerebroventricular (i.c.v.) infusion for a period of 7 d. Minipumps were primed in a 
37°C water bath for at least 6 hr prior to surgical implantation, with the exception of the 
delayed treatment study, in which an approximately 6 hr delay in treatment initiation was 
achieved via implantation of a non-primed minipump. The base of the cannula was 
secured to the skull using an instant adhesive (Loctite 454, Alzet, CA) and a set screw 
(MX-0090-01F-C; AmazonSupply.com, WA) was placed adjacent to the base of the 
cannula with a small amount of dental acrylic. The minipump was positioned in the 
subcutaneous space over the scapula of the back, lateral to the spine. The mice 
exhibited no observable impairment in mobility as a result of the location of the 
minipump. The minipumps were filled with 0.026, 0.085, 0.26, or 0.85 mg/mL 
recombinant hIGF-1 to deliver 0.3, 1, 3, or 10 µg/d; National Hormone and Peptide 
Program, CA) or vehicle (pH 7.4, 24 mM acetic acid diluted in USP grade PBS). The 
doses of IGF-1 utilized in this study were extrapolated from previous studies that 
demonstrated efficacy of IGF-1 to attenuate somatosensory impairment and reduce cell 
loss after cerebral hypoxic-ischemia (Guan et al. 1993; Zhu and Auer 1994; Guan et al. 
2001; Selvamani and Sohrabji 2010), reduce cell loss in a model of Huntington’s disease 
(Escartin et al. 2004), and promote hippocampal neurogenesis (Trejo et al. 2001). 
Following cannula implantation, a small circular disk of dental acrylic was adhered to the 
skull over the craniotomy site, the scalp was sutured, and the mouse was placed on a 
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heating pad to maintain normal body temperature. All mice received a subcutaneous 
injection of 1 mL of sterilized saline to prevent dehydration from the surgical procedure 
and implantation of the minipump. Once ambulatory, the mice were returned to their 
home cage.   
Study 1 (Effects of 10 µg/d hIGF-1 Infusion on Behavior and Hippocampal Neuron 
Survival) 
Sham-injured (n=10 per treatment group) and brain-injured mice (n=19 per 
treatment group) received central infusion of either 10 µg/d hIGF-1 or vehicle for 7 d 
post-injury at a flow rate of 0.5 µL/hr (Alzet minipump model 1007D). Blood from non-
fasted mice was collected onto test strips via tail prick by a 25G needle and glucose 
levels measured using a handheld glucometer (Onetouch Ultra, CA) prior to anesthesia, 
and at 90 minutes, 1 d and 7 d post-injury. Motor and cognitive deficits were assessed 
during the week following injury by a modified neurological severity score (NSS) and 
novel object recognition (NOR) task, respectively, as described below. At 7 d post-injury, 
mice received an overdose of Fatal-plus (65mg/kg sodium pentobarbital, Vortech MI), 
and blood was collected by transcardial puncture for measurement of serum hIGF-1. 
Mice were randomized into one of two groups to be utilized for quantification of hIGF-1 
and Akt activation by ELISA and western blot, respectively (n=5 sham-injured per 
treatment group and n=9 brain-injured per treatment group), or for cresyl violet 
histological and immature neuron immunohistochemical assessments (n=5 sham-injured 
per treatment group and n=10 brain-injured per treatment group), as described below. 
Accurate placement of the cannula in the contralateral ventricle was determined in the 
histology cohort by visual verification of the needle track during coronal sectioning of the 
brain. As a result, two animals (n=1 Sham vehicle, n=1 Sham IGF-1) were excluded from 
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the histological cohorts for inaccurate placement of the cannula. Cannula placement 
could not be verified in brains utilized for western blot and ELISA. If an animal was 
excluded for inaccurate cannula placement, it was excluded from all outcome measures 
including blood glucose measurements, neurobehavioral assessments and cellular 
quantification.  
Study 2 (Effects of 10 µg/d hIGF-1 on Regional Cerebral Edema) 
Mice were subjected to CCI and received no cannulation (n=6), or i.c.v infusion of 
either 10 µg/d hIGF-1 (n=6) or vehicle (n=6) for 7 d via osmotic minipump (model 
1007D). At 7 d post-injury, mice received an overdose of Fatal-plus and were euthanized 
by decapitation. The ipsilateral and contralateral cortical and hippocampal regions were 
rapidly dissected for quantification of water content using the wet weight/dry weight 
method (Stewart-Wallace 1939, Sun 2003 J Neurosurg, Whalen 2000 J Leuko Biol). 
Each brain sample was weighed on an aluminum foil packet to acquire the wet weight 
immediately following dissection. Samples were dried in a desiccating oven at 70°C for 
24 hr, and re-weighed to acquire the dry weight. The percent water content was 
calculated as (wet weight – dry weight) / wet weight x 100.  
Study 3 (Delayed Onset of hIGF-1 Infusion) 
Mice were subjected to 1 mm CCI and infused with either 10 µg/d IGF-1 (n=5) or 
vehicle (n=3) beginning 6 hr post-injury via implantation of a nonprimed minipump at 15 
minutes post-injury. Histological assessment and quantification of immature neuron 
density were performed at 7 d post-injury. No animals were excluded from this study.  
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Study 4 (Dose Response for hIGF-1) 
Mice subjected to CCI brain injury were randomized to receive infusion of 0.3, 1, 
3, or 10 µg/d of hIGF-1 (n=5 per dose) or vehicle (n=4) beginning 15 minutes post-injury 
for a period of 7 d (minipump model 1007D). Histological assessment and quantification 
of immature neuron density was performed at 7 d post-injury. No animals were excluded 
from this study.  
Study 5 (Effect of Changing Infusate Flow Rate in Sham-injured Mice) 
Mice were subjected to sham injury (n=5 per flow rate) and infused with vehicle, 
beginning 15 minutes post-injury, for 7 d. Differential volumes of vehicle solution were 
introduced into the brain by utilization of osmotic minipumps with different flow rates 
(model 1002: 0.25 µL/hr; model 1004: 0.11 µL/hr). Histological assessment was 
performed at 7 d post-injury and data were compared to that from sham-injured mice 
(n=4) infused with vehicle at 0.5 µL/hr from Study 1. No animals were excluded from this 
study. 
Study 6 (Efficacy of 3 µg/d hIGF-1 Infused at a Reduced Rate) 
Sham-injured (n=4 per treatment) and brain-injured mice (n=8 per treatment) 
were infused with 3 µg/d hIGF-1 or vehicle beginning 15 minutes post-injury for 7 d at a 
flow rate of 0.11 µL/hr (minipump model 1004:). At 4 d after injury, a peak time of post-
traumatic cellular proliferation, mice received three injections of 50 mg/kg (i.p.) 5-bromo-
2-deoxyuridine (BrdU, Fisher Scientific, NJ) given at 4 hr intervals to label proliferating 
cells. Histological assessment and quantification of immature neuron and proliferating 
cell densities were performed at 7 d post-injury. Two animals (n=1 vehicle CCI, n=1 
hIGF-1 CCI) were excluded for inaccurate cannula placement. 
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Motor Function Assessment Using a Modified Neurological Severity Score (NSS) 
A previously described modification of the NSS task (Pleasant, Carlson 2011) 
was utilized to assess motor dysfunction at 3 hr, 1, 3, 5, and 7 d post-injury. At 24 hr 
prior to injury, mice were acclimated to each of four Plexiglas beams of varying widths 
(3, 2, 1, 0.5 cm) and a 0.5 cm diameter wooden rod. The beams and rod were 60 cm in 
length and elevated 47 cm above a table top. Mice were given 30 seconds to traverse 
the beams and rod during both acclimation and testing. Each beam was assigned a 
maximum of three points. Three points were given for successful crossing of the beam 
with normal position and usage of the forelimb and hindlimb. Two points were given for 
successful crossing of the beam despite either a forelimb or hindlimb hanging below the 
beam, and one point was given for crossing the beam despite inverting below the beam 
one or more times. The mouse was righted and allowed to continue across the beam if it 
became inverted on the beam. A score of zero was given if the mouse did not cross in 
the allotted time or fell off the beam. For the rod, two points were given for successful 
crossing of the beam in the allotted time. A score of one was given for crossing despite 
inverting more than three times. A score of zero was given if the mouse did not traverse 
in the allotted time or fell off the rod.  
Cognitive Performance Evaluation Using a Novel Object Recognition (NOR) 
Paradigm 
At 24 hr prior to injury, mice were acclimated to a clear plastic cage (32x20x14 
cm) with an open top for a period of one hour. Mice were introduced to two identical 
Lego®Duplo® figures placed in opposite corners of the cage for 5 minutes. At 7 d post-
injury, mice were re-introduced to the testing cage and allowed to explore for one hour. 
The two original objects were re-introduced in the cage and the time spent exploring 
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each object was recorded for a period of 5 minutes. After a delay of 4 hr, the mouse was 
returned to the testing cage where one of the original objects had been replaced with a 
novel object. The time spent exploring each object was recorded for 5 minutes. A 
recognition index was calculated as the time spent exploring the novel object as a 
percentage of total object exploration time.  
Tissue Collection 
Following transcardial collection, blood was transferred to a 1.65 mL eppendorf 
tube and allowed to coagulate for 30 minutes. To extract serum, coagulated blood was 
centrifuged at 4,500xg for 10 minutes at room temperature. Serum was transferred to a 
new tube and stored at -80°C.  
For ELISA and western blotting, mice received an overdose of Fatal-plus. The 
brains were rapidly removed from the skull and placed onto an ice cold dissection plate.  
To concentrate collection of tissue on the injury site, 3 mm of the anterior brain was 
blocked in the coronal plane and the remaining ipsilateral and contralateral cortical and 
hippocampal regions were dissected and separately placed in eppendorf tubes and 
stored at -80°C. 
For histology and immunohistochemistry, mice received an overdose of Fatal-
plus at 7 d post-injury. Mice were then transcardially perfused with heparinized saline to 
clear blood from the vasculature followed by 10% neutral buffered formalin. The mice 
were decapitated and the head placed in 10% neutral buffered formalin for 24 hr. The 
brain was dissected from the head and placed in 10% neural buffered formalin for an 
additional 24 hr. Brains were then placed in 30% sucrose for 24 hr for cryoprotection 
prior to freezing in -30°C isopentanes cooled on dry ice. Brains were cut into 40 µm-thick 
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coronal sections on a freezing sliding microtome (Microm, Dolbey-Jamison, PA) at -20°C 
(Physitemp, NJ).  
Preparation of Tissue for ELISA and Western Blotting 
Cortical and hippocampal samples were homogenized by wand sonicator in cold 
lysis buffer (1% triton X-100, 20 mM Tris-HCl, 150 mM NaCl, 5 mM EGTA, 10 mM 
EDTA, 10% glycerol, and a cocktail of proteinase inhibitors (Roche, IN)) and centrifuged 
for 30 minutes at 4°C at a speed of 10,000xg. The supernatants were collected and 
utilized for analysis. Protein concentrations were determined using a BCA assay kit 
(Pierce Biotechnology, IL).  
Quantification of IGF-1 by ELISA 
Human IGF-1 was quantified using the highly-specific Quantikine® human IGF-1 
ELISA kit (DG100, R&D Systems Inc., MN) according to the manufacturer’s instructions. 
Serum and brain samples were pretreated for dissociation of IGF-1 from the binding 
proteins. Human IGF-1 standards (0.094-6.0 ng/mL) and pretreated samples were 
pipetted in duplicate into a 96 well plate coated with monoclonal antibody specific to 
human IGF-1. Following a 2 hr incubation, the wells were rinsed with the supplied wash 
buffer to remove unbound antigens. A polyclonal antibody conjugated with HRP enzyme 
was incubated in the wells for 1 hr. The wells were rinsed and incubated with a substrate 
solution for 30 minutes. Development was halted by the additional of the 1N hydrochloric 
acid stopping solution. Absorbance of each well was measured using a microplate 
reader (Tecan, NC) at 450 nm and 540 nm wavelengths. The absorbance at 540 nm 
was subtracted from the 450 nm absorbance to account for the background of each well.  
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Western Blot 
Western blot analyses were performed as previously described (Madathil et al. 
2010). Electrophoresis was completed in triplicate using 30 µg of protein supernatant 
from the ipsilateral hippocampal samples, on a 3-8% Tris-HCl gel at 150V. After transfer 
onto nitrocellulose membranes, the membranes were blocked for 1 hr in 5% dry milk 
dissolved in 0.1% Tween 20 in TBS and incubated overnight with a primary antibody for 
p-Akt ser473 (rabbit monoclonal, 1:2000 concentration, Cell Signaling Technology, MA). 
The membranes was rinsed the following day and incubated for 1 hr with a secondary 
antibody for anti-rabbit IgG (1:5000 IRDye800CW, Rockland, PA). The membrane was 
rinsed and then imaged and the optical density was quantified using the Li-Cor Odyssey 
Infrared Imaging System (Li-Cor Biosciences, NE). After pAkt development, the 
membranes were reprobed for actin using an anti-β-actin primary antibody (mouse 
monoclonal 1:5000, Calbiochem Inc, CA) and an anti-mouse IgM conjugated to an 
infrared dye (1:10000, Rockland). For quantification, OD of each pAkt band was divided 
by its respective actin OD. A mean OD was calculated for each animal from the OD 
values from the triplicate samples and normalized to the mean normalized OD for 
vehicle-treated sham-injured mice to permit comparison across gels.  
Histological (Cresyl Violet) Staining 
For each brain, every tenth brain section spaced 400µm apart was mounted and 
air-dried on gelatin-coated slides. The slides were hydrated in graded ethanol solutions, 
stained with 0.5% cresyl violet (Acros Organics, NJ), rinsed in water, dehydrated through 
graded ethanol solutions, cleared in xylenes (Fisher Scientific, NJ), and mounted with 
Permount (Fisher Scientific, NJ).  
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Immunohistochemistry 
Coronal brain sections (n=6-7 per animal), spaced 200 µm apart and centered 
with respect to the injury epicenter, were immunolabeled for doublecortin (DCx), a 
microtubule protein expressed in immature neurons, or BrdU, a thymidine analog that 
incorporates into DNA during DNA synthesis, using standard free floating 
immunohistochemistry protocols, as previously described (Cai et al. 2012). Only sections 
to be double labeled for BrdU (Study 6) were initially rinsed in TBS (pH 7.4), treated with 
2N HCl for 1 hr at room temperature to expose the BrdU epitope, and subsequently 
treated with 100 mM borate buffer (pH 8.0, Fisher Scientific, NJ) for 10 minutes. 
Sections were then rinsed and incubated in TBS overnight at 4°C. Sections from all 
studies were rinsed in TBS and blocked with 5% normal horse serum with 0.1% Triton-
X-100 in TBS for 30 minutes. Either DCx (rabbit polyclonal, 1:500, Abcam, MA) or a 
cocktail of DCx and BrdU (rat polyclonal, 1:1000, Abcam, MA) primary antibodies, where 
applicable, diluted in blocking solution, were placed on the tissues for overnight 
incubation at 4°C. The sections were rinsed with TBS and incubated with secondary 
antibodies (anti-rabbit IgG conjugated with Alexa Fluor® 488 or anti-rat IgG conjugated 
with Cyanine Cy3, Jackson ImmunoResearch, PA) diluted in blocking solution for 1 hr 
and rinsed with TBS. Sections were incubated with Hoechst (1:10,000, Invitrogen, CA) 
for 1.5 minutes to label all nuclei and rinsed with TBS. Labeled sections were mounted 
on gelatin-coated slides, coverslipped with Fluoromount (Southern Biotech, AL), and 
stored at 4°C. 
Image Acquisition 
Representative images of cresyl violet stained sections and images of DCx and 
BrdU immunoreactivity were acquired using an AX80 Olympus microscope (PA).  
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Cellular Quantification 
In comparison to Chapter 3, quantification of DCx and BrdU positive cells was 
performed  in a larger number of sections to expand the anatomical region of interest to 
the rostrocaudal extent of the ipsilateral dentate gyrus granular layer, and also the 
contralateral granular layer in Studies 3 and 4, of each section. Quantification of 
additional sections provided a more comprehensive assessment of cell populations 
throughout the dentate gyrus granular layer and not isolated to the injury core, as 
previously described for quantification of degenerating neurons within the dentate gyrus 
(Madathil 2013). All positively labeled cells were manually counted through all focal 
planes within the dentate gyrus granular layer at 40x magnification on an epifluorescent 
microscope (Olympus BX51) equipped with a FITC filter (41001, Chroma Technology, 
VT) or TRITC filter (31002, Chroma Technology). Colocalization of DCx and BrdU was 
determined using a wide band filter (51004v2, Chroma Technology) that permits 
simultaneous viewing of the emissions of both fluorophores of the secondary antibodies. 
Cells exhibiting colocalization of DCx and BrdU immunostaining were manually counted 
through all focal planes within the granular layer at 40x magnification on the same 
microscope. Colocalization was confirmed by scanning through the z-axis to ensure 
colabeling within each cell. Cellular counts were normalized to the volume of the dentate 
gyrus granular layer of each section to control for differences in dentate gyrus size 
across sections. The area of the Hoechst-labeled dentate gyrus granular layer was 
imaged (Olympus, AX80) and was measured using ImagePro (MediaCybernetics, MD). 
The thickness of each section was measured, in microns, using an epifluorescent scope 
(Olympus BX51) equipped with a stereology stage. Granular layer area and thickness 
measurements were used to calculate granular layer volume. Volumetric density 
measurements (1000 cells/mm3) represent the entire granular layer, inclusive of the 
123 
 
subgranular, inner, and outer granular layers.  A mean cell density was calculated for all 
quantified sections for each animal. To reduce animal usage, sham-injured mice were 
not included in Studies 3 and 4. Therefore, immature neuron densities in the ipsilateral 
hemisphere were normalized to those in the non-impacted hemisphere (contralateral) 
hemisphere and were expressed as a percentage of contralateral immature neuron 
density. Due to the fact that brain injury results in immature neuron loss predominantly in 
the impacted hemisphere (ipsilateral), the contralateral hippocampus can provide an 
approximation of immature neuron density in the uninjured brain. Quantification of all 
sections was performed by an investigator blinded to the treatment and injury conditions 
of each animal. 
Statistical Analysis 
All data is presented as mean + standard error of the mean (SEM). Serum levels 
of hIGF-1 (Fig. 4.1D) and cellular densities (Fig. 4.5C) were compared by Student’s t-
test. Brain levels of hIGF-1 (Fig. 4.1A) and the NSS motor function scores (Fig. 4.2B) 
were compared using a repeated measures one-way analysis of variance (ANOVA). 
NOR recognition indices (Fig. 4.2A), regional water content (Fig. 4.4G) and cellular 
densities (Fig. 4.7B) were compared by one-way ANOVA. Baseline blood glucose levels 
(Table 4.1), Akt activation (Fig. 4.1C), (Fig. 4.2A), and cellular densities (Fig. 4.3B, 4.9I, 
J, K) were compared using a two-way ANOVA. Blood glucose levels (Table 4.1) were 
compared using a repeated measures two-way ANOVA. In all cases, the Newman-Keuls 
post-hoc t-tests were performed when appropriate. Statistical tests were completed 
using Statistica (Statsoft Inc, OK). A p value less than 0.05 was considered statistically 
significant. 
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Results 
By using recombinant human insulin-like growth factor-1 (hIGF-1), exogenously 
infused IGF-1 could be distinguished from endogenous mouse IGF-1 using an ELISA kit 
highly-specific for hIGF-1. Human IGF-1 was not detected in serum or brain samples of 
vehicle-treated mice. A 7 d intracerebroventricular infusion of 10 µg/d hIGF-1 into the 
contralateral ventricle in Study 1 resulted in measureable hIGF-1 in the hemisphere 
ipsilateral to the impact, with equivalent levels in the cortex and hippocampus, 
suggesting widespread delivery. The contralateral hippocampus (same hemisphere as 
the cannula) had significantly higher concentrations of IGF-1 compared to the ipsilateral 
cortex or hippocampus (#p<0.05, Fig. 4.1A).  
Brain injury in vehicle-treated mice resulted in a small, but non-significant 
decrease in hippocampal levels of phosphorylated Akt compared to sham-injury in 
vehicle-treated mice. Consistent with appropriate signaling after binding to its cognate 
receptor, infusion of IGF-1 in sham-injured and brain-injured mice resulted in significantly 
enhanced phosphorylation of Akt, a potent pro-survival and growth permissive signal, in 
the ipsilateral hippocampus, compared to infusion of vehicle (main treatment effect, 
*p<0.05, Fig. 4.1B, C).  These data demonstrated that central infusion of IGF-1 results in 
a measureable and widespread increase of IGF-1 in the brain and promotes the 
activation of a pro-survival pathway after severe CCI.  
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Figure 4.1: Central infusion of 10 µg/d human insulin-like growth factor-1 (IGF-1) 
over 7 d elevates brain levels of hIGF-1 and enhances Akt activation in the 
hippocampus after severe controlled cortical impact (CCI). (A) hIGF-1 was detected 
in the ipsilateral (ipsi) cortex (CTX) and ipsilateral and contralateral (contra) hippocampi 
(Hipp) at 7 d after sham injury (Sham) or severe (CCI) using a human-specific ELISA 
(#p<0.05, contra Hipp compared to ipsi CTX or Hipp). (B) Representative western blot 
images of phosphorylated Akt (pAkt) and actin at 7 d post-injury for vehicle (Veh) or 
hIGF-1 treated mice. (C) Hippocampal levels of pAkt as determined by semiquantitative 
Western blot.  Infusion of hIGF-1 resulted in a significant increase in Akt activation within 
the hippocampi of sham-injured and CCI-injured mice at 7 d post-injury (*p<0.005, IGF-1 
treated compared to vehicle treated). The optical density (OD) for each pAkt band was 
normalized to its respective actin band OD; the mean of the triplicate samples for each 
mouse was normalized to the mean OD value of the vehicle-treated sham group. The 
results are presented as mean + SEM. (n=5 sham-injured and n= 9 CCI-injured per 
treatment group).  
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 A previous study showed that IGF-1 is cleared from cerebrospinal fluid and 
enters systemic circulation (Nagaraja et al. 2005). We used the same highly-specific 
hIGF-1 kit to quantify the levels of hIGF-1 in systemic circulation. Human IGF-1 was not 
detected in the serum of vehicle-treated mice. IGF-1-infused, brain-injured mice 
exhibited significantly higher concentrations of hIGF-1 in the systemic circulation (79.4 + 
4.7 ng/mL), as compared to sham-injured mice infused with IGF-1 (*p<0.05; 58.2 + 10.8 
ng/mL). To determine whether elevated serum IGF-1 resulted in systemic hypoglycemia, 
systemic blood glucose was measured at several time points following surgical 
procedures. Blood glucose levels were not significant among treatment groups (Table 
4.1). Anesthesia and surgical procedures induced a significant elevation in blood 
glucose levels at 90 minutes post-injury, independent of injury and treatment condition 
(*p<0.05 compared to all other time points), but blood glucose levels returned to 
baseline at 1 d and 7 d post-injury (Table 4.1).  
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Table 4.1: 
Blood glucose levels were elevated in both vehicle (Veh) and insulin-like growth 
factor-1 (IGF-1) treated mice at an acute time point following sham injury (Sham) 
or controlled cortical impact (CCI). Blood glucose was measured prior to injury, and at 
several time points after surgical procedures in non-fasted mice. Blood glucose levels 
were significantly higher at 90 minutes after surgical procedures compared to all time 
points, independent of treatment and injury status (*p<0.05). Data are presented as 
mean + SEM. (n= 9 sham-injured per treatment and n=19 brain-injured per treatment).  
Blood glucose measurements following central infusion (mg/dL) 
  Baseline 90 minutes 1 d 7 d 
Veh Sham 176+ 7 233+ 11 * 183+ 8 200+ 11 
IGF-1 Sham 165+ 6 210+ 10 * 171+ 11 163+ 7 
Veh CCI 187+ 9 229+ 9 * 203+ 17 192+ 16 
IGF-1 CCI 179+ 9 231+ 12 * 170+ 9 189+ 11 
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 To evaluate if central infusion of hIGF-1 improves neurobehavioral performance 
after severe CCI, we evaluated cognitive performance using the novel object recognition 
task at 7 d after injury in mice from Study 1. Vehicle-infused mice exhibited significant 
memory impairment after CCI as compared to sham-injured vehicle-treated mice, as the 
recognition index scores indicated impaired recognition of the familiar object (*p<0.01, 
Fig. 4.2A). Infusion of IGF-1 reduced the brain injury associated decline in cognitive 
performance, improving posttraumatic memory function of IGF-1-treated brain-injured 
mice to a level equivalent to IGF-1-treated sham-injured mice (Fig. 4.2A). Recognition 
indices of sham-injured mice treated with IGF-1 were not significantly different from 
sham-injured vehicle-treated mice (Fig. 4.2A). 
A modified neurological severity score (NSS) was utilized to evaluate motor 
coordination during the week following severe CCI. Motor performance was equivalent 
for sham-injured mice treated with either vehicle or IGF-1 (Fig. 4.2B). Sham-injured 
exhibited a small, but significant impairment in motor function at 1 d post-injury, but 
exhibited no impairment for the remainder of the testing, independent of treatment status 
(p<0.05, Fig. 4.2B).  Brain-injured mice exhibited significantly impaired motor function 
during the week post-injury, compared to sham-injured mice, independent of treatment 
condition (p<0.01). Vehicle-treated brain-injured mice exhibited a significant reduction in 
motor function at 1, 2, 3, and 5 d after injury, compared to sham-injured mice (*p<0.001, 
Fig. 4.2B). Conversely, IGF-1-treated brain-injured mice exhibited a significant 
impairment in motor function at only 1, 2, and 3 d post-injury (p<0.001 compared to IGF-
1-treated sham-injured mice, Fig. 4.2B). Mice infused with IGF-1 after brain injury 
showed significantly improved motor function at 1, 2, 3, and  5 d after CCI, compared to 
vehicle-infused brain-injured mice (#p<0.01, Fig. 4.2B). These data demonstrated that 
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central infusion of hIGF-1 reduces cognitive impairment and attenuates motor 
dysfunction associated with severe CCI.  
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Figure 4.2: Central infusion of 10 µg/d human insulin-like growth factor-1 (IGF-1) 
over 7 d attenuates cognitive and motor impairment after severe controlled 
cortical impact (CCI). (A) Brain injury resulted in a significant reduction in the novel 
object recognition index of vehicle-treated mice at 7 d post-injury (*p<0.05, compared to 
sham-injured (Sham) vehicle-treated (Veh) mice. Infusion of IGF-1 reduced the brain 
injury-induced decline in cognitive performance. (B) Vehicle-infused brain-injured mice 
exhibited significant impairment in motor function at 1, 2, 3, and 5 d post-injury as 
assessed by a modified neurological severity score (NSS) (*p<0.001, compared to 
vehicle-treated sham-injured mice). IGF-1-infused brain-injured mice exhibited a 
significant motor impairment at 1, 2, and 3 d post-injury compared to IGF-1 infused 
sham-injured mice (p<0.001). Treatment with IGF-1 improved motor function at 1, 2, 3, 
and 5 d post-injury compared to vehicle-infused brain-injured mice (#p<0.01). Data are 
presented as mean + SEM. (n=9 sham-injured per treatment and n=19 CCI-injured per 
treatment).  
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 In order to evaluate if a 7 d infusion of 10 μg/d hIGF-1 enhances hippocampal 
immature neuron density after injury, we quantified DCx+ cells in the dentate gyrus 
granular layer from mice in Study 1. CCI induced a significant reduction in DCx+ cell 
density in vehicle-treated mice at 7 d post-injury compared to sham-injured mice 
(*p<0.05, Fig. 4.3A, B). Brain-injured mice infused with IGF-1 had significantly higher 
DCx+ cell densities compared to brain-injured mice infused with vehicle (#p<0.05, Fig. 
4.3B). The density of immature neurons in brain-injured mice infused with IGF-1 was not 
significantly different from sham-injured mice receiving IGF-1 (Fig. 4.3B). IGF-1 
treatment did not affect immature neuron density in sham-injured mice (Fig. 4.3A, B).  
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Figure 4.3: Central infusion of 10 µg/d human insulin-like growth factor-1 (IGF-1) 
protects immature neurons in the injured hippocampus after severe controlled 
cortical impact (CCI). (A) Representative images of doublecortin (DCx, green) 
immunoreactivity in the ipsilateral hippocampus of vehicle (Veh) and IGF-1 infused 
sham-injured (Sham) and CCI-injured mice at 7 d post-injury. Scale bar represents 100 
µm.  Granular layer (GL) and Hilus (H). (B) DCx+ cell density is significantly decreased 
following brain injury in vehicle-treated mice (*p<0.05, compared to sham-injured 
vehicle-treated mice). Infusion of IGF-1 significantly attenuated the reduction in DCx+ cell 
density at 7 d after CCI injury (#p<0.05, compared to vehicle-treated brain-injured mice). 
(n=4 sham-injured per treatment, n=10 vehicle-treated brain-injured and n=9 IGF-1-
treated brain-injured). Immature neuron counts obtained from the ipsilateral granular 
layer were normalized to the volume of the ipsilateral granular layer to calculate cellular 
density (1000/mm3). Data are expressed as mean + SEM.  
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 Histological evaluation by cresyl violet staining indicated that severe CCI 
produced cortical cell loss and cavitation, subcortical white matter loss and thinning of 
the hippocampal granular layer at 7 d post-injury (Fig. 4.4C).  Qualitative assessment of 
cresyl violet staining revealed that the majority of IGF-1-infused mice subjected to CCI 
exhibited similar gross pathology (7 of 10, Fig. 4.4D, E), although the ipsilateral 
hippocampus was distorted in some mice (Fig 4.4E). However, a subset of mice showed 
profound swelling of subcortical regions and hippocampal distortion after CCI (3 of 10, 
Fig. 4.4F) raising concerns that central infusion of IGF-1 may promote or exacerbate 
posttraumatic cerebral edema Assessment of sham-injured vehicle-treated mice 
revealed a small degree of brain swelling 7 d post-injury without any indications of 
damage to the exposed dura at the time of craniotomy (Fig. 4.4A). Central infusion of 
IGF-1 in sham-injured mice resulted in mild cortical tissue swelling at the craniotomy site 
(Fig. 4.4B) that appeared more pronounced than for vehicle infusion.  
To evaluate if cerebral edema contributed to the brain swelling observed in a 
subset of IGF-1-infused, brain-injured mice, in Study 2 we generated a cohort of brain-
injured mice for evaluation of regional water content in the absence of infusion, with 
infusion of vehicle, or with infusion of 10 µg/d hIGF-1. Brain injury-induced edema 
develops within 24 after CCI brain injury and resolves towards non-injured levels by 7 d 
post-injury (Kochanek et al. 1995). Analysis of the cortices and contralateral hippocampi 
of all mice revealed no statistically significant changes in water content across 
experimental groups (Fig. 4.4G). The water content percentages observed in these 
regions (77-80%) were comparable to those reported after sham injury (Trabold et al. 
2008; Kenne et al. 2012; Terpolilli et al. 2013). However, a modest increase in water 
content in the ipsilateral hippocampus of brain–injured mice infused with 10 µg/d hIGF-1  
appeared to be driven by a subset of mice (2 of 6) that exhibited a much higher than 
134 
 
normal water content (81-82%; Fig 4.4G). This data suggested that edema in the injured 
hippocampus of IGF-1-infused mice may contribute to the brain swelling and tissue 
distortion observed in a subset of mice from Study 1. Differences in age or body weight 
did not correlate with the incidence of brain swelling. We sought to modulate parameters 
of the infusion paradigm that may attenuate brain swelling observed in IGF-1-infused 
mice after severe CCI. 
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Figure 4.4: Central infusion of 10 µg/d human insulin-like growth factor-1 (IGF-1) 
promotes brain swelling and deformation in a subset of mice after severe 
controlled cortical impact (CCI). (A-F) Representative images of cresyl violet staining 
of the cortex (CTX) and hippocampus (Hipp) ipsilateral (ipsi) to impact at 7 d post-injury 
from vehicle (Veh) and IGF-1-treated mice subjected to sham injury (Sham) or brain 
injury. Sham-injured mice infused with either (A) vehicle (Veh) or (B) IGF-1 exhibited 
brain swelling at the craniotomy site. (C) Brain-injured mice treated with vehicle exhibited 
cortical cavitation and hippocampal cell loss consistent with severe CCI. The majority of 
IGF-1-infused brain-injured mice (7 of 10) exhibited characteristic histopathology with 
either (D) minimal or (E) modest brain swelling. (F) However, a subset of IGF-1-infused 
brain-injured mice (3 of 10) showed severe distortion of the hippocampus at 7 d post-
injury. (n=4 sham-injured per treatment and n=10 brain-injured per treatment). Scale bar 
represents 500 µm. (G) Water content was quantified in brain-injured mice receiving CCI 
without cannulation or infusion or CCI with central infusion of either vehicle or 10 µg/d 
IGF-1 (n=6 per group).  Infusion of IGF-1 did not result in significant regional cerebral 
edema; however a small subset of mice (2 of 6) had markedly increased water content in 
the ipsilateral hippocampus. Contralateral (contra). Data are presented as mean + SEM.  
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 In an effort to minimize central infusion of infusate during the development of 
edema within the initial hours following CCI (Kochanek et al. 1995), we sought to delay 
infusion of IGF-1 until 6 hr following severe CCI. After induction of brain injury, a 
nonprimed minipump was implanted to deliver 10 µg/d hIGF-1, achieving a delay in 
infusion onset of approximately 6 hr (Study 3). Brain-injured mice infused with vehicle 
beginning 6 hr post-injury exhibited cortical cavitation and dentate gyrus granular layer 
thinning consistent with severe CCI (Fig. 4.5A). Delayed infusion of 10 µg/d of IGF-1 
resulted in no observable brain swelling in the majority of mice (4 of 5), while a subset of 
mice exhibited hippocampal distortion qualitatively similar to that observed with the acute 
onset of infusion (1 of 5; Fig. 4.5A). Although delaying IGF-1 administration did not 
appear to ameliorate infusion-related brain swelling, we evaluated whether efficacy for 
protection of immature neurons was retained. Given that the initiation of treatment in 
clinical trials typically occurs between 3 and 8 hr following the TBI (Maas et al. 2007), 
this delayed IGF-1 infusion paradigm is highly clinically relevant.  DCx immunoreactivity 
appeared to be reduced in vehicle-treated mice, but was conserved in IGF-1-treated 
mice (Fig. 4.5B). Quantification of DCx+ cell density demonstrated that delayed treatment 
with IGF-1 significantly enhanced immature neuron density at 7 d post-injury, as 
compared to vehicle treatment (#p<0.05, Fig. 4.5C). Thus, IGF-1-mediated 
enhancement of immature neuron density was retained in this clinically relevant 
treatment paradigm.  
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Figure 4.5: Delayed infusion of 10 µg/d human insulin-like growth factor-1 (hIGF-1) 
resulted in brain swelling and increased hippocampal immature neuron density at 
7 d after severe controlled cortical impact (CCI). (A) Images of cresyl violet staining 
of vehicle (Veh) and hIGF-1-treated brain-injured mice. Brain-injured vehicle-treated 
mice showed cortical and hippocampal cell loss consistent with severe CCI. The majority 
of IGF-1-treated brain-injured mice (4 of 5) exhibited minimal to modest brain swelling, 
but one mouse (shown) exhibited pronounced brain swelling at 7 d post-injury. Scale bar 
represents 500 µm. (B) Compared to vehicle-treated CCI-injured mice, doublecortin 
(DCx, green) immunoreactivity appeared to be enhanced in IGF-1-treated brain-injured 
mice. Scale bar represents 100 µm. (C) IGF-1-treated brain-injured mice showed 
significantly increased immature neuron density at 7 d post-injury, compared to vehicle-
treated brain-injured mice (*p<0.05). Data are presented as mean + SEM. (n=3 vehicle-
treated brain-injured and n=5 IGF-1-treated brain-injured mice). 
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 Because infusion-related brain distortion appeared worse with hIGF-1 than with 
vehicle (see Fig. 4.4C, F), we next sought to evaluate if the incidence and severity of 
brain swelling could be reduced by decreasing the dose of IGF-1. In Study 4, 10 µg/d 
hIGF-1 was compared to doses of 3, 1, 0.3, and 0 (vehicle) µg/d. As assessed in cresyl 
violet stained tissue sections, infusion of 10 µg/d hIGF-1 resulted in marked cortical and 
hippocampal distortion in the ipsilateral hemisphere in a subset of mice (2 of 5; Fig 
4.6A), consistent with observations in Study 1 (see Fig. 4.4F).  However, the severity 
and incidence of infusion-related brain swelling at 7 d following CCI appeared to be 
dose-dependent. Infusion of 3 µg/d hIGF-1 reduced the incidence of exacerbated brain 
swelling (1 of 5), and decreased the severity of brain swelling (Fig. 4.6B), as compared 
to infusion of 10 µg/d hIGF-1. Animals infused with 1 or 0.3 µg/d hIGF-1 exhibited mild or 
no hippocampal swelling (Fig. 4.6C, D) similar to mice infused with vehicle (Fig. 4.6E). 
These observations suggest that the dose of IGF-1 may be a contributing component of 
i.c.v infusion-related brain swelling after severe CCI.  
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Figure 4.6: Reductions in the concentration of centrally infused human insulin-like 
growth factor-1 (hIGF-1) appeared to reduce the severity and incidence of brain 
swelling following severe controlled cortical impact (CCI). (A-E) For doses that 
resulted in brain swelling, images of cresyl violet staining were selected from the 
subgroup of hIGF-1-treated mice in each dose that exhibited notable brain swelling at 7 
d post-injury. While the majority of mice infused with 10 µg/d hIGF-1 (3 of 5) exhibited 
characteristic histopathology after severe CCI with minimal hippocampal swelling, (A) a 
subset of mice (2 of 5) showed brain swelling and gross distortion of the hippocampus at 
7 d after injury. (B) Infusion of 3 µg/d hIGF-1 resulted in reduced incidence (1 of 5) and 
severity of hippocampal swelling, when compared to infusion of 10 µg/d hIGF-1. Infusion 
of (C) 1 µg/d or (D) 0.3 µg/d hIGF-1 largely mitigated the infusion-induced hippocampal 
swelling after CCI, with pathology appearing comparable to vehicle-infused mice (E).  
Scale bar represents 500 µm. (n=4 vehicle-treated and n=5 per dose IGF-1-treated 
brain-injured mice). 
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To evaluate if the effects of IGF-1 on immature neuron density were dose 
dependent, DCx+ cell staining and immature neuron density was assessed in brain-
injured mice for each dose of IGF-1 examined in Study 4. DCx immunoreactivity was 
greatly diminished in brain-injured vehicle-treated mice.  Brain injury-induced loss of DCx 
immunoreactivity was attenuated by IGF-1, and the effect appeared more robust with 
increasing doses of infused IGF-1 (Fig. 4.7A). After CCI, DCx+ cell density was 
decreased indicating a reduction in immature neurons in vehicle-treated mice. Analysis 
of immature neuron densities as a function of dose by one-way ANOVA did not reach 
statistical significance.  However, IGF-1-treated mice exhibited an apparent dose-
dependent enhancement of immature neuron density at 7 d post-injury (Fig. 4.7B). 
Although this relationship was not statistically significant, these data suggest a dose-
dependent increase in hippocampal immature neuron density with central infusion of 
IGF-1. 
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Figure 4.7: Central infusion of human insulin-like growth factor-1 (IGF-1) enhances 
hippocampal immature neuron density in an apparent dose-dependent manner 
after controlled cortical impact. (A) Brain injury in vehicle-treated (Veh) mice results in 
a robust loss of DCx immunoreactivity in the dentate gyrus granular layer. In IGF-1-
treated mice, DCx immunoreactivity appeared to increase in a dose-dependent manner. 
Granular layer (GL) and hilus (H). Scale bar represents 50 µm. (B) Increases in 
immature neuron density were proportional to increasing concentrations of IGF-1 
infusate. Data are presented as mean + SEM. (n=4 vehicle-treated brain injured and n=5 
per dose IGF-1-treated brain-injured mice).  
GL 
H 
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 Because infusion of vehicle alone at a 0.5 µL/hr flow rate over 7 d resulted in a 
small amount of brain swelling in sham-injured mice (Fig 4.4A, reproduced in Fig. 4.8A), 
we next evaluated whether reducing the infusate volume would eliminate brain swelling 
after prolonged central infusion. In Study 5, osmotic minipumps with different flow rates 
were utilized to reduce the volume of vehicle infusate introduced into the contralateral 
ventricle of sham-injured mice over a 7d infusion period. The brains of the sham-injured 
mice exhibited no indications of dural damage or herniation at the completion of the 
craniotomy. Compared to the flow rate of 0.5 µL/hr used previously (Alzet model 1007D; 
Fig. 4.8A), reducing the rate to 0.25 µL/hr (model 1002; Fig. 4.8B) appeared to decrease 
brain swelling at the craniotomy site. Swelling was negligible at a flow rate of 0.11 µL/hr 
(model 1004; Fig 4.8C). Therefore, the volume of infusate introduced into the 
contralateral ventricle appears to influence the development of brain swelling after 
craniotomy.  
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Figure 4.8: Volume of infusate introduced into the influences brain swelling after 
craniotomy. Representative images of cresyl violet staining of sham-injured vehicle-
treated mice at 7 d post-surgery. (A) The 1007D osmotic minipump (0.5 µL/hr flow rate) 
produced mild brain swelling at 7 d post-injury (reproduced from Fig 4.4A). Utilization of 
osmotic minipumps with lower flow rates of (B) 0.25 µL/hr (model 1002) and (C) 0.11 
µL/hr (1004) resulted in reduced cortical swelling at the craniotomy site. Scale bar 
represents 500 µm. (n=4 1007D, n=5 1002, and n=5 1004).  
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 In light of these data implicating IGF-1 concentration and infusate volume as 
contributing factors to brain swelling after CCI, we sought to complete a follow up 
experiment to determine if utilizing a lower dose of hIGF-1 (3 µg/d) in combination with a 
slower infusion rate (0.11 µL/hr, model 1004) would reduce brain swelling while retaining 
the beneficial effects of IGF-1 infusion on immature neuron density after injury. The dose 
of 3 µg/d hIGF-1 was selected as this dose had reduced brain swelling and enhanced 
immature neuron density in the previous studies. In Study 6, mice were subjected to 
sham injury or CCI and centrally infused with vehicle or 3 µg/d hIGF-1 beginning 15 
minutes after injury. At 7 d post-injury, cresyl violet stained tissue sections from vehicle-
infused sham-injured mice revealed reduced brain swelling (Fig. 4.9A) compared to 
vehicle-treated sham-injured mice from Study 1 (Fig. 4.4A). Infusion of 3 µg/d hIGF-1 in 
sham-injured mice appeared to reduce the severity of brain swelling compared to IGF-1-
treated sham-injured mice from Study 1; however, evidence of cortical swelling at the 
craniotomy site was observed in a subset of sham-injured mice (2 of 4, Fig. 4.9B). 
Similar to the previously described observations, severe CCI resulted in a characteristic 
cortical cavitation and granular layer thinning with minimal hippocampal distortion 
associated with infusion of vehicle (Fig. 4.9C). Infusion of 3 µg/d hIGF-1 at 0.11 µL/hr 
after brain injury resulted in minimal brain swelling in the majority of mice (6 of 8) with a 
subset of mice (2 of 8) exhibiting brain swelling at 7 d post-injury (Fig. 4.9D). However, 
the severity of brain swelling observed following infusion of 3 µg/d hIGF-1 was notably 
reduced compared to central infusion of 10 µg/d IGF-1 at 0.5 µL/hr (see Fig. 4.4F). 
DCx immunoreactivity was assessed in these mice to evaluate if IGF-1-
stimulated enhancement of immature neuron density after severe CCI was retained 
using this altered infusion paradigm. Sham-injured mice treated with either vehicle or 
IGF-1 exhibited a similar extent of DCx immunoreactivity (Fig. 4.9E, F, I). Brain-injured 
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mice exhibited a marked reduction in immature neuron density at 7 d post-injury, 
independent of genotype (main effect of injury, p<0.005, Fig. 4.9I). Central infusion of 
IGF-1 resulted in significantly elevated immature neuron density at 7 d post-injury (main 
effect of treatment, p<0.05, Fig. 4.9I), but this effect was not dependent on injury 
(interaction effect, p=0.1). Brain-injured mice treated with vehicle exhibited a 51% 
reduction in immature neuron density at 7 d post-injury compared to sham-injured mice 
treated with vehicle (Fig. 4.9I). In contrast, brain-injured mice treated with IGF-1 
exhibited only a 17% reduction in immature neuron density compared to sham-injured 
mice treated with IGF-1 (Fig. 4.9I). Infusion of 3 µg/d hIGF-1 at a flow rate of 0.11 µL/hr 
resulted in increased immature neuron density at 7 d following severe CCI.  
We next sought to evaluate if an increase in post-traumatic granular cell 
proliferation contributed to the observed increase in immature neuron density in IGF-1-
treated mice. BrdU immunoreactivity was utilized to identify the number of newly 
proliferated cells in the dentate gyrus granular layer after CCI. Brain injury resulted in a 
significant increase in the density of BrdU+ cell density compared to sham injury, 
independent of treatment (main effect of injury, p<0.05, Fig. 4.9J). Brain-injured mice 
treated with vehicle exhibited a 53% increase in newly proliferated cells compared to 
sham-injured mice treated with vehicle. In contrast, brain-injured IGF-1-treated mice 
showed a 90% increase in the density of proliferated cells compared to sham-injured 
IGF-1-treated mice at 7 d post-injury. Sham-injured mice treated with IGF-1 showed a 
small increase in BrdU+ cell density compared to sham-injured mice treated with vehicle 
(Fig. 4.9J). These data suggest that enhanced post-traumatic proliferation with treatment 
with IGF-1 may contribute to the increased immature neuron density observed at 7 d 
post-injury. 
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To evaluate if IGF-1 enhanced the generation of newborn neurons after CCI, 
DCx immunoreactivity was colocalized with BrdU to identify immature neurons born after 
brain injury. Quantification revealed that treatment with IGF-1 resulted in a significant 
increase in the density of newborn neurons at 7 d post-injury, independent of injury 
(main effect of treatment, p<0.01, Fig. 4.9K). Brain-injured mice treated with vehicle 
exhibited a 55% reduction in newborn neuron density compared to sham-injured mice 
treated with vehicle. In contrast, brain-injured mice treated with IGF-1 showed no 
reduction in the number of newborn neurons generated after injury compared to IGF-1 
infused sham-injured mice (Fig. 4.9K) and an approximate 3-fold increase relative to 
vehicle-treated, brain-injured mice. Sham-injured mice treated with IGF-1 showed a 42% 
increase in newborn neuron density compared to sham-injured mice treated with vehicle 
(Fig. 4.9K). These data demonstrated that although the decreased dose of 3 µg/d of 
IGF-1 and the slower flow rate of the osmotic minipump did not fully eliminate infusion-
related brain swelling, the severity of brain swelling was reduced with these infusion 
modifications. Moreover, these data highlight that increased immature neuron density 
with treatment of 3 µg/d hIGF-1 may be due in part to the increased generation of 
newborn neurons following severe CCI. 
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Figure 4.9 (cont.): Central infusion of 3 µg/d human insulin-like growth factor-1 
(IGF-1) via a lower infusion rate (0.11 µL/hr) resulted in modest infusion-related 
brain swelling and enhanced post-traumatic neurogenesis at 7 d following severe 
controlled cortical impact (CCI). (A-D) Representative images of cresyl violet staining. 
Compared to (A) infusion of vehicle (Veh), (B) infusion of hIGF-1 in sham-injured mice 
(Sham) resulted in minor cortical swelling with no appearance of hippocampal distortion. 
(C) Brain-injured mice treated with vehicle exhibited characteristic CCI-induced cortical 
cavitation with minimal indication of brain swelling. (D) Infusion of 3 µg/d hIGF-1 at 0.11 
µL/hr produced mild or no hippocampal swelling in the majority of mice (6 of 8, shown). 
Scale bar represents 500 µm. (E-H) Representative images of doublecortin (DCx, green) 
and 5-bromo-2-deoxyuridine (BrdU, red) immunohistochemistry. Scale bar represents 
100 µm. (E-F) DCx and BrdU immunoreactivity and colocalization of DCx and BrdU 
appeared equivalent between treatment groups of sham-injured mice. (G) DCx 
immunoreactivity and the incidence of colocalization appeared to be reduced in vehicle-
treated mice after controlled cortical impact compared to vehicle-treated sham-injured 
mice. (H) IGF-1-treated brain-injured mice exhibited increased DCx immunoreactivity 
and an increased incidence of DCx and BrdU colocalization compared to vehicle-treated 
brain-injured mice. (I) Brain-injured mice resulted in significantly reduced immature 
neuron density (main effect of injury, p<0.005). Treatment with IGF-1 significantly 
increased immature neuron density (main effect of treatment, p<0.05). (J) Brain injury 
produced a significant increase in BrdU+ cell density (main effect of injury, p<0.05). (K) 
Quantification of DCx and BrdU colocalization revealed a significant increase in the 
density of newborn neurons of mice infused with IGF-1 at 7 d compared to mice infused 
with vehicle (main effect of treatment, p<0.05). Data are presented as mean + SEM. 
(n=4 sham-injured per treatment and n=8 brain-injured per treatment group).  
149 
 
Discussion  
Systemic administration of IGF-1 has been shown to improve motor function 
(Saatman et al. 1997) and/or cognitive performance (Saatman et al. 1997; Rubovitch et 
al. 2010) in rodents subjected to experimental TBI; however, in Chapter 3 we showed 
that systemic infusion of IGF-1 did not attenuate motor impairment in mice subjected to 
severe CCI. We also demonstrated that we were unable to detect hIGF-1 in the brain 
following systemic infusion of 4 mg/kg/d of hIGF-1. Considering that increasing doses of 
systemically administered IGF-1 can produce hypoglycemia and increase mortality in 
rats after experimental TBI (Saatman et al. 1997), we chose to pursue central infusion to 
achieve greater levels of IGF-1 in the brain and reduce potential complications 
associated with systemic administration of doses above 4 mg/kg/d. In the current study, 
we demonstrate for the first time that central administration of IGF-1 improves motor 
function, reduces cognitive impairment and enhances immature neuron density in mice 
after experimental TBI. 
Intracerebroventricular injection of radiolabeled IGF-1 into adult rats results in 
increased radioactivity and IGF-1 immunoreactivity throughout the brain parenchyma, 
including the cortex, white matter tracts and the hippocampus within 30 minutes post-
injection (Guan et al. 1996; Thorne et al. 2004). These studies highlight that 
intracerebroventricular administration results in widespread distribution of IGF-1 in the 
brain, and suggest that central administration is applicable for broad delivery of IGF-1 
throughout the brain following experimental TBI. However, prolonged central infusion 
may be necessary to achieve sustained elevations of IGF-1 in the injured brain. 
Nagajara et al. (2005) demonstrated that following a single intracerebroventricular 
injection, radiolabeled IGF-1 is rapidly cleared into systemic circulation with limited 
penetrance of radiolabeled IGF-1 in the brain parenchyma by 3 hr after injection. By 
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utilizing a continuous central infusion of hIGF-1 into the lateral ventricle contralateral to 
the contusion injury we established that levels of hIGF-1 were elevated in the injured 
cortex and bilaterally in the hippocampus, two of the most vulnerable brain regions 
following severe CCI, even at 7 days after injury. While we observed a significantly 
greater level of hIGF-1 in the contralateral hippocampus, this is likely due to its proximity 
to the site of infusion.  
Although it is well established that IGF-1 in the systemic circulation can pass into 
the brain through receptor-mediated endocytosis (Reinhardt and Bondy 1994), a 
previous study demonstrated the converse, that centrally infused IGF-1 can be cleared 
from cerebrospinal fluid (CSF) and enter systemic circulation, likely via the lymphatic 
system and cranial and/or spinal nerve roots (Nagaraja et al. 2005). We demonstrate 
that hIGF-1 infused into the lateral ventricle was detected at concentrations of 
approximately 60-80 ng/mL in the systemic circulation at the cessation of central 
infusion. Surprisingly, the levels of hIGF-1 in the systemic circulation were comparable to 
levels quantified in the ipsilateral cortex or hippocampus, suggesting that a moderate 
proportion of centrally infused hIGF-1 was cleared from the brain and entered the 
systemic circulation. Therefore it is possible that elevated levels of hIGF-1 in the brain 
reflect, in part, secondary entry of hIGF-1 into the brain from systemic circulation via 
receptor-mediated endocytosis. However, it is likely that this contribution is minimal, in 
light of data in Chapter 3 demonstrating that serum levels of hIGF-1 nearly 2-fold higher 
following systemic infusion of hIGF-1 resulted in undetectable levels in the brain at 7 d 
following severe CCI. Our findings from Chapter 3 suggest that the elevation of brain 
levels of hIGF-1 in the current study is likely reflective of central infusion and not 
increased brain uptake of hIGF-1 from systemic circulation.  
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Central infusion was selected to minimize systemic hypoglycemia in IGF-1-
infused brain-injured animals at 1 d following brain injury. Even though central infusion 
resulted in elevated serum hIGF-1, central infusion of IGF-did not produce systemic 
hypoglycemia at 24 hr after brain injury, as was previously reported following systemic 
infusion of IGF-1 in rats after moderate TBI (Saatman et al. 1997). This finding highlights 
that central infusion of IGF-1 eliminated a potential side effect of systemic administration 
of IGF-1 after experimental TBI.  
The IGF-1 receptor is expressed by neurons and astrocytes, and in the 
vasculature, choroid plexus and the hippocampus throughout adulthood (Bondy and Lee 
1993; Bondy and Cheng 2004). Binding of IGF-1 to its cognate receptor elicits activation 
of Akt and the subsequent inhibition of pro-apoptotic factors including caspase-9, Bad 
and NF-kB (Peruzzi et al. 1999; Fukunaga and Kawano 2003). Enhanced Akt activation 
is associated with increased neuronal survival after CNS injury; conversely, low levels of 
Akt activation have been linked to increased cellular susceptibility to damage and death 
(Noshita et al. 2001; Noshita et al. 2002). Brain injury results in an acute and transitory 
rise in endogenous levels of IGF-1 in the brain (Madathil et al. 2010) and a transient 
increase in Akt activation for hours after experimental TBI (Zhang et al. 2006; Madathil et 
al. 2010; Rubovitch et al. 2010). Subsequently, activity of Akt is reduced by 24 hr and 
this depression persists for at least 72 hr in the hippocampus following CCI (Zhang et al. 
2006), suggesting that continuous infusion of IGF-1 may be required to promote 
sustained elevations in Akt activity after brain injury. IGF-1-treated mice in this study 
exhibited a significant increase in Akt phosphorylation in the hippocampus after 7 d of 
IGF-1 infusion. While increased activation of Akt suggested enhanced protective 
signaling during the IGF-1 infusion, future studies will need to elucidate the acute time 
course of Akt activation in response to IGF-1 treatment and assess other mediators of 
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IGF-1 signaling including MAPK and mTOR. Additional work is also needed to 
investigate the potency of IGF-1 to exert long-lasting protective and reparative effects 
after the cessation of treatment. Together, these studies will afford a better 
understanding of the time course of IGF-1 signaling and provide valuable insight into 
designing effective therapeutic treatment paradigms for IGF-1 in the context of TBI.  
Previous work from our lab demonstrated that astrocyte-specific overexpression 
of IGF-1 in the contused mouse brain significantly attenuated motor dysfunction during 
the week following severe CCI (Madathil 2013). In the current study, we corroborate 
these findings using a more clinically relevant strategy for elevating brain IGF-1. Central 
infusion of IGF-1 significantly attenuated motor impairments at 1, 2, 3, and 5 d post-
injury in mice subjected to severe CCI. An earlier study in which systemic injections of 1 
mg/kg IGF-1 twice a day resulted in significantly improved motor function, beginning only 
after 5 d of treatment in rats subjected to moderate TBI (Saatman et al. 1997), 
suggested that IGF-1 promotes delayed plasticity or regeneration that may underlie the 
observed recovery of motor function. Our findings of acute recovery of motor function 
after central infusion of IGF-1 differ somewhat from these previously published findings. 
It is possible that elevated levels of IGF-1 in the brain, as observed after targeted 
astrocyte-specific overexpression or central infusion of IGF-1 is needed to promote 
acute recovery of motor function, as this was not observed following systemic 
administration of IGF-1. The observation that central infusion of IGF-1 attenuates motor 
dysfunction during the week after severe CCI supports our hypothesis that exogenous 
administration of IGF-1 promotes neurobehavioral improvement after experimental TBI.  
We demonstrate that central infusion of IGF-1 reduces injury-induced cognitive 
dysfunction associated with severe CCI at 7 d post-injury. Our findings corroborate 
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previous work from our lab demonstrating that targeted astrocyte-specific 
overexpression of IGF-1 attenuated cognitive deficits in the novel object recognition task 
at 7 d following severe CCI (Madathil 2013). Exogenous administration of IGF-1 has also 
been shown to promote recovery of cognitive function after experimental TBI. Following 
mild weight drop injury, systemic injections of 4 µg/kg IGF-1 at 24 and 48 hr post-injury 
improved performance in a Y-maze assessment of cognitive function at 7 d post-injury 
(Rubovitch et al. 2010). Continuous systemic infusion of 4 mg/kg/d IGF-1 improved 
spatial learning and memory at 2 weeks post-injury in rats subjected to moderate TBI 
(Saatman et al. 1997). Collectively these previous reports and our current findings 
highlight that administration of IGF-1 promotes recovery of cognitive function in rats and 
mice in multiple models of TBI and across the spectrum of severity of brain injury. The 
observed improvements in cognitive function may be related to neuroprotection or post-
traumatic neurogenesis.  
Reductions in hippocampal immature neuron density result in impaired spatial 
learning and memory (Clelland et al. 2009; Deng et al. 2009; Jessberger et al. 2009). 
Immature neurons are particularly vulnerable to CCI, as demonstrated by a marked 
reduction in the numbers of immature neurons within days after injury (Rola et al. 2006; 
Gao et al. 2008; Yu et al. 2008). Similarly, we observed a marked reduction in immature 
neuron density in the injured dentate gyrus granular layer at 7 d after severe CCI, a time 
point shown to be near the peak of immature neuron loss (Rola et al. 2006). In this 
report, mice centrally infused with either 10 g/d or 3 g/d IGF-1 after CCI exhibited 
enhanced hippocampal immature neuron density at 7 d post-injury, as compared to 
vehicle-infused brain-injured mice. This response appeared dose-dependent over the 
range of 0.3 to 10 μg/d hIGF-1. In a rat model of cerebral hypoxic-ischemic injury, doses 
of 50 g and 5g of IGF-1, but not 0.5µg of IGF-1, injected into the lateral ventricle 
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promoted enhanced neuroprotection in the cortex and dentate gyrus of the hippocampus 
(Guan et al. 1993), corroborating dose-dependent effects of IGF-1 in the brain after 
acute CNS injury. In the clinical setting, the average administration window of 
therapeutic agents in clinical trials is 3-8 hr after TBI for a variety of reasons including 
transportation, stabilization and enrollment of the patient into the trial (Maas et al. 2007). 
Using a clinically relevant delayed administration paradigm, we demonstrate that 
infusion of IGF-1 initiated 6 hr following severe CCI was effective at increasing immature 
neuron density.  
Increases in immature neuron density at 7 d after TBI may reflect survival of 
existing immature neurons or enhanced generation of new immature neurons. IGF-1 is a 
potent neurotrophic factor that promotes cell survival of cultured neurons and reduces 
cell loss following acute CNS injury (Guan et al. 1993; Russell et al. 1998; Guan et al. 
2001; Brywe et al. 2005; Bendall et al. 2007), but can also increase cellular proliferation 
and promote neuronal differentiation (Arsenijevic and Weiss 1998; Aberg et al. 2000; 
Brooker et al. 2000; Arsenijevic et al. 2001; Yan et al. 2006). In our current study, we did 
not evaluate survival of immature neurons acutely after injury; this would need to be 
investigated in future studies. However, our findings in Chapter 3 (and in Chapter 5) 
suggest that IGF-1 may not protect against acute immature neuron loss. Instead IGF-1 
may enhance the generation of new neurons in the injured brain. Following the robust 
loss of immature neurons after CCI, a slow recovery of immature neuron density to pre-
injury levels occurs in the days to weeks following CCI (Rola et al. 2006; Yu et al. 2008). 
IGF-1 enhances the generation of newborn neurons in the hippocampus by enhancing 
neuronal differentiation of newly proliferated cells (Aberg et al. 2000; Trejo et al. 2001). 
Increased immature neuron density at 7 d following severe CCI with treatment of IGF-1 
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may be indicative of post-traumatic neurogenesis, potentially driven by enhanced cellular 
proliferation and neuronal differentiation.  
Brain injury results in increased cellular proliferation in the hippocampus following 
CCI (Dash et al. 2001; Rola et al. 2006; Zhou et al. 2012) and increased proliferation of 
neural progenitor cells can contribute to the generation of newborn neurons following 
brain injury (Rola et al. 2006; Sun et al. 2009). We confirmed that severe CCI produced 
a significant increase in BrdU-positive cells in the dentate gyrus granular layer at 7 d 
after CCI. Injury-induced cellular proliferation can be enhanced by 
intracerebroventricular infusion of growth factors, including bFGF, VEGF and EGF 
following experimental TBI (Sun et al. 2009; Sun et al. 2010; Thau-Zuchman et al. 2010; 
Thau-Zuchman et al. 2012). Consistent with the cellular proliferative effects of IGF-1 
(Aberg et al. 2000; Arsenijevic et al. 2001), we observed a small, but not statistically 
significant increase in BrdU positive cells following central infusion of 3 g/d of hIGF-1, 
suggesting that IGF-1-mediated increases in cellular proliferation may contribute to the 
increased immature neurons density observed after severe CCI. 
Colocalization of DCx and BrdU revealed that brain injury in vehicle-infused mice 
resulted in a marked reduction in the number of neurons born between 4 and 5 days 
after severe CCI. Central infusion of IGF-1 significantly increased the number of 
newborn neurons, suggesting that IGF-1 enhanced the generation of newborn neurons 
after brain injury. This is likely the result of enhanced neuronal differentiation of newly 
proliferated cells after brain injury. A small proportion of newly proliferated cells in the 
granular layer of the dentate gyrus will adopt a neuronal lineage after CCI (Rola et al. 
2006; Gao et al. 2008), but the majority of the newly proliferated cells will express 
markers characteristic of glial cells including astrocytes, microglia, and oligodendrocytes 
156 
 
(Rola et al. 2006; Urrea et al. 2007). Our data suggests that treatment with IGF-1 may 
shift the ratio of cellular differentiation of newly proliferated cells from a predominantly 
glial lineage towards a neuronal lineage after CCI. Peripheral infusion of IGF-1 in 
hypophysectomized rats results in increased generation of newborn neurons and not 
astrocytes (Aberg et al. 2003), consistent with our observations of an IGF-1-mediated 
enhancement of neuronal differentiation. IGF-1 is also a potent promoter of 
oligodendrocyte differentiation (Aberg et al. 2007), and future studies will need to 
elucidate if prolonged central infusion of IGF-1 also enhances the generation of new 
oligodendrocytes in the dentate gyrus granular layer after CCI.  
Immature neurons generated after fluid percussion injury project processes to 
CA-3 and incorporate into the dentate gyrus during the weeks following injury (Emery et 
al. 2005; Sun et al. 2007). Of the newborn neurons generated after brain injury, only a 
small proportion will integrate into the dentate gyrus granular layer (Sun et al. 2007). In 
the current study we showed that IGF-1 overexpression increases the number of 
immature neurons at 7 d post-injury. Future studies will need to determine if treatment 
with IGF-1 promotes long-term survival, maturation, and functional incorporation of the 
newly generated immature neurons into the hippocampus after severe CCI. Newborn 
neurons are speculated to contribute to improved spatial learning at 8 weeks post-injury 
in rats subjected to moderate fluid percussion injury (Sun et al. 2007). Experimental 
blockage of the immature neuron recovery phase after CCI exacerbates injury-induced 
spatial learning deficits at 1 month after CCI (Blaiss et al. 2011), suggesting that 
immature neurons are important for cognitive function after brain injury. The findings 
reported by Blaiss et al. (2011) also support the hypothesis that therapeutic strategies 
that attenuate immature neuron loss or enhance the generation of immature neurons 
may improve cognitive outcome following TBI.  
157 
 
Severe CCI produces cortical cavitation, loss of subcortical white matter, and 
regional hippocampal neurodegeneration by one week post-injury (Hall et al. 2005; 
Saatman et al. 2006; Hall et al. 2008; Pleasant et al. 2011). Treatment with hIGF-1 
following severe CCI did not appear to reduce overt cortical or hippocampal cell loss 
after brain injury. While previous work from our lab showed that targeted astrocyte-
specific overexpression of IGF-1 reduced hippocampal neurodegeneration at 3 d post-
injury (Madathil 2013), no previous study evaluating the efficacy of exogenous 
administration of IGF-1 examined neuroprotection. In Chapter 3, we showed that 
systemic administration of IGF-1 did not show overt neuroprotection, but brain levels of 
IGF may have been below a therapeutic threshold. Quantification of the number of 
neurons in the dentate gyrus granular layer, CA3 and CA1 may be needed to determine 
if centrally infused IGF-1 protects against hippocampal neuron loss. Future studies may 
also need to determine if the brain swelling observed in the subset of mice led to tissue 
damage that may have counteracted potential neuroprotective effects in the injured 
brain.  
Infusion of hIGF-1 resulted in notable brain swelling in a subset of mice. 
Parameters of body weight, age, and blood glucose did not predict the occurrence of 
infusion related swelling. The observance of increased brain swelling may be related to 
fluid effects such as raised intracranial pressure in the brain, exacerbation of brain injury-
induced edema, or to effects of IGF-1 itself.     
Increases in fluid loading in the brain during central infusion may contribute to 
brain swelling at 7 d following continuous infusion. Prolonged intracerebroventricular 
infusion in mice resulted in modest indications of cortical brain swelling that were 
particularly evident at the craniotomy site in sham-injured mice. Cerebrospinal fluid 
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turnover occurs approximately four times a day with a total volume of approximately 40 
L of fluid present in the adult mouse brain depending on the age and weight of the 
mouse (Pardridge 1991). Utilization of osmotic minipumps with flow rates of 0.11 L/hr to 
0.5 L/hr resulted in infusion of approximately 2.5 L to 12 L during a period of 24 hr, 
suggesting that the volume of infusate represents a small volume (<10%) of total 
cerebrospinal fluid volumes in the brain. However, the volume of infusate may have 
contributed to brain swelling as we showed that a reduction in the volume of infusate in 
sham-injured mice resulted in decreased cortical swelling at the craniotomy site. To the 
best of our knowledge, brain swelling has not been reported as a consequence of 
prolonged central infusion using osmotic minipumps similar to those utilized in the 
current study. The completion of a decompressive craniotomy prevents increases in 
intracranial pressure associated with severe CCI (Zweckberger et al. 2003). The 
presence of a craniotomy, in sham-injured and brain-injured mice in the current study 
may have facilitated brain swelling in response to increases in intracranial pressure 
during prolonged infusion. The physical shape and proximity of the cannula base used in 
the current study prevented complete sealing of the cranioplasty over the craniotomy 
site, potentially allowing swelling of the brain tissue and equilibration of intracranial 
pressure during the infusion period. There is a gap in our understanding of the effect of 
increased fluid loading on intracranial pressure in the mouse brain after central infusion 
in the context of TBI. Only a handful of studies have evaluated prolonged 
intracerebroventricular infusion in mice following experimental TBI, including weight drop 
injury (Thau-Zuchman et al. 2010; Thau-Zuchman et al. 2012). A single bolus injection of 
2 µL saline into the lateral ventricle of CCI-injured mice resulted in an approximate 2-4 
mmHg or 8-15% increase in intracranial pressure to 26 mmHg at 24 hr post-injury 
(Trabold et al. 2008). With our highest flow rate, 2 L was infused over a period of 
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approximately 4 hr. The cannula base utilized in the present study prevented the 
implantation of an intracranial pressure-monitoring device into the lateral ventricle, but 
our findings highlight that future studies should examine potential temporal changes in 
intracranial pressures that may result from prolonged continuous central infusion after 
severe CCI. It is unlikely that fluid loading alone resulted in brain swelling as sham-
injured mice exhibited less brain swelling than brain injured mice. While increases in fluid 
loading does not appear to be the only cause of brain swelling, increasing volumes of 
infusate may contribute to the incidence of brain swelling after prolonged central 
infusion. 
Brain edema develops in the contused cortex and hippocampus ipsilateral to 
injury within hours, reaching maximal levels by 24 hr post-injury and resolving towards 
non-injured values by 7 d after CCI (Kochanek et al. 1995; Trabold et al. 2008; Terpolilli 
et al. 2013). The mean water content values reported in this study for all groups (77-
80%) are comparable to water content values reported in sham-injured mice 
(approximately 79%) and consistent with the resolution of injury-induced edema by one 
week post-injury (Trabold et al. 2008). However, central infusion of hIGF-1 after severe 
CCI resulted in edema (81-82%) far above the normal range in the injured hippocampus 
of a subset of mice. Delaying the onset of infusion for approximately 6 hr post-injury in 
an effort to reduce fluid loading during acute development of post-traumatic edema did 
not reduce brain swelling in the subset of mice at 7 d post-injury. Our findings suggested 
that prolonged central infusion was not a main contributor to the exacerbation of brain 
injury-induced edema in the subset of mice, and instead may be related to IGF-1 itself. 
Because cortical brain swelling in sham-injured mice and hippocampal distortion 
in brain-injured mice appear much more pronounced in IGF-1 infused mice, IGF-1 may 
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be mediating direct or indirect effects that potentiate the development of brain swelling. 
Reductions in the dose of infused IGF-1 resulted in decreases in the incidence and 
severity of brain swelling after injury, with mice infused with the lowest doses of IGF-1 
(0.3 and 1 µg/d) exhibiting no notable brain swelling after severe CCI. Our findings 
suggest that IGF-1 may change fluid dynamics in the brain that could promote the 
development of exacerbated brain-injury-induced brain swelling in after severe CCI.  
Changes in CSF production or absorption could lead to alterations in intracranial 
pressure after brain injury. Evidence is emerging that growth factors can disrupt normal 
CSF formation and absorption. Intracerebroventricular infusion of bFGF promoted the 
development of hydrocephalus, possibly as a result of reduced CSF absorption 
(Johanson et al. 1999; Krishnamurthy et al. 2009). Increased levels of endogenous 
transforming growth factor β (TGFβ) have been observed in the CSF of patients with 
posthemorrhagic hydrocephalus, suggesting that TGFβ is associated with the 
development of hydrocephaly after hemorrhage in the brain (Whitelaw et al. 1999; Flood 
et al. 2001). Although little is known about the capacity of IGF-1 to disrupt CSF 
dynamics, brain-specific overexpression of IGF-1 results in increased brain size and 
weight (Ye et al. 1996; Popken et al. 2004; Ye et al. 2004), and one study observed that 
overexpression of IGF-1 appeared to reduce the volumes of the lateral, third and fourth 
ventricles in the postnatal brain (Popken et al. 2004), suggesting that elevated levels of 
IGF-1 in the brain does not promote the development of hydrocephalus. Systemic co-
administration of IGF-1 and growth hormone for a period of 14 d to moderate-to-severely 
brain-injured patients did not alter fluid retention or increase intracranial pressure (Hatton 
et al. 2006), suggesting that systemic infusion of IGF-1 does not disrupt CSF balance in 
the context of human contusion TBI. However, additional work is needed to ensure that 
central infusion of IGF-1 does not modulate CSF balance in the context of TBI, as brain 
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injury-induced increases in intracranial pressure could be exacerbated by changes in 
CSF dynamics (Marmarou et al. 1978).   
In summary, we have demonstrated that prolonged intracerebroventricular 
infusion of IGF-1 attenuates motor and cognitive dysfunction after severe CCI in mice. 
Treatment with IGF-1 showed an apparent dose-dependent increase in immature neuron 
density after brain injury. Central infusion of either 10 µg/d or 3 µg/d resulted in 
significantly increased immature neuron density, an effect retained even with a clinically 
relevant 6 hr delayed infusion onset. This IGF-1-mediated increase in immature neuron 
density at 7 d post-injury may be the result of increased cellular proliferation and 
enhanced neuronal differentiation, important aspects of post-traumatic neurogenesis. 
This study also highlights the need for careful consideration of the administration 
paradigm utilized for central infusion of growth factor like therapeutic agents for the 
treatment of TBI.  
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Chapter 5: Targeted Astrocyte-specific Conditional IGF-1 Overexpression 
Enhances Post-Traumatic Neurogenesis by Promoting Neuronal Differentiation 
Introduction 
In Chapter 4 we demonstrated that central infusion of IGF-1 attenuated motor 
and cognitive impairments and increased immature neuron density in the dentate gyrus 
granular layer after severe CCI. Moreover, we provided evidence that increased 
immature neuron density may be the result of an IGF-1-mediated enhancement of post-
traumatic neurogenesis. However, we observed that direct infusion of IGF-1 can 
exacerbate brain swelling after severe CCI. In order to minimize complications of 
hippocampal distortion after central infusion of IGF-1, we chose to pursue our evaluation 
of the efficacy of IGF-1 to promote post-traumatic neurogenesis in a conditional 
astrocyte-specific IGF-1 overexpressing transgenic mouse model. In this chapter we 
sought to evaluate the potential mechanisms, i.e. cell survival, cellular proliferation, 
neuronal differentiation, morphological maturation of immature neurons, by which IGF-1 
may promote hippocampal neurogenesis after severe CCI. 
The controlled cortical impact (CCI) model of brain injury is well characterized 
and widely utilized to study not only widespread cortical cell death after contusion, but 
also selective regional hippocampal cell loss and the manifestations of functional 
impairments including altered hippocampal long term potentiation and cognitive 
dysfunction (Hamm et al. 1992; Smith et al. 1995; Fox et al. 1998; Albensi et al. 2000; 
Saatman et al. 2006; Hall et al. 2008; Norris and Scheff 2009; Blaiss et al. 2011; Gao et 
al. 2011; Pleasant et al. 2011). The severity of hippocampal cell loss after CCI can be 
modulated by altering injury parameters, such as impact depth (Goodman et al. 1994; 
Saatman et al. 2006; Huh et al. 2011), velocity (Goodman et al. 1994), or impactor tip 
geometry (Nishibe et al. 2010; Pleasant et al. 2011). Mild CCI typically results in acute 
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degeneration in the dentate gyrus and hilus, whereas increases in the injury severity 
result in observable degeneration in CA3 and ultimately CA1 (Goodman et al. 1994; 
Anderson et al. 2005; Saatman et al. 2006; Elkin et al. 2010; Pleasant et al. 2011). Due 
to the fact that the dentate gyrus appears to be most sensitive to trauma after impact, 
the CCI model is applicable for investigating the evolution and mechanisms of post-
traumatic neurogenesis (Rola et al. 2006; Gao et al. 2008; Yu et al. 2008; Zhou et al. 
2012).  
Newborn neurons are generated throughout adulthood in the subgranular (SGZ) 
and subventricular zones of the brains of humans and rodents (Eriksson et al. 1998; 
Zhao et al. 2008). In the dentate gyrus of the hippocampus, this population of neurons 
migrates from the SGZ into the inner and outer layers of the granular layer, and 
ultimately extends axonal and dendritic processes to integrate into the dentate gyrus 
circuitry (van Praag et al. 2002; Jessberger and Kempermann 2003; Zhao et al. 2008). 
This population of newborn neurons is thought to contribute to learning and the 
formation of new memories as demonstrated by the fact that genetic depletion of the 
immature neuron population impairs spatial learning at 1 month following CCI (Clelland 
et al. 2009; Deng et al. 2009; Jessberger et al. 2009).  
CCI results in a marked reduction in the numbers of immature neurons in the 
hippocampal granular layer within days after injury (Rola et al. 2006; Gao et al. 2008; Yu 
et al. 2008). Markers of degenerating neurons are observed in the inner granular layer 
and found to predominantly colocalize with markers of immature neurons (Gao et al. 
2008). Brain injury promotes cellular proliferation in the granular layer and the expansion 
of the SGZ neurogenic niche (Dash et al. 2001; Kernie et al. 2001; Rola et al. 2006; Gao 
et al. 2009) that contributes to the recovery of the newborn neuron population in the 
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days to weeks following injury (Rola et al. 2006; Yu et al. 2008). A recent study 
highlights that blocking post-traumatic neurogenesis for the 4 weeks following brain 
injury, by genetic depletion of the immature neuron population, is sufficient to exacerbate 
injury-induced deficits in spatial learning at 1 month following CCI (Blaiss et al. 2011). 
Only a portion of the newborn neurons generated after brain injury will survive and 
develop into mature granular neurons that incorporate into the granular layer (Sun et al. 
2005; Rola et al. 2006; Sun et al. 2007). Due to the importance of immature neurons in 
cognition, it is possible that enhancement of post-traumatic neurogenesis attenuates 
learning and memory deficits associated with TBI.   
Several studies have demonstrated that post-traumatic neurogenesis can be 
enhanced after TBI with therapeutic agents and growth factors, including S100B, 
erythropoietin, vascular endothelial growth factor and basic fibroblast growth factor 
(Kleindienst et al. 2005; Lu et al. 2005; Sun et al. 2005; Thau-Zuchman et al. 2010). 
Similar to the aforementioned growth factors, IGF-1 has been shown to promote 
neurogenesis in the rodent hippocampus (Aberg et al. 2000; Trejo et al. 2001; Trejo et 
al. 2008); however, the efficacy of IGF-1 to promote neurogenesis in the context of TBI 
is not known. Insulin-like growth factor-1 (IGF-1) is a potent neurotropic factor, which 
upon binding to its cognate receptor increases activation of Akt and MAPK (Seger and 
Krebs 1995; Manning and Cantley 2007). Numerous studies have demonstrated that 
enhanced IGF-1 signaling promotes stages of neurogenesis including cell survival, 
proliferation, dendritic growth, and neuronal differentiation of newly proliferated cells 
(Arsenijevic and Weiss 1998; Brooker et al. 2000; Niblock et al. 2000; Arsenijevic et al. 
2001; Cheng et al. 2003; McCurdy et al. 2005). Overexpression of IGF-1 by glial and 
neuronal-specific promoters results in increased numbers of neurons and glial cells in 
the brain (Carson et al. 1993; Ye et al. 1995; Chrysis et al. 2001; Popken et al. 2004; Ye 
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et al. 2004), due to increased cellular proliferation and reduced apoptosis (Ye et al. 
1996; Chrysis et al. 2001). IGF-1 has been implicated as a mediator of exercise-induced 
hippocampal neurogenesis evident by increased serum levels and increased brain 
uptake of IGF-1 that accompany increases in hippocampal proliferation and newborn 
neuron production (Trejo et al. 2001; Llorens-Martin et al. 2010). Furthermore, blocking 
uptake of serum IGF-1 into the brain abolishes exercise-induced increases in 
neurogenesis (Trejo et al. 2001; Llorens-Martin et al. 2010). In addition to promoting 
neurogenesis, central administration of IGF-1 in aged rats reverses an age-induced 
reduction in hippocampal neurogenesis (Lichtenwalner et al. 2001). Collectively, these 
studies highlight that IGF-1 is a potent promoter of neurogenesis in the adult brain. 
To evaluate the ability of IGF-1 to promote neurogenesis after TBI, we utilized an 
astrocyte-specific conditional IGF-1 overexpressing transgenic mouse (Ye et al. 2004) to 
increase brain levels of IGF-1 following severe CCI. The expression of IGF-1 is restricted 
to glial fibrillary acidic protein (GFAP) expressing cells and is regulated by a Tet-off 
expression system. Dietary supplementation of doxycycline suppresses expression of 
IGF-1 during postnatal development, thereby minimizing potentially confounding effects 
of IGF-1 overexpression during brain development. Brain injury is associated with 
increased astrogliosis and increased GFAP expression in injured tissue after injury. 
Reactive astrocytosis and enhanced GFAP expression in the hippocampus after CCI 
(Saatman et al. 2006; Sandhir et al. 2008) provides targeted expression of IGF-1 in the 
damaged hippocampus (Madathil 2013).  
Using the conditional astrocyte-specific IGF-1 overexpression transgenic mouse 
model, we will assess the densities of immature neurons, newly proliferated cells, and 
immature neurons generated in the hippocampal granular layer after CCI in order to 
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evaluate the efficacy of IGF-1 to enhance neurogenesis in the context of severe CCI. In 
this chapter we demonstrate that elevated brain levels of IGF-1 promotes post-traumatic 
neurogenesis by enhancing neuronal differentiation of newborn cells. We demonstrate 
that severe CCI induced a significant reduction in immature neuron dendritic arbor 
complexity, a previously unidentified pathological consequence in this population of 
neurons. We also establish that overexpression of IGF-1 in brain-injured mice restores 
immature neuron dendritic process complexity to that observed in mice subjected to 
sham injury.  
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Materials and Methods 
Animals  
All experimental procedures were approved by the University of Kentucky 
Institutional Animal Care and Use Committee in accordance with the Guide for the Care 
and Use of Laboratory Animals established guidelines from the National Institutes of 
Health. Animals were housed 5 mice per cage in the University of Kentucky Medical 
Center vivarium with a 14:10 hour light/dark photoperiod and were provided food and 
water ad libitum, but food consumption was not monitored in animals utilized for this 
study. Adult male transgenic IGF-1 overexpressing mice (IGF TG) and wild-type (WT) 
littermates aged 8-12 weeks, weighing 22-30g, were utilized for all experiments. 
The astrocyte-specific conditional overexpression of human IGF-1 in the 
transgenic mouse has been previously described (Ye et al. 2004).  The production of the 
tetracycline transactivator (tTA) protein is linked to the glial fibrillary acidic protein 
(GFAP) promoter in tTAGFAP mice. The transgene for human IGF-1 was inserted into a 
pTRE plasmid and utilized to generate IGF-1pTRE mice. Crossing of tTAGFAP and IGF-
1pTRE mice yields double transgenic mice that carry both transgenes and conditionally 
express IGF-1 in GFAP expressing cells. Expression of IGF-1 was suppressed for the 
first 4 weeks of postnatal development by utilizing a Tet-off strategy and dietary 
supplementation of doxycycline in mouse chow (200 mg/kg). The binding of tTA to the 
tetracycline response element that drives IGF-1 expression is blocked by the binding of 
doxycycline to the tTA protein. Mice received standard mouse chow for at least 4 weeks 
to provide sufficient time for transgene expression prior to surgical procedures.  
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Controlled Cortical Impact  
Mice were anesthetized using 3% isoflurane in order to shave their heads and 
place them in a stereotaxic frame (David Kopf Instruments, CA), where anesthesia was 
maintained using 3% isoflurane via a nose cone for the duration of the surgical 
procedure. A midline scalp incision was performed and the skin reflected to expose the 
skull. A 5 mm craniotomy was performed centered between bregma and lambda lateral 
to the sagittal suture of the left hemisphere of the brain with the dura left intact. Animals 
were randomly assigned to receive either sham or CCI injury. Sham-injured mice 
received anesthesia and only a craniotomy prior to the cranioplasty and closure of the 
incision. The CCI injury was completed using a computer-controlled pneumatically driven 
piston that rapidly impacts the brain (TBI-0310 Impactor, Precision Systems and 
Instrumentation, VA). Mice subjected to brain injury received a 1 mm severe CCI injury 
with a velocity of 3.5 m/s using a 3 mm diameter rounded impactor tip. Following injury, 
a cranioplasty was completed using a small circular disk of dental acrylic adhered to the 
skull over the craniotomy site, the scalp was sutured, and the mice were placed on a 
heating pad to maintain normal body temperature. Once ambulatory, the mice were 
returned to their home cage.  
In one cohort, mice (n=4 sham-injured/genotype and n=8 CCI-injured/genotype) 
were injected with 50 mg/kg (i.p.) 5-bromo-2-deoxyuridine (BrdU; Fisher Scientific, NJ) to 
identify proliferating cells 4 hr prior to perfusion at 3 d post-injury. A second cohort of 
mice (n=8 sham-injured/genotype and n=13 brain-injured/genotype) received daily BrdU 
injections (50 mg/kg i.p.) beginning 1 hr after injury for 7 d to identify proliferating cells 
during the first week following injury. After 3 additional days of survival to provide 
sufficient time for newly proliferated cells to differentiate into immature neurons and 
express DCx (Encinas 2003), mice were euthanized at 10 d post-injury.  
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Tissue Collection and Processing  
Animals received an overdose of Fatal-plus (65 mg/kg sodium pentobarbital, i.p.) 
at either 3 or 10 d post-injury, and were transcardially perfused with heparinized saline 
followed by 10% neutral buffered formalin. Brains were removed from the skull 24 hr 
following post-fixation in 10% neutral buffered formalin, post-fixed for an additional 24 hr 
in 10% neutral buffered formalin, cryoprotected in 30% sucrose for 24 hr and rapidly 
frozen in -30°C isopentanes cooled on dry ice. Brains were cut into 40 µm-thick coronal 
sections using a sliding microtome (Dolby-Jamison, Pottstown, PA) and stored in 
cryoprotectant in parallel sets at -20°C.  
Immunohistochemistry 
Coronal brain sections, spaced 400 µm apart, between -1 mm and -3.5 mm 
bregma (Paxinos and Franklin 2001) were stained using standard free-floating 
immunohistochemistry staining protocols. Primary antibodies utilized were anti-
doublecortin (DCx; rabbit polyclonal, 1:500, Abcam, MA) to label the microtubule-
associated protein expressed exclusively in immature neurons and anti-BrdU (1:1000, 
Abcam) to label proliferating cells. Secondary antibodies were conjugated with Alexa 
Fluor® 488 (1:1000, Invitrogen, CA) or Cy3 (1:1000, Jackson ImmunoResearch, PA). 
Sections were initially rinsed in TBS and treated with 2N HCl (Fisher Scientific) for 1 hr 
at room temperature to expose the BrdU epitope, followed by treatment of 100mM 
borate buffer (pH 8.0, Fisher Scientific) for 10 minutes. Sections were rinsed in TBS 
overnight at 4°C. On the second day, sections were rinsed in TBS and blocked in 5% 
normal horse serum and 0.1% Triton-X-100 in TBS for 30 minutes. Both DCx and BrdU 
primary antibodies were diluted in blocking solution and sections incubated overnight at 
4°C.  The following day tissue was rinsed with TBS, incubated with secondary antibodies 
for 1hr, rinsed with TBS, incubated with Hoechst (1:10,000, Invitrogen, CA) for 1.5 
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minutes and rinsed with TBS. Labeled sections were mounted on gelatin-coated slides, 
coverslipped with fluoromount (Southern Biotech, AL), and stored at 4°C. 
Image Acquisition and Quantification 
Representative images utilized in the figures are maximum intensity projections 
of images collected as a z stack (1.5 µm step size) at 20X magnification using a C2+ TiE 
Nikon confocal microscope. The densities of immature neurons and proliferated cells 
were quantified in the ipsilateral dentate gyrus granular layer (DGGL) of each section, 
with sections spanning the rostrocaudal extent of the hippocampus from -1.06 to -3.5 
mm to bregma (Paxinos and Franklin 2001). We sampled one set of parallel sections (an 
average of 6 sections), spaced 400 µm apart, for each animal. All DCx or BrdU positive 
cells were manually counted in the upper and lower blades of the DGGL for each section 
at 40X (Olympus, BX51) using a FITC filter (41001, Chroma Technology, VT), or a 
TRITC filter (31002, Chroma Technology).  The incidence of DCx and BrdU 
colocalization was assessed using a wide band filter (51004v2, Chroma Technology) 
that permits simultaneous viewing of the emissions of both fluorophores of the 
secondary antibodies. Colocalization was verified by scanning through the z-axis to 
ensure colabeling within each quantified cell. Cell counts were normalized to the volume 
of the DGGL of each section in order to control for differences in granular DGGL size 
across sections. The Hoechst-stained DGGL of each quantified section was imaged 
(Olympus AX80, PA) and the area was measured using ImagePro (MediaCybernetics, 
MD). The thickness of each section was measured, in microns, using a stereology stage 
(Olympus BX51). Density measurements reflect the entire granular layer inclusive of 
subgranular, inner, and outer granular layers. For each animal, a mean hippocampal cell 
density was calculated for all quantified sections. In order to evaluate cell density as a 
function of proximity to injury, we evaluated the location of each section and assigned 
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the section to a specific bregma level according to the plates in the Paxinos and Franklin 
mouse brain atlas (2001). Sections were sorted into one of five bregma intervals 
spanning approximately 500 µm, with the center bregma level interval (-2.06 to -2.46 
mm) representing the epicenter of injury. In the event that two sections for a given 
animal fell within a single bregma interval, an average density measurement was 
determined for the two sections and this single value was used for that interval. Newborn 
neurons (DCx+/BrdU+) were also expressed as a percentage of total proliferated cells 
(BrdU+) to illustrate differences in cellular differentiation between the genotypes following 
injury. Quantification was performed by an investigator blinded to the genotype and 
injury conditions of each animal. 
Scholl Analysis 
Images of DCx were acquired as a z-stack (1.5 µm step size) at 20X 
magnification using a CKX31 A1 Nikon confocal microscope from a subset of mice (n=6 / 
sham-injured / genotype and n=6 brain-injured / genotype) were randomly selected from 
the 10 d cohort. Confocal images were obtained of eight randomly selected immature 
neurons from the upper blade of the DGGL from a section at the epicenter of injury (-
2.06 to -2.46 mm). The neuron was not utilized if dendritic fibers could not be traced 
through the confocal z-stack images. Dendritic processes of DCx expressing 
hippocampal granular neurons were manually traced on maximum intensity projection 
images, created from the z-stacks, and total dendritic length was analyzed using the 
NeuronJ plug-in for NIH ImageJ, as previously described (Cai et al. 2012). The number 
of dendritic intersections was quantified for each DCx+ neuron by a series of concentric 
circles (10 µm intervals) drawn from the center of the cell body using a Scholl analysis 
plug-in for NIH ImageJ. All image acquisition and subsequent analysis was completed by 
an investigator blinded to the genotype and injury status of each animal. 
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 Statistical Analysis 
All data is presented as mean + standard error of the mean (SEM). Cellular 
densities and measurements of dendritic morphology were compared using a two-way 
analysis of variance (ANOVA) followed by Newman-Keuls post-hoc t-tests when 
appropriate. Statistical tests were completed using Statistica (Statsoft Inc, OK). A p 
value less than 0.05 was considered statistically significant for all tests.  
173 
 
Results 
 TBI results in acute cell loss throughout the hippocampus, with the dentate gyrus 
being particularly susceptible to contusion injury (Anderson et al. 2005; Saatman et al. 
2006; Hall et al. 2008). To examine if IGF-1 overexpression confers protection to 
immature neurons in the hippocampus after severe CCI, we labeled immature neurons 
using doublecortin (DCx). Immunohistochemical staining for DCx in WT mice revealed 
loss of immunoreactivity consistent with cell loss scattered throughout the upper and 
lower blades of the granular layer 3 d after CCI, and an apparent recovery of cell 
number, similar to sham injury, at 10 d post-injury (Fig. 5.1A). Qualitative assessment of 
DCx immunoreactivity demonstrated that IGF TG mice exhibited a reduction in 
immunoreactivity consistent with cell loss throughout the upper and lower blades of the 
granular layer at 3 d after CCI, similar to WT mice. At 10 d after CCI, brain-injured IGF 
TG mice exhibited a robust increase in DCx immunoreactivity within each positive cell 
and an apparent increase in cell number above IGF TG mice subjected to sham injury 
(Fig. 5.1B). 
CCI resulted in a 37% reduction in the numbers of DCx+ neurons in WT mice (25 
+  2 cells/mm3) at 3 d post-injury with a recovery to sham levels (40 + 3 x 1000/mm3) by 
10 d (40 + 3 x 1000/mm3) following injury (Fig. 5.1C). IGF-1 overexpressing mice 
exhibited a similar basal immature neuron density in sham-injured mice (43 + 7 x 
1000/mm3), and a 23% decrease in DCx density at 3 d post injury (33 + 2 x 1000/mm3). 
However, brain-injured IGF TG mice exhibited an 86% increase over sham–injured IGF 
TG mice and an enhanced recovery of immature neuron density at 10 d post-injury (80 + 
8 x 1000/mm3) compared to brain-injured WT mice (#p<0.05, Fig. 5.1C). 
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To determine if immature neuron loss varied as a function of proximity to injury, 
DCx+ density was evaluated along the rostrocaudal extent of the dentate gyrus granular 
layer (-1.06mm to -3.4mm bregma). At 3 d following CCI, WT mice exhibited the greatest 
reduction in immature neuron density (53%), compared to sham-injured mice, at the 
epicenter of impact (-2.06 to -2.46mm), but reductions in immature neuron density were 
notable in regions as far as approximately 500 µm rostral or caudal to the injury 
epicenter (Fig. 5.1D). At 3 d following CCI, immature neuron loss in IGF TG mice was 
evident in regions approximately 500 μm rostral and caudal to the epicenter of injury, 
similar to CCI in WT mice (Fig. 5.1D). While DCx+ density returned to sham levels by 10 
d post-injury at most bregma levels in WT mice, IGF-1 TG mice showed significant 
increases, above sham levels, at the epicenter of injury and as far as approximately 500 
µm rostral and caudal to the epicenter (# p<0.05, compared to all groups within that 
bregma interval; Fig. 5.1D). 
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Figure 5.1: IGF-1 overexpression increases immature neuron density in the 
dentate gyrus granular layer following controlled cortical impact. (A, B) 
Representative images of doublecortin (DCx, green) immunoreactivity in the upper blade 
of the dentate gyrus granular layer of sham and brain-injured (A) wild-type (WT) and (B) 
IGF-1 overexpressing transgenic (IGF TG) mice at 3d and 10d after injury. Scale bar 
represents 50 µm. Granular layer (GL). (C) DCx+ cell density in WT mice recovered to 
sham levels by 10 d post-injury. IGF TG mice exhibited a significant increase in DCx+ cell 
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Figure 5.1 (cont.): density at 10 d post-injury (# p<0.05, compared to all groups). (D) 
The increase in DCx+ cell density with IGF-1 overexpression is present over a large 
rostrocaudal extent of the injured granular layer, presented along the x-axis as intervals 
spanning Bregma coordinates (mm). Data are presented as mean cell density (x 
1000/mm3) + SEM. (n=8 sham-injured/genotype, n=8 brain-injured/genotype at 3 d, and 
n=13 brain-injured/genotype at 10 d post-injury). Two-way ANOVAs were utilized for 
statistical analyses in (C) and at each bregma interval in (D), and followed by Newman-
Keuls post-hoc t-tests where appropriate. 
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 Severe CCI results in increased cellular proliferation within the granular layer of 
the hippocampus within days following brain injury (Dash et al. 2001; Rola et al. 2006). 
To evaluate if IGF-1 overexpression enhances immature neuron density at 10 d post-
injury by promoting cellular proliferation within the SGZ, we evaluated the extent of 
proliferation using two BrdU injection paradigms: 1) a single injection at 3 d post-injury, a 
peak time of proliferation (Dash et al. 2001) and 2) a cumulative injection paradigm to 
capture proliferation over the first 7 d following CCI. Immunohistochemical labeling of 
BrdU+ cells demonstrated no qualitative difference in the extent of proliferation in the 
granular layer of WT and IGF-TG sham-injured mice in either injection paradigm (Fig. 
5.2A, B). While CCI stimulated a significant 5-fold increase in cellular proliferation within 
the ipsilateral granular layer mice at 3 d post-injury (main injury effect, p<0.01), IGF-1 
overexpression did not affect early proliferation (Fig. 5.2C). The cumulative labeling 
paradigm of repeated daily BrdU injections for 7 d revealed a similar extent of cellular 
proliferation between WT and IGF TG sham-injured mice (Fig. 5.2B, D). Brain injury 
produced a significant 3-fold increase in proliferation during the week following the injury 
(main injury effect, p<0.01); however, proliferation was not enhanced by IGF-1 
overexpression (Fig. 5.2D). These data suggest that the increased immature neuron 
density observed in IGF TG mice at 10 d after CCI was not afforded by an IGF-1-
meditated enhancement of cellular proliferation.  
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Figure 5.2: IGF-1 overexpression does not enhance brain injury-induced cellular 
proliferation in the hippocampal granular layer following controlled cortical 
impact. (A, B) Representative images of proliferated cells identified by bromo-
deoxyuridine (BrdU, red) immunoreactivity counterstained with Hoechst stain (blue) in 
the upper blade of the granular layer of wildtype (WT) and IGF-1 overexpressing (IGF 
TG) mice 3 d (A) and 10 d (B) post-injury. Scale bar represents 50 µm. (C, D) BrdU+ cell 
density is significantly increased at 3 d (C) and 10 d (D) post-injury (main injury effect, 
p<0.01), independent of genotype. Data are presented as mean cell density (x 
1000/mm3) + SEM. (n=8 sham-injured/genotype, n=8 brain-injured/genotype at 3 d, and 
n=13 brain-injured/genotype at 10 d post-injury). Two-way ANOVAs were utilized for 
statistical analyses. 
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 New neurons are constantly generated in the hippocampal SGZ throughout 
adulthood by neuronal differentiation of newly proliferated progenitor cells (Zhao et al. 
2008). To evaluate if IGF-1 enhances total immature neuron density at 10 d post-injury 
by promoting neuronal differentiation, we assessed DCx+ and BrdU+ colocalization to 
identify the population of immature neurons generated during the week after injury. 
Colocalization of DCx and BrdU was observed in the SGZ, with DCx immunoreactivity in 
the cell body encapsulating the nucleus containing the BrdU-labeled DNA (Fig. 5.3A). 
IGF TG mice exhibited increased density of newborn neurons compared to WT mice 
(main genotype effect, p<0.05), but this effect was more pronounced in brain-injured 
mice (interaction effect, p<0.05). IGF-1 overexpression elicited a small, but non-
significant increase in the density of newborn neurons in sham-injured mice (10 + 2 x 
1000/mm3) compared to WT sham-injured mice (6 + 1 x 1000/mm3; Fig 5.3B). In WT 
mice, brain injury did not result in a change in the density of newborn neurons (7 + 1 x 
1000/mm3), compared to sham injury (Fig. 5.3B). However, IGF-1 overexpression 
resulted in a significant 2.5-fold increase in newborn neuron density 10 d following CCI 
(25 + 5 x 1000/mm3), compared to the density of IGF-1 overexpressing sham-injured 
mice and a significant 3.5 fold increase in density compared to WT brain-injured mice (# 
p<0.005; Fig. 5.3B). When evaluated by proximity to injury, as a function of bregma 
level, the selective increase in newborn neurons in IGF TG brain-injured mice was 
observed at all levels except the most rostral (-1.06 to -1.46 mm bregma)(#p<0.05, 
compared to all groups within each bregma interval; Fig. 5.3C).  
 In sham WT and IGF TG mice, newborn neurons represent approximately 40-
50% of all proliferating cells in the dentate gyrus granular layer. The percentage of 
newborn neurons that comprised total proliferated cells was slightly increased in IGF TG 
sham-injured mice (50%) compared to sham-injured WT mice (35%, Fig 5.3D). Although 
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proliferation is markedly increased after brain injury in WT mice, newborn neurons 
represented only approximately 10% of all proliferating cells (Fig. 5.3D). Conversely, 
overexpression of IGF-1 in brain-injured mice resulted in an increased the proportion of 
proliferated cells that became neurons to approximately 42% (Fig 5.3D).  
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Figure 5.3: IGF-1 overexpression promotes neuronal differentiation of newly 
proliferated cells in the granular layer following controlled cortical impact. (A) 
Representative images of doublecortin (DCx, green) and bromo-deoxyuridine (BrdU, 
red) immunoreactivity and Hoechst staining (blue) in the granular layer of sham-injured 
and brain-injured wildtype (WT) and IGF-1 overexpressing transgenic (IGF TG) mice 10 
d post-injury. Newborn neurons were identified by colocalization of DCx and BrdU. Scale 
bar represents 50 µm. Granular layer (GL). (B) Newborn neuron (DCX+/BrdU+) density in 
WT mice following brain injury was similar to WT sham-injured mice. However, IGF TG 
mice exhibited a significant increase in newborn neuron density 10 d post-injury (# 
p<0.05, compared to all other groups). (C) Overexpression of IGF-1 appeared to 
increase newborn neuron density throughout most of the injured hippocampus (# 
p<0.05, compared to all other groups classified by bregma interval). (D) Following brain 
injury in WT mice, newborn neurons comprised a much smaller proportion of the total 
proliferated cells than in sham injured controls. However, in IGF TG brain-injured mice a 
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Figure 5.3 (cont.): greater proportion of proliferated cells adopted a neuronal 
phenotype. Data are presented as mean cell density (1000/mm3) + SEM. (n=8 sham-
injured/genotype and n=13 brain-injured/genotype at 10 d post-injury). Two-way 
ANOVAs were utilized for statistical analyses in (B) and (C), and were followed by 
Newman-Keuls post-hoc t-tests where appropriate.  
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 In addition to increased immature neuron density in IGF TG mice after CCI, we 
observed a qualitative increase in the complexity of the dendritic arbors IGF TG mice, 
compared to WT mice at 10 d following CCI (Fig. 5.1A). Examination of the dendritic 
arbor of DCx+ labeled cells located within the SGZ of WT mice at 10 d post-injury 
demonstrated a brain injury-induced reduction in dendritic complexity (Fig. 5.4B). To 
evaluate the efficacy of IGF-1 to attenuate or reverse damage to dendritic processes 
after CCI, we quantified total dendritic process length and dendritic arbor complexity of 
DCx+ neurons within the granular layer. WT sham-injured and IGF TG sham-injured 
mice exhibited similar total dendritic lengths (Fig. 5.4C). Following CCI, WT mice 
exhibited a significant reduction in the total length of dendritic processes (143 + 8 µm), 
as compared to WT sham-injured mice (305 + 21 µm, *p<0.005; Fig. 5.4C). The total 
dendritic length for IGF TG brain-injured mice (292 + 18 µm) was significantly increased 
(#p<0.001) compared to WT brain-injured mice and was not significantly different from 
WT sham-injured or IGF TG sham-injured mice (346 + 16 µm). Quantification of the 
intersections per shell, a measure of dendritic bifurcations, revealed no difference in the 
number of intersections between WT and IGF TG sham-injured mice (Fig. 5.4D). Brain 
injury in WT mice induced a pronounced reduction in the number of intersections as well 
as early termination of the dendritic arbor, compared to WT sham-injured mice (p<0.001, 
Fig. 5.4D). Brain-injured IGF TG mice exhibited similar complexity of dendritic 
arborization to IGF TG sham-injured mice. These data demonstrate that IGF-1 
overexpression ameliorates the disruption of immature neuron dendritic morphology 
associated with CCI.  
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Figure 5.4: IGF-1 overexpression restores immature neuron dendritic arbor 
complexity after controlled cortical impact (CCI). (A, B) Representative images (A) 
and tracings (B) of doublecortin (DCx+, green) neurons in the granular layer of wildtype 
(WT) sham-injured (top), WT brain-injured (middle) and IGF-1 overexpressing transgenic 
(IGF-1 TG) brain-injured mice (bottom). (C) WT brain-injured mice exhibited a significant 
reduction in total dendritic length that was attenuated in IGF TG brain-injured mice (* 
p<0.005, compared to WT sham-injured mice; # p<0.001, compared to WT brain-injured 
mice). (D) Scholl analysis revealed that IGF-1 overexpression protected against injury-
induced reduction in dendritic arbor complexity at 10 d after brain injury. Data are 
presented as mean + SEM. (n=6 sham-injured/genotype and n=6 brain-
injured/genotype). Scale bars represent 50 µm. 
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Discussion  
 In Chapter 4 we presented compelling evidence that central infusion of IGF-1 
increases hippocampal immature neuron density at 7 d post-injury, and that this may be 
the result of enhanced post-traumatic neurogenesis. In this chapter, we build upon our 
findings in Chapter 4 using a complementary approach and demonstrate that brain-
specific overexpression of IGF-1 robustly increases immature neuron density at 10 d 
following severe CCI. This increase in immature neuron density appears to be driven not 
by protection against acute cell death but by enhanced generation of newborn neurons 
during the week following brain injury. Following CCI, we also show that overexpression 
of IGF-1 restores immature neuron dendritic arbor complexity to that observed following 
sham injury.  
In this chapter, we utilized a conditional astrocyte-specific IGF-1 overexpressing 
transgenic mouse model to increase levels of IGF-1 in regions of enhanced GFAP 
expression after CCI. Reactive astrocytosis has been reported in the dentate gyrus 
within 24 hr after CCI injury (Saatman et al. 2006; Sandhir et al. 2008; Madathil 2013). 
Previous work from our lab has shown that reactive astrocytosis in the injured 
hippocampus increased expression of IGF-1 at 24 hr with further increases at 72 hr 
following CCI in the IGF-1 overexpressing mouse model utilized in this chapter (Madathil 
2013). Similar to infusion of exogenous IGF-1 in Chapters 3 and 4, targeted 
overexpression of IGF-1 in astrocytes led to a biologically appropriate increase in Akt 
activation following severe CCI (Madathil 2013). Targeted overexpression of IGF-1 also 
protected against acute hippocampal neuron loss in the dentate gyrus, CA3, and CA1 
and improved cognitive performance following severe CCI (Madathil 2013). While the 
observation of improved neurobehavioral function may be related to hippocampal 
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neuroprotection, an IGF-1-mediated enhancement of post-traumatic neurogenesis may 
also contribute to improved cognitive function.  
In Chapter 3, systemic administration of rhIGF-1 was shown to result in a modest 
reduction in hippocampal neurodegeneration in the granular layer, visualized by 
Fluorojade-B staining, suggesting that IGF-1 reduces neurodegeneration acutely after 
brain injury. Moreover, previous work from our lab, utilizing the conditional astrocyte-
specific IGF-1 overexpressing mouse model demonstrated that overexpression of IGF-1 
reduced the number of Fluorojade-C positive cells, an indication of degenerating 
neurons, in the dentate gyrus granular layer at 3 d post-injury (Madathil 2013). We 
postulated that reductions in hippocampal neurodegeneration in the granular layer may 
be reflective of improved immature neuron survival. Several studies demonstrate that 
immature neurons are selectively vulnerability to moderate and severe CCI and, 
consequently, immature neuron density is markedly reduced in the days following CCI 
(Rola et al. 2006; Gao et al. 2008; Yu et al. 2008). Consistent with these studies 
reporting acute immature neuron loss, we show an approximate 35% reduction in 
numbers of DCx-positive cells in the injured granular layer at 3 d after severe CCI. 
However, overexpression of IGF-1 did not significantly increase immature neurons 
density at 3 d following brain injury. These findings are also consistent with our findings 
in Chapter 3 that systemic infusion of IGF-1 did not increase immature density at 3 d 
following systemic infusion. Taken together, these studies highlight that IGF-1 reduces 
hippocampal neurodegeneration, but may not promote the survival of immature neurons 
acutely following CCI.  
One possible explanation for the lack of IGF-1-mediated protection of immature 
neurons could be related to immature neuron insensitivity to IGF-1. The IGF receptor is 
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highly expressed in hippocampal neurons throughout the granular layer in the 
developing and adult brain, suggesting that the niche should be capable of responding to 
IGF-1 (Werther et al. 1990; Bondy and Lee 1993; Bracko et al. 2012). However, changes 
in IGF-1 receptor cellular localization or expression levels could reduce the actions of 
IGF-1 in the injured brain. In the context of brain injury, internalization of plasma 
membrane receptors, including NMDA and AMPA, has been reported to occur within 
hours after experimental TBI (Biegon et al. 2004). A reduction in the levels or 
presentation of IGF-1 receptors on the plasma membrane could blunt the anti-apoptotic 
effects of IGF-1 on hippocampal neurons, including immature neurons in the granular 
layer. Our lab has previously demonstrated that levels of the IGF-1 receptor do not 
change in the cortex for at least 72 hr following severe CCI (Madathil et al. 2010). 
However, this work did not evaluate if expression patterns differ in the hippocampus or if 
cellular localization and presentation of IGF-1 receptor on the plasma membrane is 
altered as a consequence of brain injury. A more comprehensive evaluation of IGF-1 
receptor expression in hippocampal immature neurons and receptor localization after 
injury may provide insight to help explain why IGF-1 does not appear to protect against 
acute hippocampal immature neuron loss.  
In order to better understand immature neuron loss relative to proximity of injury, 
we analyzed the density of immature neurons as a function of bregma level. The 
epicenter of injury exhibited the greatest reduction in immature neuron density with 
observable reductions at least 500 µm from the epicenter of injury. To the best of our 
knowledge, this is the first study to evaluate hippocampal immature neuron loss as a 
function of proximity to injury. These data demonstrate that future studies need to 
incorporate methodology to quantify post-traumatic alterations in neurogenesis 
throughout the entire dentate gyrus granular layer, and not restrict quantification to the 
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site of maximal injury. We demonstrate that overexpression of IGF-1 enhanced newborn 
neuron density throughout the granular layer and not only at the epicenter of injury. 
Adoption of rigorous quantification methodology throughout the granular layer may be 
especially critical for therapeutic studies evaluating immature neurons loss and 
modulation of neurogenesis following experimental TBI. 
CCI results in a marked reduction in immature neurons within the DGGL, but 
brain injury also initiates an endogenous self-renewal process, including increased 
cellular proliferation that promotes a gradual recovery of the number of immature 
neurons to pre-injury levels (Rola et al. 2006; Yu et al. 2008). The data presented in this 
chapter demonstrates that IGF-1 does not confer acute protection of the immature 
neurons, but instead enhances the recovery of immature neurons at 10 d post-injury. 
Brain injury induces proliferation of glial cells and stem cells within the dentate gyrus, 
during the first week after brain injury (Dash et al. 2001; Chirumamilla et al. 2002; Emery 
et al. 2005; Sun et al. 2005; Rola et al. 2006; Urrea et al. 2007). Several studies 
demonstrate that cellular proliferation can be enhanced with the treatment of growth 
factors, including VEGF, bFGF, and EGF, after experimental TBI (Yoshimura et al. 2003; 
Sun et al. 2009; Sun et al. 2010). However, only a portion of the newly proliferated cells 
will adopt a neuronal phenotype following severe CCI (Rola et al. 2006). IGF-1 has been 
shown to enhance the generation of new neurons by promoting progenitor cell 
proliferation and enhancing neuronal differentiation (Arsenijevic and Weiss 1998; Aberg 
et al. 2000; Brooker et al. 2000; Arsenijevic et al. 2001). 
We were surprised that overexpression of IGF-1 did not enhance post-traumatic 
proliferation. Previous in vitro and in vivo studies have demonstrated that IGF-1 
promotes proliferation of cultured neural stems cells (Brooker et al. 2000; Arsenijevic et 
189 
 
al. 2001) and increases the proliferation of neural progenitor cells in the granular layer of 
the hippocampus (Aberg et al. 2000; Trejo et al. 2001; Yan et al. 2006). IGF-1 is an 
important mediator of exercise-induced neurogenesis by enhancing proliferation in the 
DGGL (Trejo et al. 2001; Trejo et al. 2008). Together, these studies suggested that we 
might expect an IGF-1-mediated enhancement of cellular proliferation in the DGGL. 
However, in the current study we did not observe an IGF-1-mediated enhancement of 
cellular proliferation at 3 or 10 d post-injury. Our findings from Chapter 4 showed that 
central infusion of IGF-1 may have promoted increased cellular proliferation after CCI. 
The BrdU injections paradigms utilized in the studies from Chapter 4 and this chapter 
are different and may explain the disparity between our findings. Differences in the BrdU 
injection paradigms including the time post-injury in which injections are given, the 
frequency of injections and the duration between last injection and euthanasia may 
begin to reflect a combination of both cellular proliferation and cell survival. Future 
studies will need to incorporate evaluations of cellular proliferation using BrdU injection 
paradigms that utilize single injections of BrdU with euthanasia within hours in order to 
minimize contributions of cell survival in assessments of cellular proliferation.   
Overexpression of IGF-1 appeared to promote the generation of newborn 
immature neurons by promoting neuronal differentiation of newly proliferated cells after 
injury. This effect was present throughout most bregma levels of the hippocampus, and 
not restricted to regions exhibiting maximal injury or DCx+ cell loss. IGF-1 
overexpression appears to promote neurogenesis in the neurogenic niche throughout 
the injured hippocampus. Our observations of enhanced neuronal differentiation are 
consistent with a previous report showing that systemic administration of IGF-1 in 
hypophysectomized rats increased the generation of new neurons, but did not promote 
the generation of astrocytes in the DGGL (Aberg et al. 2000). Although only a portion of 
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newborn neurons generated after brain injury develop into mature granular neurons and 
functionally incorporate, these newborn neurons may contribute to delayed 
improvements in cognitive function (Sun et al. 2007), suggesting that therapies that 
increase the number of immature neurons generated after brain injury may promote 
cognitive recovery. Moreover, a recent study highlights that supraphysiological increases 
in immature neuron numbers, similar to our observation at 10 d post-injury in IGF TG 
mice, are sufficient to improve cognition as assessed by a contextual pattern separation 
task (Sahay et al. 2011). Previous work from our lab demonstrated that IGF-1 
overexpressing mice subjected to brain injury exhibited improved cognitive performance 
compared to wildtype mice at 7 d following severe CCI (Madathil 2013). The findings in 
this current study suggest that an IGF-1-mediated enhancement of post-traumatic 
neurogenesis may contribute to the improved cognitive performance reported in this 
transgenic mouse model following severe CCI.  
It is also possible that the increased number of newborn neurons observed in 
IGF-1 overexpressing mice at 10 d post-injury is reflective of increased survival of new 
neurons generated after CCI and not exclusively due to increased likelihood of neuronal 
differentiation. Additional work is needed to determine if IGF-1 reduces death of newborn 
neurons, using markers of neurodegeneration, apoptosis, and necrosis, in the post-
traumatic immature neuron recovery phase between 7 and 10 d following severe CCI. 
Future studies will also need to elucidate if overexpression of IGF-1 promotes long-term 
survival and maturation of newborn neurons generated after brain injury.   
 Despite the recovery of immature neuron density in WT mice at 10 d post-injury, 
we demonstrate that the immature neurons in the injured granular of WT mice exhibit 
significant reductions in dendritic complexity following CCI. Recent studies highlight that 
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brain injury results in damage to the dendritic processes of neocortical and hippocampal 
mature granular neurons after CCI (Gao et al. 2011), but changes in immature neuron 
dendritic morphology after brain injury have not been evaluated. Immature neurons from 
WT mice exhibited reduced total dendrite length and arbor complexity after injury, 
however, immature neurons from brain-injured IGF-1 overexpressing mice exhibited 
significant restoration of dendritic morphology that was equivalent to the morphology 
observed in sham-injured mice. There are two possible explanations for the IGF-1-
mediated restoration of dendritic arbor complexity after severe CCI. IGF-1 protects 
against injury-induced damage to immature neuron dendritic processes or IGF-1 
promotes the more complete formation of dendritic arbors of immature neurons during 
the process of neuronal differentiation and maturation. At 3 d following CCI, both WT 
and IGF-1 overexpressing mice exhibited a visible reduction in dendritic arbor 
complexity, suggesting that IGF-1 did not protect against injury-induced damage. 
However, future studies will need to quantify dendritic arbor complexity at 3 d following 
CCI to definitively determine if IGF-1 protects against reductions in dendritic arbor 
complexity in immature neurons after brain injury.  
Alternatively, overexpression of IGF-1 may have enhanced the growth of 
dendritic arbors in newly generated immature neurons after brain injury. Reductions in 
levels of endogenous IGF-1 are associated with reduced dendritic growth and branching 
(Cheng et al. 2003). Conversely, IGF-1 stimulates dendritic growth and enhances 
branching of pyramidal neurons in organotypic primary cortical slice cultures and neurite 
outgrowth in dissociated neurons (Torres-Aleman et al. 1989; Niblock et al. 2000). 
Knockout of PTEN, the negative regulator of phosphatidylinositol-3-kinase signaling, 
resulted in prolonged Akt activation and produced immature granular neurons with 
elongated dendrites and increased arborization (Amiri et al. 2012). Taken together, 
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these studies suggest that the re-establishment of sham injury-like dendritic morphology 
in IGF-1 overexpressing brain-injured mice may be the result of enhanced dendritic 
growth within newborn neurons. Reductions in mature neuron dendritic arbor complexity 
and synaptic spine density likely contribute to reduced neuronal excitability of dentate 
gyrus granular cells after CCI (Gao et al. 2011). Decreases in the length and complexity 
of dendritic arbors of immature neurons may contribute to reduced synaptic connections 
in the molecular layer and lead to functional impairments in long-term potentiation in the 
hippocampus after CCI. Restoration of normal dendritic morphology in immature 
neurons may have important functional implications in promoting recovery of function in 
the hippocampus and contribute to improved cognitive function after TBI. While this 
study did not evaluate the precise mechanism by which IGF-1 overexpression improves 
dendritic morphology after brain injury, these data reveal a novel pathological 
phenomenon and identify a new therapeutic target in experimental TBI in a population of 
cells critical for learning and memory. A better understanding of the time course of 
dendritic process recovery may provide better insight into the regenerative capacity of 
dendritic arbors in the injured brain and help develop effective therapeutic strategies, 
including IGF-1, that promote structural plasticity in the injured brain. 
 In summary, we demonstrate that targeted overexpression of IGF-1 does not 
attenuate early loss of hippocampal immature neurons in the SGZ after severe CCI, but 
promotes a robust recovery of the immature neuron population, most likely by enhancing 
neuronal differentiation of hippocampal progenitors. We also establish that IGF-1 
overexpression promotes a more complete recovery of the dendritic arbor of newborn 
neurons after trauma.  The data presented in this chapter provides additional evidence 
for IGF-1 as a promising therapeutic agent that promotes post-traumatic neurogenesis 
and structural plasticity in the hippocampus following experimental TBI.  
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Chapter 6: Summary of Dissertation  
The major findings in this dissertation provide evidence for the therapeutic 
efficacy of insulin-like growth factor-1 (IGF-1) in attenuating motor and cognitive 
dysfunction and enhancing post-traumatic neurogenesis in a mouse model of contusion 
traumatic brain injury (TBI). In Chapter 2, we demonstrated that a modification to the 
geometry of the impactor tip utilized in the well-established controlled cortical impact 
(CCI) injury model modulated the rate of acute cortical cell loss and extent of acute 
regional hippocampal neurodegeneration, without altering other important pathological 
features of contusion brain injury. In Chapter 3, we showed that prolonged continuous 
systemic infusion of IGF-1 promoted the activation of Akt in the contused brain and 
modestly reduced hippocampal neurodegeneration in the granular layer, but did not 
attenuate motor dysfunction in mice subjected to severe CCI. In Chapter 4, we 
demonstrated that prolonged intracerebroventricular infusion of IGF-1 significantly 
improved motor function and reduced cognitive impairment associated with severe CCI. 
We also highlighted that central infusion of IGF-1 increased immature neuron density in 
a number of infusion paradigms, and this increase may be driven by enhanced post-
traumatic neurogenesis following brain injury. In Chapter 5, we established that IGF-1-
mediated increases in hippocampal immature neuron density occurred by enhanced 
neuronal differentiation of newly proliferated cells in the dentate gyrus granular layer 
after CCI. We also showed that IGF-1 attenuated a reduction in dendritic arbor 
complexity of immature neurons following CCI, a previously unknown pathological 
phenomenon in immature neurons. We hypothesized that treatment with IGF-1 
attenuates motor and cognitive impairments and enhances hippocampal neurogenesis in 
the mouse brain following brain injury. Taken together, the findings reported in this 
dissertation supported our hypothesis and demonstrated that treatment with IGF-1 
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improved neurobehavioral function and enhanced post-traumatic neurogenesis following 
severe CCI in mice. 
 
Controlled Cortical Impact and Impactor Tip Geometry 
 CCI is advantageous for studies evaluating mechanisms of injury or therapeutic 
interventions of TBI, as the model is highly reproducible, well-characterized, and 
produces pathology, including neurological and cognitive impairments (Dixon et al. 1991; 
Hamm et al. 1992; Smith et al. 1995; Saatman et al. 2006), reflective of contusion injury 
observed in brain-injured patients (Levin 1998; Serra-Grabulosa et al. 2005; Alahmadi et 
al. 2010). Results from finite element mathematic models indicated that the geometrical 
shape of the impactor tip can influence maximal tissue strain during the initial tissue 
deformation and that an impactor tip with rounded shape reduced the predicted maximal 
principal strains compared to an a beveled shape (Mao et al. 2011; Pleasant et al. 
2011). Data from Chapter 2 demonstrated that use of a rounded impactor tip, as 
compared to a beveled impactor tip, slowed the progression of cortical cell loss and 
reduced acute hippocampal neurodegeneration in CA1 without altering other key 
aspects of contusion injury, including axonal injury, breakdown of the blood-brain barrier, 
and motor and cognitive impairment after severe CCI (Pleasant et al. 2011). The 
accelerated rate of cortical cell loss within 4 hr of CCI with a beveled tip creates difficult 
technical and experimental constraints for studies in which elucidation of acute injury 
mechanisms is a primary outcome measure. The extent or rate of neurodegeneration in 
the granular layer or CA3 regions of the hippocampus was not greatly modulated by 
geometry of the impactor tip. This is an important finding and suggests that evaluation of 
hippocampal neurodegeneration in these regions can be compared between studies 
utilizing different impactor tip shapes. 
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The slowed progression of tissue damage after impact with a rounded impactor 
tip more closely recapitulates the progression of injury pathology observed by 
radiological scans of patients following a contusion TBI (Alahmadi et al. 2010; Kurland et 
al. 2012). Furthermore, the average treatment onset of therapeutic agents in TBI clinical 
trials occurs between 3 and 8 hr post-injury (Maas et al. 2007). Considering the delay of 
therapeutic intervention in the clinical setting, utilization of the rounded impactor tip may 
provide a more clinically relevant and experimentally feasible evaluation of therapeutic 
agents intended to reduce acute secondary injury and promote cell survival. Use of a 
rounded impactor tip may also be critically important for therapeutic studies that aim to 
initiate delivery of therapeutic agents in a clinically relevant treatment window. Our 
findings in Chapter 2 highlight that the parameter of impactor tip geometry, in addition to 
impact depth and velocity, should be considered as injury parameters that can modify 
contusion impact pathology. The rounded impactor tip was therefore used in all studies 
to evaluate the efficacy of IGF-1 to attenuate neurobehavioral dysfunction and enhance 
hippocampal post-traumatic neurogenesis after TBI. 
 
Levels of Human IGF-1 in the Brain and Systemic Circulation after CCI 
 The long-term goal of this dissertation work is to provide additional insight and 
data that contributes to a preclinical evaluation of IGF-1 as a therapeutic strategy for the 
treatment of TBI. In this dissertation research, we utilize multiple therapeutic paradigms 
including prolonged systemic and central infusions and targeted astrocyte-specific 
overexpression of IGF-1 to facilitate delivery of IGF-1 to the injured brain. In order to 
compare effects of IGF-1 across these treatment strategies, we needed to establish the 
levels of human IGF-1 (hIGF-1) in the injured brain. 
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 Findings from a Phase II open-label, prospective randomized clinical trial showed 
that brain-injured patients treated with 0.01 mg/kg/hr IGF-1 by intravenous infusion who 
achieved plasma levels of IGF-1 greater than 350 ng/mL showed improved metabolic 
health and Glasgow Outcome Scale scores at 6 months post-injury (Hatton et al. 1997), 
suggesting that systemic levels of IGF-1 need to exceed 350 ng/mL to improve outcome 
after brain injury. In Chapter 3, we demonstrated that prolonged systemic infusion of 4 
mg/kg/d hIGF-1 resulted in sustained levels of approximately 150 ng/mL of hIGF-1 in 
systemic circulation over 1 week, but did not produce detectable levels of hIGF-1 in the 
brain. The endogenous systemic circulating levels of IGF-1 in C57/BL6 naïve mice are 
reported to be approximately 250 ng/mL (Yuan R 2013), suggesting that systemic 
infusion of hIGF-1 resulted in total serum levels of IGF-1, including endogenous and 
exogenous, above the therapeutic threshold of 350 ng/mL. We did not quantify 
endogenous levels of IGF-1, warranting future studies to evaluate endogenous levels of 
IGF-1 to ensure that continuous infusion of hIGF-1 did not reduce production of IGF-1. 
Our inability to detect hIGF-1 in the brain following systemic infusion may be reflective of 
several possible explanations, including limited penetrance of hIGF-1 into the brain as a 
result of sealing of the blood-brain barrier at the time point in which hIGF-1 was 
quantified, a short half-life of IGF-1 in the brain, or limited sensitivity of the ELISA kit that 
was utilized. Additional studies may need to evaluate the penetrance and residence time 
of systemically infused IGF-1 in the brain by additional techniques, including 
radiolabeled or tagged IGF-1 that would afford increased sensitivity in detecting low 
levels of IGF-1 in the brain parenchyma.   
 In Chapter 4 we show that supplementation of hIGF-1 resulted in quantifiable 
increases in the levels of hIGF-1 in the cortex and hippocampus. Following central 
infusion of 10 µg/d hIGF-1, we measured approximately 30 to 50 ng/mL hIGF-1 in both 
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the injured cortex and hippocampus, two of the most vulnerable regions following severe 
CCI. Previous work from our lab demonstrated that targeted astrocyte-specific 
overexpression of IGF-1 resulted in progressively increasing levels of hIGF-1 that 
reached 15 ng/mL hIGF-1 in the hippocampus at 72 hr post-injury and promoted 
improved neurobehavioral function at 7 d following severe CCI (Madathil 2013), 
suggesting that levels of 15 ng/mL hIGF-1 or greater in the brain can promote functional 
recovery after brain injury. We measured levels of hIGF-1 2 to 3-fold higher in the brain 
following central infusion, demonstrating that we achieved a therapeutic level of IGF-1 in 
the injured brain. In Chapter 5, we utilized the aforementioned targeted astrocyte-
specific overexpression to elevate levels of hIGF-1 in areas exhibiting reactive 
astrocytosis following brain injury. Currently, we have not fully examined the time course 
of elevation of hIGF-1 following CCI for either central infusion or overexpression of hIGF-
1. Additional work is needed to elucidate the temporal profile of increasing levels of 
hIGF-1 in the brain as this has important implications for the efficacy of IGF-1 to protect 
against acute cell loss after TBI. In Chapter 4, we also demonstrated that prolonged 
central infusion of 10 µg/d hIGF-1 into the lateral ventricle resulted in approximately 60-
80 ng/mL of hIGF-1 in systemic circulation at 7 d after the initiation of infusion. While it is 
known that IGF-1 is rapidly cleared from the brain and enters systemic circulation 
following intracerebroventricular injection, we were surprised to observe that central 
infusion of IGF-1 resulted in relatively similar systemic circulation concentrations as 
observed after systemic infusion. These findings argue that additional work may be 
needed to better understand the interplay between the levels of IGF-1 in systemic 
circulation and the brain following prolonged infusion. We did not measure the 
concentrations of hIGF-1 in serum collected from IGF-1 overexpressing mice, but our 
findings argue that future studies should incorporate this as an additional assessment of 
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IGF-1 overexpression. The findings in this dissertation provide an important first step in 
understanding of how plasma levels of IGF-1 may be used as a clinical indicator of 
levels of IGF-1 in the brain parenchyma of TBI patients. 
 
IGF-1 Signaling in the Brain after CCI 
In light of our findings, we sought to determine if elevated levels of hIGF-1 
resulted in increased activation of Akt, a potent pro-survival downstream mediator of 
IGF-1 signaling. In Chapters 3 and 4 we demonstrated that both systemic and central 
infusion of exogenous IGF-1 promoted activation of Akt in the brain. Previous work from 
our lab demonstrated that targeted overexpression of IGF-1 significantly increased Akt 
activation in the hippocampus at both 24 and 72 hr following severe CCI (Madathil 
2013). Taken together, these studies show that supplementation of IGF-1, independent 
of treatment strategy, significantly increased Akt activity in the brain after severe CCI. 
These findings highlight the ability of IGF-1 to promote protective signaling in the brain, 
and strongly support the development of IGF-1 as a therapeutic strategy across the 
continuum of severity of TBI. 
 
Capacity of IGF-1 to Promote Survival of Hippocampal Immature Neurons 
 Following moderate or severe CCI, a precipitous drop in hippocampal immature 
neuron density occurs within 24 hr and continues for days following injury (Rola et al. 
2006; Gao et al. 2008; Yu et al. 2008). Consistent with published reports of immature 
neuron susceptibility after TBI, we demonstrated at 3 d (Chapter 3 and 5) and at 7 d 
(Chapter 4) that brain-injured vehicle-treated mice exhibited significant reductions in 
immature neuron density at 7 d post-injury.  
200 
 
 Increases in IGF-1 signaling are associated with improved neuron survival both 
in vitro and in vivo (Guan et al. 1993; Russell et al. 1998; Chrysis et al. 2001; Zheng et 
al. 2002; Bendall et al. 2007). Targeted astrocyte-specific overexpression of IGF-1 
reduced the number of Fluorojade-C-positive cells, indicative of degenerating neurons, 
in the dentate gyrus granular layer, but not CA3 at 3 d following severe CCI (Madathil 
2013). In Chapter 3, we observed a modest decrease in the number of Fluorojade-B 
positive cells in the dentate gyrus of mice systemically infused with IGF-1 after severe 
CCI. Considering the neurodegenerative marker Fluorojade-B is found to colocalize with 
doublecortin, a marker of immature neurons, in the granular layer at 24 hr after CCI (Gao 
et al. 2008), we postulated that the reduced number of degenerating neurons observed 
after systemic infusion or overexpression of hIGF-1 was reflective of improved immature 
neuron survival. However, neither systemic infusion of hIGF-1 (Chapter 3) or astrocyte-
driven IGF-1 overexpression (Chapter 5) increased immature neuron density at 3 d 
following severe CCI, suggesting that the reduced number of degenerating neurons 
likely reflects improved survival of mature neurons and not immature neurons. Additional 
studies are required to quantify the frequency that immature and mature neurons are 
found to positively label with markers of neurodegeneration following treatment with IGF-
1 after brain injury. To the best of our knowledge, no studies have reported that 
immature neuron loss can be attenuated by therapeutic interventions within the first 3 d 
following CCI. Together, our findings suggest that IGF-1 provides limited protection 
against acute loss of immature neurons following severe CCI.  
 
Susceptibility of Immature Neurons after CCI 
Immature neurons are particularly vulnerable to brain injury, but the mechanism, 
including the mode of cell death, underlying this susceptibility is unknown. If immature 
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neurons are found to die predominately from necrotic cell death, this may help explain 
why IGF-1, a potent anti-apoptotic signal, did not protect against acute immature neuron 
loss after severe CCI. Rola et al (2006) previously demonstrated that cells positively-
labeled with the cell death marker TUNEL (terminal deoxynucleotidly transferase dUTP 
nick end labeling) were predominantly observed in the subgranular zone, within the 2 d 
following severe CCI. TUNEL is a marker of DNA damage and may be reflective of 
either apoptotic or necrotic cellular death (de Torres et al. 1997). Caspase-3, a marker of 
apoptosis, was rarely observed in the granular layer at 4 hr, 1, 3, or 7 d following CCI, 
but receptor interacting protein-1 (RIP-1), a marker of necrosis, was observed at 1 d 
after CCI and was also found to colocalize with Fluorojade-B (Zhou et al. 2012). These 
observations suggest that degenerating neurons in the granular layer may predominantly 
die by necrosis and not apoptosis. Additional work is needed to colocalize indicators of 
apoptosis and necrosis with markers of immature neurons to quantify and delineate the 
cell death mechanisms in this subpopulation of neurons, and to elucidate if the 
mechanisms of cell death change as a function of time following CCI.  
 
Calpain-mediated Proteolysis in the Hippocampal Neurogenic Niche 
Necrotic cell death of immature neurons within 24 hr following brain injury may be 
related to calcium dysregulation and the acute activation of calcium mediated proteases, 
including calpain. Cultured primary hippocampal neurons subjected to mechanical 
stretch injury show increased membrane permeability and a rapid elevation in 
concentrations of intracellular calcium within seconds that is sustained for minutes after 
the initial stretch (Geddes et al. 2003). While regulated cellular microdomains of elevated 
calcium are critical for normal cellular function, the increases in intracellular calcium 
observed post-stretch can result in the pathological activation of proteases (Pike et al. 
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2000). Increased calpain-mediated and caspase-meditated breakdown of α-spectrin, a 
cytoskeletal protein, in hippocampal cell cultures occurs within hours following stretch 
injury (Pike et al. 2000; DeRidder et al. 2006).  
Considering the selective vulnerability of immature neurons after brain injury, we 
sought to determine if calpains were activated in immature neurons. Calpain-mediated 
cleavage of spectrin can be visualized by Ab37 immunoreactivity; as the antibody 
recognizes the COOH-terminus of the NH2-terminal fragment generated during calpain 
cleavage of spectrin (Saatman et al. 2000). In a preliminary study, in a small number of 
mice (n=3) at 24 hr following severe CCI, Ab37 immunoreactivity in the subgranular zone 
did not colocalize with DCx (Fig. 6.1A), but instead was found to colocalize with nestin, a 
marker of radial stem cells and astrocytes within the subgranular zone (Fig. 6.1B). The 
cellular morphology and location of nestin in these images is suggestive of neural 
progenitor cells; however, based on these parameters alone we cannot eliminate the 
possibility that Ab37 is also present in astrocytes within the subgranular zone. These 
images suggest that calpain-mediated spectrin cleavage occurs in neural progenitor 
cells, and not immature neurons. This observation argues that activation of calpains may 
not be related to the loss of immature neurons, but may contribute to post-traumatic 
changes in neural progenitor cells in the subgranular zone of the hippocampus.  
Calpain has been identified as a mediator of cellular migration and structural 
plasticity (Huttenlocher et al. 1997; Zadran et al. 2010), and may be important for neural 
progenitor proliferation, differentiation, migration, and regulation of the neurogenic niche 
(Santos et al. 2012). Alternatively, the presence of calpain-mediated spectrin breakdown 
in nestin-positive cells could be a pathological response to injury in the niche. Following 
moderate CCI, the number of quiescent progenitor cells increases robustly between 4 
and 72 hr post-injury in the subgranular zone (Gao et al. 2009), which likely contributes 
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to increased neurogenesis following CCI. The acute increase in proliferation at 4 hr post-
injury is consistent with the timing of injury-induced activation of calpain (Hall et al. 
2005), suggesting that pathological activation of calpains could be involved in injury-
induced responses of the neurogenic niche. While these findings are preliminary 
observations, they propose intriguing questions about the role of calpain-mediated 
proteolysis in the neurogenic niche after brain injury.  
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Fig. 6.1: Calpain-mediated spectrin cleavage was observed in nestin-positive, but 
not DCx-positive cells in the granular layer at 24 hr following controlled cortical 
impact (CCI). (A) A marker of immature neurons (DCx, green) did not colocalize with a 
marker of calpain-mediated spectrin cleavage (Ab37, red) in the dentate gyrus inner 
granular layer at 24 hr following severe CCI. (B) Nestin (red) a marker of neural 
progenitor cells and astrocytes in the dentate gyrus granular layer, colocalized with a 
marker of calpain-mediated spectrin cleavage (Ab37, green) at 24 hr after severe CCI. 
Granular layer (GL) and hilus (H). Scale bar represents 50 µm.  
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Recovery of Hippocampal Immature Neurons after CCI 
 In Chapter 4, we observed a significant reduction in immature neuron density in 
brain-injured mice treated with vehicle compared to sham-injured mice at 7 d post-injury. 
This finding is consistent with the observation that mice subjected to severe CCI exhibit 
maximal immature neuron loss at 7 d post-injury (Rola et al. 2006). Subsequent to this 
initial reduction, immature neuron numbers recover towards baseline in the days to 
weeks following CCI (Rola et al. 2006; Yu et al. 2008). Consistent with post-traumatic 
recovery of immature neurons, in Chapter 5 we showed that wildtype mice subjected to 
severe CCI exhibit immature neuron density similar to sham-injured mice at 10 d post-
injury. Considering we observed a marked reduction in immature neuron density in 
wildtype mice at 3 d post-injury, it is likely that increased post-traumatic neurogenesis, 
including increased cellular proliferation and neuronal differentiation, contributed to the 
recovery of immature neuron numbers in wildtype mice after severe CCI. 
IGF-1 is a potent promoter of neurogenesis by increasing cellular proliferation 
and enhancing neuronal differentiation of newly proliferated cells (Ye et al. 1996; 
Arsenijevic and Weiss 1998; Aberg et al. 2000; Brooker et al. 2000; Arsenijevic et al. 
2001; Yan et al. 2006). We postulated that the neurogenic properties of IGF-1 would 
enhance post-traumatic neurogenesis and promote the recovery of immature neuron 
numbers in the dentate gyrus granular layer after severe CCI. In Chapter 4 we found that 
central infusion of 10 μg/d and 3 μg/d of hIGF-1 resulted in a significant increase in 
immature neuron density in brain-injured mice compared to treatment with vehicle, and 
that the density of immature neurons was equivalent to sham-injured mice treated with 
IGF-1. We showed that increasing concentrations of centrally infused IGF-1 resulted in 
proportional elevations in immature neuron density following severe CCI. Importantly, 
delayed central infusion of IGF-1 with a clinically relevant 6 hr post-injury onset retained 
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the significantly increased immature neuron density that was previously observed using 
an acute 15 minute post-injury treatment onset. We also found in Chapter 5 that targeted 
overexpression of IGF-1 significantly enhanced the recovery of immature neuron density 
in brain-injured mice, exceeding the immature neuron density of IGF-1 overexpressing 
sham-injured mice. Findings from Chapter 4 and 5 highlight that elevated levels of IGF-1 
in the brain are associated with increased immature neuron density following brain 
injury. Additional work is needed to determine if systemically infused IGF-1 promotes the 
recovery of immature neuron numbers after severe CCI or if our observations from 
Chapters 4 and 5 are exclusive to central infusion of IGF-1. Taken together, our findings 
strongly support that IGF-1 enhances post-traumatic neurogenesis which may be the 
result of increased cellular proliferation or enhanced neuronal differentiation of newly 
proliferated cells in the granular layer after severe CCI.   
 
Proliferative Response of the Neurogenic Niche with Treatment of IGF-1 after CCI 
 Several reports demonstrate that brain injury results in cellular proliferation in the 
injured dentate gyrus granular layer within 24 hr which is sustained for days following 
experimental TBI (Dash et al. 2001; Kernie et al. 2001; Sun et al. 2005; Rola et al. 
2006). In Chapters 4 and 5 we observed significant increases in hippocampal cellular 
proliferation in mice subjected to severe CCI compared to mice subjected to sham injury. 
Central infusion of IGF-1 appeared to augment brain injury-induced cellular proliferation, 
but this effect was not statistically significant (Chapter 4). Overexpression of IGF-1 did 
not enhance cellular proliferation at 3 d post-injury, a time of increased post-traumatic 
proliferation (Dash et al. 2001; Rola et al. 2006; Gao et al. 2009; Gao and Chen 2013), 
or cumulatively over the first 7 d following CCI (Chapter 5). 
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While our data provide strong evidence that IGF-1 does not significantly 
modulate cellular proliferation in the injured brain, we need to acknowledge that bromo-
deoxyuridine (BrdU) incorporation may not be reflective of only cellular proliferation. The 
dose of BrdU, number of injections, duration between injections, and euthanasia time 
after last dose can introduce aspects of cellular survival, and ongoing cellular 
proliferation that can dilute BrdU staining in neural progenitor cells or proliferating 
astrocytes (Taupin 2007), thereby complicating interpretation. Several studies evaluating 
proliferation after experimental TBI euthanize the animal between 4 and 24 hr following a 
single injection of BrdU to evaluate cellular proliferation (Sun et al. 2005; Gao and Chen 
2013). A single BrdU injection with 4 hr euthanasia post-injection was utilized in Chapter 
5 to evaluate cellular proliferation. Injection paradigms that utilize short durations 
between the last injection and the time of euthanasia reduce, but do not fully eliminate, 
aspects of cellular survival, particularly during times of widespread cell loss after severe 
CCI. However, euthanasia within hours of the BrdU injection does not provide insight 
into neuronal differentiation. Alternatively, repeated injections, as utilized in Chapters 4 
and 5 provide insight into IGF-1-mediated changes in cellular differentiation. 
 
IGF-1-mediated Enhancement of Neuronal Differentiation after CCI 
 Genetic ablation of immature neurons is associated with learning and memory 
impairments (Clelland et al. 2009; Deng et al. 2009; Jessberger et al. 2009), suggesting 
that the profound loss of immature neurons may contribute to cognitive impairments 
observed after brain injury, and that enhanced recovery of immature neurons after CCI 
could contribute to improvements in cognitive function. In addition to promoting cellular 
proliferation, IGF-1 has also been shown to be a potent promoter of neuronal 
differentiation of newly proliferated cells (Arsenijevic and Weiss 1998; Aberg et al. 2000; 
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Brooker et al. 2000; Arsenijevic et al. 2001). In Chapter 4, we demonstrated that central 
infusion of hIGF-1 promoted the generation of newborn neurons, which likely contributed 
to the recovery of total immature neuron density to near control (sham-injured) levels. 
Similarly, in Chapter 5 we demonstrated that hIGF-1 overexpression promoted the 
generation of newborn neurons above sham-injured levels after CCI. Taken together, the 
data from our two treatment paradigms illustrates that IGF-1-mediated neuronal 
differentiation is likely a predominant factor in promoting the recovery and enhancement 
of immature neuron density in the hippocampus after severe CCI. However, it is also 
possible that IGF-1 promotes the survival of newly differentiation neurons after injury that 
would increase newborn neuron density independent of enhanced differentiation. 
Additional studies are needed to delineate these two possibilities to determine if the IGF-
1-mediated increase in newborn neurons is reflective of enhanced neuronal 
differentiation, increased immature neuron survival, or potentially a combination of both 
possibilities.  
 The findings in this dissertation show that IGF-1 resulted in increased post-
traumatic neurogenesis in the subgranular zone of the hippocampus. However, we did 
not evaluate the efficacy of IGF-1 to enhance neurogenesis in the subventricular zone 
(SVZ), a second site of ongoing neurogenesis in the adult brain. Several studies have 
demonstrated that experimental TBI results in increased cellular proliferation and may 
promote the generation of newborn neurons in the subventricular zone (Kernie et al. 
2001; Rice et al. 2003; Ramaswamy et al. 2005; Sun et al. 2009). Central infusion of 
either basic fibroblast growth factor or S100B after fluid percussion injury results in 
increased cellular proliferation (Kleindienst et al. 2005; Sun et al. 2009), suggesting that 
administration of therapeutic agents can enhance post-traumatic neurogenesis in the 
SVZ. Preliminary findings from our lab suggest that IGF-1 may enhance the generation 
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of newborn neurons in the SVZ (Kizhakke Madathil S 2010), but additional work is 
needed to determine if IGF-1 promotes neurogenesis in the SVZ after experimental TBI. 
A handful of studies highlight that newly proliferated cells can express markers of 
neurons, astrocytes, oligodendrocytes, and microglia after experimental TBI (Sun et al. 
2005; Rola et al. 2006; Sun et al. 2009). While the observations discussed in this 
dissertation have been focused on the generation of newborn neurons after brain injury, 
it is imperative to understand the potential implications of other cell types generated in 
injured areas of the brain following treatment of IGF-1, considering glial cells likely 
contribute to recovery after brain injury (Myer et al. 2006). The potential for the 
generation of new oligodendrocytes with treatment of IGF-1 after TBI will be discussed 
later in this chapter. 
In only the last couple years, the methodology for assessing changes in 
neurogenesis has been revolutionized to incorporate additional markers of neural 
progenitor cells and neuroblasts in an effort to understand the complex hierarchy of 
progenitor cells in the neurogenic niche of the adult brain. Recent work by Gao et al 
(2013, 2009) illustrates that future studies evaluating post-traumatic neurogenesis may 
need to incorporate confocal microscopy and detailed assessments of cellular 
morphology to investigate aspects of neural progenitor cell proliferation and cellular 
differentiation in the subgranular zone after experimental TBI. Considering the ongoing 
debate of neural progenitor self-renewal and potential differences in multi-lineage 
differentiation (Lugert et al. 2010; Ming and Song 2011), we need to strive for a more 
comprehensive evaluation of the responses of neural progenitor cells to therapeutic 
agents. This may provide valuable insight into understanding how therapeutic agents 
can modulate the neurogenic niche and be used to target enhanced differentiation of 
specific cells types, i.e. neurons or oligodendrocytes, in the neurogenic niche after TBI.  
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Structural Plasticity with Treatment of IGF-1 after CCI 
Formation and extension of dendritic processes is a hallmark morphological 
feature of immature neuron maturation (Zhao et al. 2006; Deng et al. 2010). In Chapter 
5, we demonstrate for the first time that immature neurons exhibit reduced dendritic 
arbor complexity after brain injury. Moreover, we demonstrate that elevated levels of 
IGF-1 in the brain restore dendritic arbor complexity to control (uninjured) levels 
following severe CCI. Future studies need to evaluate the time course of reductions and 
the potential endogenous recovery of dendritic arbor complexity in immature neurons 
following severe CCI. Additional work is also needed to elucidate if IGF-1 protects 
against acute reductions in dendritic arbor complexity or if IGF-1 promotes the formation 
of dendrites in immature neurons generated after brain injury. Enhanced growth of new 
dendrites is plausible as IGF-1 promotes dendritic growth and arborization during 
development of neurons in the cerebellum and cerebral cortex (Niblock et al. 2000; 
Ozdinler and Macklis 2006). Protection or enhanced formation of dendritic arbor 
complexity following treatment with IGF-1 may have important functional implications in 
promoting recovery in the injured hippocampus. 
 Reductions in dendritic arbor complexity may have functional consequences in 
and potentiate the manifestation of neurobehavioral deficits after brain injury. Reductions 
in dendritic length, as observed in brain-injured wildtype mice in Chapter 5, may reduce 
the number of synaptic connections of immature neurons with axonal projections from 
the entorhinal cortex. Following moderate CCI, mature granular neurons in the 
hippocampal dentate gyrus exhibit a robust reduction in dendritic arbor complexity and 
synaptic spine density, likely contributing to their decreased neuronal excitability at 3 d 
post-injury (Gao et al. 2011). The juxtaposition of immature and mature neurons in the 
dentate gyrus granular layer suggests that following CCI, immature neurons could also 
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exhibit reductions in synaptic density of the remaining dendritic processes. CCI has also 
been shown to result in a marked reduction in synaptic number at 2 d post-injury (Scheff 
et al. 2005). Multiple studies demonstrate that functional deficits in hippocampal long-
term potentiation occur within hours and can lasting at least two weeks following brain 
injury (Miyazaki et al. 1992; Reeves et al. 1995; Albensi et al. 2000; Schwarzbach et al. 
2006; Atkins 2011). The hippocampus may possess capabilities of endogenous 
recovery, as suggested by a slow recovery of synapse strength in CA1 within 14 d post-
injury after an initial deficit at 2 d post-injury (Norris and Scheff 2009). However, CCI is 
associated with cognitive dysfunction that persists for at least weeks post injury (Scheff 
et al. 1997; Dixon et al. 1999), suggesting that recovery of dendritic arborization, in 
addition to recovery of synaptic number and strength, in the dentate gyrus may be 
necessary to help promote recovery of cognitive function after TBI.  
Synaptogenesis is another defining property of immature neuron maturation. 
IGF-1 overexpression promotes synaptogenesis in dendritic processes of hippocampal 
granular layer neurons in the brains of postnatal mice (O'Kusky et al. 2000). Increased 
activation of Akt has been implicated as a crucial event in synapse plasticity and 
maintenance of late-phase long-term potentiation (Horwood et al. 2006; Karpova et al. 
2006). In light of our observations of reduced immature neuron dendritic arborization 
complexity at 10 d following CCI, future studies need to evaluate if brain injury reduces 
synaptic density in immature neurons following severe CCI. Moreover, in the event that 
the reduction in synaptic density is observed, future studies will also need to evaluate 
the efficacy of IGF-1 to protect against synapse loss or promote synaptogenesis in 
immature neurons after experimental TBI.  
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While IGF-1-mediated hippocampal plasticity may contribute to improved 
recovery after brain injury, excessive plasticity could result in aberrant sprouting, altered 
hippocampal function, or potentiate the development of maladaptive conditions, such as 
post-traumatic epilepsy. Following a 1 mm CCI, aberrant mossy fiber sprouting was 
observed in the inner molecular layer between 6 and 10 weeks after injury, a time in 
which increased spontaneous seizures were also observed (Hunt et al. 2009). 
Hippocampal granular neuron excitability is also increased as a result of reduced 
inhibitory synaptic input from hilar GABAergic interneurons following brain injury (Hunt et 
al. 2011). The formation of basal dendrites of mature and more recently immature 
granular neurons has also been implicated as a precipitating feature of aberrant 
sprouting and the development of seizure activity after pilocarpine-induced status 
epilepticus (Parent et al. 1997; Spigelman et al. 1998; Scharfman et al. 2000; Dashtipour 
et al. 2003; Walter et al. 2007). These studies suggest that enhanced outgrowth of 
dendrites may facilitate the development of epilepsy after contusion injury. In our 
studies, treatment with IGF-1 restored dendritic complexity to the morphology observed 
with sham injury, suggesting that IGF-1 did not promote aberrant sprouting. Moreover, 
we rarely observed basal dendrites on immature neurons, and the isolated observations 
of basal dendrites may reflect a normal and transient structural property of immature 
neurons (Jones et al. 2003; Ribak et al. 2004). While we did not observe indications of 
aberrant sprouting at 10 d post-injury, future studies need to evaluate if immature 
neurons begin to show indications of aberrant sprouting in the weeks following injury, 
particularly during 6 to 10 weeks post-injury in which spontaneous seizures are observed 
after severe CCI (Hunt et al. 2009). This additional work will be imperative to elucidate if 
IGF-1 promotes appropriate and long-term plasticity in the injured hippocampus after 
CCI.  
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Improvements in Motor Function with Treatment of IGF-1 after CCI 
 Systemic administration of IGF-1 has been shown to promote delayed recovery 
of motor function in rats following moderate fluid percussion injury (Saatman et al. 1997). 
Using either repeated injections or continuous infusion, IGF-1 significantly improved 
motor function as early as 5 days or as late as 2 weeks post-injury (Saatman et al. 
1997). In Chapter 4 we showed that central infusion of IGF-1 significantly attenuated 
motor dysfunction at 1, 2, 3, and 5 d following severe CCI. These data corroborate 
previous findings from our lab demonstrating that targeted overexpression of IGF-1 
significantly attenuated motor dysfunction at 1, 2, 3, and 4 d following severe CCI 
(Madathil 2013). IGF-1 overexpressing mice and mice centrally infused with IGF-1 
exhibited significantly improved motor function by 1 d following severe CCI. Previous 
work from our lab showed that IGF-1 promoted delayed recovery of motor function in 
rats systemically treated with IGF-1 (Saatman et al. 1997). In Chapter 3 we showed that 
systemic infusion of 4 mg/kg/d hIGF-1, the same dose previously used by Saatman et al. 
(1997), did not result in measureable levels of hIGF-1 in the brain and did not promote 
acute recovery of motor function. Elevated levels of IGF-1 in the brain, as observed after 
central infusion and overexpression of IGF-1, may be needed to promote acute recovery 
of motor function in addition to the delayed recovery of motor function observed after 
systemic infusion (Saatman et al. 1997). In Chapter 3 we were unable to assess delayed 
recovery of motor function as CCI in the mouse results in more transient motor deficits 
with nearly complete recovery of motor function by 7 d post-injury, which is not observed 
after lateral fluid percussion in the rat (Saatman et al. 1997). Future studies will need to 
incorporate more sensitive tests or other models of experimental TBI with more 
persistent motor deficits to evaluate the efficacy of IGF-1 to promote delayed recovery of 
motor function.  
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Improvements in Cognitive Function with Treatment of IGF-1 after CCI 
Lasting cognitive dysfunction is reported in brain-injured patients (Levin 1998; 
Lundin et al. 2006; Jang 2009) and has been observed for up to one year following CCI 
(Smith et al. 1997; Dixon et al. 1999). The Morris water maze is a frequently utilized tool 
to evaluate learning and memory dysfunction after CCI (Hamm et al. 1992; Scheff et al. 
1997; Dixon et al. 1999; Saatman et al. 2006; Pleasant et al. 2011). The Morris water 
maze cognitive task has more recently been utilized to demonstrate that reductions in 
the number of immature neurons results in significant impairments in learning and 
memory (Clelland et al. 2009; Deng et al. 2009; Jessberger et al. 2009). Moreover, 
prevention of the endogenous recovery of immature neurons after TBI results in 
impaired learning of the platform location in the Morris water maze task (Blaiss et al. 
2011), highlighting the importance of post-traumatic neurogenesis in cognitive function 
following CCI. The novel object recognition task is also utilized to assess cognitive 
function following experimental TBI (Pullela et al. 2006; Tsenter et al. 2008; Schoch et 
al. 2012; Prins et al. 2013). In Chapter 4 we showed that mice subjected to severe CCI 
exhibited significant cognitive impairment compared to mice subjected to sham injury, as 
assessed by the novel object recognition task at 7 d post-injury. 
Several studies have demonstrated that treatment with IGF-1 promotes cognitive 
improvement after experimental TBI (Saatman et al. 1997; Rubovitch et al. 2010; 
Madathil 2013). Supplementation of IGF-1 in mice significantly attenuated brain injury-
induced cognitive dysfunction in a Y maze at 7 d following mild TBI (Rubovitch et al. 
2010) or in a novel object recognition task at 7 d following severe CCI (Madathil 2013). 
Systemic infusion of IGF-1 significantly improved spatial learning and memory in the 
Morris water maze cognitive task at 2 weeks post-injury in rats subjected to moderate 
fluid percussion injury (Saatman et al. 1997). In Chapter 4 we demonstrated that central 
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infusion of IGF-1 reduced brain injury-induced impairments in cognitive function at 7 d 
following CCI. Taken together, these studies demonstrate that treatment with IGF-1 
attenuates cognitive dysfunction across a spectrum of injury severities in rodent models 
of TBI.  
Future studies may need to incorporate additional cognitive tasks to evaluate the 
specific contribution of post-traumatic neurogenesis in improvements of cognitive 
function after TBI. A recent study highlights that an enhancement of neurogenesis 
improves pattern separation in a contextual discrimination task, but does not improve 
spatial memory in Morris water maze (Sahay et al. 2011), suggesting that enhancement 
of post-traumatic neurogenesis may improve specific aspects of cognition. Considering 
we observed an increase in immature neuron density after brain injury above sham 
injury levels, future studies may need to incorporate additional assessments of cognitive 
performance, including pattern separation and aspects of contextual learning and 
memory, to evaluate potential functional implications of hippocampal plasticity after 
experimental TBI. 
Long-term Assessments of Cognitive Improvement after Treatment with IGF-1  
 The development of immature neurons into mature granular neurons is an 
important stage of adult neurogenesis as surviving mature granular neurons can 
functionally incorporate into the granular layer circuitry in the weeks following 
differentiating into an immature neuron (Zhao et al. 2006). In a newly generated neuron, 
expression of NeuN, a marker of mature neurons, and gradual cessation of DCx 
expression occurs approximately 2 to 3 weeks following neuronal differentiation and is 
indicative of the transition from an immature neuron into a mature neuron (van Praag et 
al. 2002; Zhao et al. 2006). Future studies will need to evaluate if IGF-1 promotes the 
survival, maturation and incorporation of newborn neurons generated after injury into the 
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hippocampus by using markers of mature granular neurons, i.e. NeuN, and indicators of 
neuronal activity, i.e. c-fos, in the weeks following CCI. In addition, future studies will 
also need to evaluate if the neurobehavioral improvements afforded by IGF-1 are 
sustained and correlate with increases in survival and maturation of newborn neurons. In 
Appendix 1, we show that the novel object recognition task can be utilized to evaluate 
persistent injury-induced cognitive impairments for at least 6 weeks following CCI 
(Figure A1.1). The novel object recognition task will need to be incorporated into future 
studies to evaluate if the IGF-1-mediated improvements in neurobehavioral function 
described in Chapter 4 are sustained following severe CCI.  
 
Generation of Oligodendrocytes in the Injured Hippocampus and IGF-1 
 In addition to enhanced neuronal differentiation, it is possible that treatment with 
IGF-1 promotes oligodendrocyte survival and promotes the generation of new 
oligodendrocytes in the injured brain. As demonstrated by Rola et al. (2006), cellular 
proliferation in the dentate gyrus granular layer after CCI results in increased numbers of 
oligodendrocytes as well as neurons, astrocytes, and microglia. The anti-apoptotic 
capacity of IGF-1 may also promote oligodendrocyte survival. Administration of IGF-1 
into the lateral ventricle of fetal sheep reduced demyelination and caspase-3 activation 
in oligodendrocytes, and increased the number of phospholipid protein (PLP) positive 
cells after ischemic injury (Guan et al. 2001). Overexpression of IGF-1 reduces 
oligodendrocyte apoptosis and promotes remyelination by 5 weeks following cuprizone-
induced demyelination (Mason et al. 2000). Systemic administration of IGF-1 in 
hypophysectomized rats resulted in increased cellular proliferation in the piriform and 
parietal cortex after 20 d of daily BrdU injections and increased the number of the newly 
proliferated cells that expressed markers of oligodendrocytes, including myelin basic 
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protein and 2,3-cyclic nucleotide 3-phophodiesterase (Aberg et al. 2007). A previous 
study suggests that IGF-1 signaling and increased inhibition of bone morphogenic 
proteins (BMP) is instructive to drive oligodendrocyte and neuronal differentiation, but 
not astrocytic differentiation, of the neural stem cells (Hsieh et al. 2004). Future studies 
will need to evaluate if IGF-1 promotes the survival and generation of oligodendrocytes 
following brain injury.  
   
Therapeutic Strategies for IGF-1 after TBI 
The incidence of TBI has been on the rise for many years, with an estimated 1.7 
million cases in 2010, an increase of 200,000 cases annually since 2000 (Summers et 
al. 2009; Faul M 2010). The majority of the estimated cases encompass mild or less 
severe cases of TBI (Faul M 2010). Despite the increasing incidence of mild TBI, the 
frequency of fatal TBIs has also steadily increased (Summers et al. 2009; Faul M 2010), 
highlighting the need for therapeutic strategies that encompass the entire range of TBI 
severities. Therapeutic interventions that aim to reduce injurious mechanisms while also 
promoting regenerative mechanisms hold promise in counteracting a wide range of 
pathological consequences of TBI. The pleiotropic effects of IGF-1 make it a promising 
therapeutic agent for the treatment of TBI. While the findings in this dissertation and 
additional work from our lab highlight the therapeutic potential of IGF-1 in the context of 
severe contusion brain injury, we need to consider and pursue clinically relevant 
therapeutic paradigms tailored for varying severities and pathoanatomical types of TBI. 
While central administration of IGF-1 may be feasible for severely brain-injured patients, 
additional considerations for therapeutic strategies need to be evaluated to afford 
treatment of IGF-1 for less severe cases of TBI. 
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 In this dissertation we found that conditional astrocyte-specific overexpression of 
IGF-1 enhanced post-traumatic hippocampal neurogenesis by promoting neuronal 
differentiation of newly proliferated cells. While the transgenic overexpressing mouse 
model provides valuable information about IGF-1-mediated effects in the brain, the 
findings need to be verified in a clinically relevant systemic or central administration 
paradigm. We corroborated our findings from the astrocyte-specific IGF-1 
overexpressing transgenic mouse model using a more clinically relevant treatment 
intervention in which IGF-1 was infused into the lateral ventricle following severe CCI. 
We also demonstrated that IGF-1 consistently increased immature neuron density after 
CCI in a number of infusion paradigms, including a clinically relevant delayed treatment 
onset of 6 hr post-injury. Together these findings underscore the efficacy of central 
delivery of IGF-1 in the brain to attenuate neurobehavioral dysfunction and enhance 
post-traumatic neurogenesis. In order to expand the therapeutic applicability of IGF-1 
across the spectrum of brain injury, we need to continue our evaluation of systemic 
administration of IGF-1.   
A Phase II safety and efficacy trial demonstrated that intravenous infusion of 0.01 
mg/kg/hr IGF-1 for a period of 14 d in moderate-to-severely brain-injured patients 
promoted metabolic stability and improved outcome at 6 months post-injury in patients 
(Hatton et al. 1997). IGF-1-treated brain-injured patients achieved average peak levels 
of approximately 460 ng/mL during the infusion period, with 11 out of 17 patients 
achieving serum levels of IGF-1 above 350 ng/mL, while control patients achieved an 
average of approximately 160 ng/mL, a value at the low end of the 150 to 400 ng/mL 
physiological range of IGF-1 in systemic circulation (Hatton et al. 1997). In this same 
study, intravenous infusion of IGF-1 resulted in elevated levels of IGF-1 above 350 
ng/mL for an average of 8 d, but the heightened concentrations of plasma IGF-1 could 
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not be sustained for the entire infusion period of 14 d (Hatton et al. 1997). The inability to 
maintain sustained elevations of IGF-1 was attributed to a significant reduction in the 
concentration of IGF binding protein 3 (IGFBP3). IGFBP3 is the primary carrier protein of 
IGF-1 and formation of the IGF-1/IGFBP3 complex results in a prolonged circulating half-
life of IGF-1 (Guler et al. 1989). Prolonged infusion of IGF-1 likely resulted in negative 
feedback of IGF-1 on the growth hormone axis and resulted in reduced IGFBP3 
production.  
In two subsequent placebo-controlled clinical trials, intravenous infusion of 0.01 
mg/kg/hr IGF-1 was paired with daily subcutaneous injections of 0.05 mg/kg growth 
hormone because growth hormone promotes the production of IGFBP3. Co-
administration of IGF-1 and growth hormone resulted in peak concentrations of IGF-1 
above 1000 ng/mL in systemic circulation, and the elevated levels were sustained during 
the infusion period (Rockich et al. 1999; Hatton et al. 2006). Co-administration of IGF-1 
and growth hormone resulted in elevated levels of IGFBP3 in systemic circulation, 
suggesting that increased IGFBP3 expression likely contributed to the sustain elevations 
of IGF-1 above the therapeutic threshold of 350 ng/mL (Rockich et al. 1999; Hatton et al. 
2006). The clinical trial (Hatton 2006) for co-administration of IGF-1 and growth hormone 
was halted in response to findings from a European clinical trial in which administration 
of growth hormone alone resulted in increased morbidity and mortality from increased 
infection and septic shock (Takala et al. 1999). While no adverse side effects were 
observed in brain-injured patients receiving IGF-1 and growth hormone, a moratorium on 
growth hormone administration prevented additional investigation of this therapeutic 
approach to deliver IGF-1 and growth hormone after TBI. The promising findings 
reported by Hatton et al. (1997, 2006) warrant additional studies to investigate 
alternative approaches to achieving sustained elevations of IGF-1 in systemic circulation 
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without co-administration of growth hormone. In Chapters 3 and 4, we demonstrated that 
systemic and central infusion of IGF-1 resulted in elevated and sustained levels of hIGF-
1 in systemic circulation. We also demonstrated that elevated levels of IGF-1 in the brain 
resulted in improved neurobehavioral function and enhanced post-traumatic 
neurogenesis in the injured hippocampus. Future studies will need to explore alternative 
methods to achieve sustained elevations in the levels of IGF-1 using treatment 
strategies that may prevent degradation and improve the circulating half-life of IGF-1.  
 
Administration of IGF-1 Encapsulated PLGA Microspheres after TBI 
 Due to the short half-life of IGF-1, repeated injections or continuous infusion are 
often required to sustain elevated therapeutic concentrations of IGF-1 in the systemic 
circulation. A therapeutic strategy requiring less frequent administration may provide 
greater compliance and convenience for hospital staff, caregivers, and brain-injured 
patients with milder TBIs. Poly(lactic-co-glycolitic acid) is an FDA approved copolymer 
frequently utilized to create microspheres to encapsulate and provide controlled 
sustained release of a therapeutic agent (Crotts and Park 1998). Administration of 
microsphere encapsulated IGF-1 promotes prolonged residence time of IGF-1 in 
circulation and can provide continuous delivery of IGF-1 for weeks following a single 
injection of microspheres (Meinel et al. 2001; Singh et al. 2001; Carrascosa et al. 2004). 
Carrascosa et al. (2004) demonstrated that a single injection of 1.4mg/kg IGF-1 
encapsulated microspheres increased serum concentrations of IGF-1 for 12 d and brain 
concentrations for 5 d after injection. Repeated injections of IGF-1 encapsulated 
microspheres also improved motor function, as assessed by rotarod, in a mouse model 
of purkinje cell degeneration (Carrascosa et al. 2004). These finding suggest that IGF-1 
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encapsulated microspheres could be utilized to promote sustained elevations in plasma 
concentrations of IGF-1 following TBI.  
In collaboration with Heidi Mansour, Ph.D. at the University of Kentucky, we 
sought to produce IGF-1 encapsulated microspheres that could provide controlled and 
sustained release of IGF-1 for days to weeks after brain injury. In Appendix 2, we 
highlight our concerted efforts to produce PLGA microspheres using the solvent 
extraction method (Yuan et al. 2009) and the spray dry method (Vehring 2008). We 
aimed to produce spherical IGF-1 encapsulated microspheres 1-5 µm in diameter with a 
drug loading efficiency of 75% to provide sustained systemic release of 4.5 mg/kg of 
IGF-1 over a period of 2 weeks. Using the solvent extraction method (Figure A.2.1), we 
produced microspheres of the target diameter and shape (Figure A.2.2A, B), but were 
unable to encapsulate sufficient concentrations of IGF-1. We next pursued the spray 
drying method to improve the IGF-1 loading efficiency.  
Using the spray drying method, we produced spherical microspheres 1-5 µm in 
diameter (Figure A2.3.A, B). We achieved a drug loading efficiency of approximately 
75% using insulin as a structural analog to reduce cost during the development process. 
In vitro release kinetics revealed that insulin encapsulated PLGA microspheres resulted 
in an initial burst release of insulin within the first 12 hr and sustained release of insulin 
for at least 7 d after reconstitution (Figure A2.3C), suggesting that microspheres 
produced with IGF-1 could provide controlled sustained release of IGF-1 during the 
week post-injury. However, additional work is required to determine if the release pattern 
is altered in vivo and that encapsulation of IGF-1 does not produce different release 
kinetics. Our preliminary studies demonstrate that PLGA microspheres of target shape 
and size could be produced, and warrant future studies to consider IGF-1 encapsulated 
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PLGA microspheres as a viable clinically relevant strategy to achieve sustained delivery 
of IGF-1 after TBI. 
 
Treatment with PEGylated IGF-1 after TBI 
The addition of a polyethylene glycol moiety to proteins, referred to as protein 
PEGylation, represents a successful strategy to prolong the half-life of subcutaneously 
injected IGF-1. PEGylation is thought to enhance the pharmacokinetics of therapeutic 
agents by reducing antigenicity, immunological degradation and renal clearance of the 
PEGylated molecule (Milla et al. 2012). PEGylation of IGF-1 at Lys68 reduced the 
association rates of IGF-1 for its receptor and the binding proteins; however, this 
modification did not alter Akt or MAPK signaling or glucose uptake in cultured myoblasts 
(Metzger et al. 2011). In vivo, subcutaneous injection of PEGylated IGF-1 increased the 
circulating half-life of IGF-1, and increased systemic levels of IGF binding proteins 2 and 
3 compared to recombinant human IGF-1 (Metzger et al. 2011). Two week 
administration of PEGylated IGF-1, injected subcutaneously twice a week, reduced 
soluble Aβ and increased synaptic markers (SNAP25 and PSD95) in a mouse model of 
amyloidosis (Saenger et al. 2012). Moreover, treatment of PEGylated IGF-1 improves 
muscle force generation, motor coordination, and improved rotarod performance in a 
mouse model of amyotrophic lateral sclerosis (Saenger et al. 2012), suggesting that the 
PEGylation process improves therapeutic applicability of IGF-1. PEGylation of IGF-1 
prolongs the circulating half-life and reduces the potential detrimental side effects 
associated with systemic administration of IGF-1. Considering the studies that 
demonstrate the efficacy of systemically administered IGF-1 after TBI (Hatton et al. 
1997; Saatman et al. 1997; Hatton et al. 2006; Rubovitch et al. 2010), PEGylated IGF-1 
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should be evaluated as an alternative approach to achieving sustained plasma 
concentrations of IGF-1 for the treatment of TBI.  
 
Intranasal Delivery of IGF-1 after TBI 
 Intranasal delivery of IGF-1 represents an alternative non-invasive therapeutic 
approach to paradigms designed to protect against degradation of IGF-1, and instead 
would afford rapid delivery of IGF-1 to the brain. Intranasal administration of radiolabeled 
IGF-1 results in a widespread distribution and rapid delivery of IGF-1 throughout several 
regions of the brain, including the hippocampus, via movement along olfactory and 
trigeminal pathways within 30 minutes following initial delivery (Thorne et al. 2004). 
Previous studies illustrate that intranasal administration of IGF-1 protects against cell 
loss and promotes improved neurological function after hypoxic-ischemic injury (Liu et al. 
2001; Lin et al. 2009). IGF-1 encapsulated microspheres could also be adapted for 
intranasal administration to achieve sustained delivery of IGF-1 throughout the injured 
brain. Intranasal administration of IGF-1 is a promising therapeutic strategy for TBI due 
in part to the non-invasive delivery and rapid uptake and distribution in the brain.  
 
Final Conclusions 
The findings reported in this dissertation provide strong evidence that 
supplementation of IGF-1 attenuates neurobehavioral dysfunction and enhances 
hippocampus neurogenesis in the controlled cortical impact mouse model of contusion 
brain injury. Using clinically relevant treatment strategies of continuous systemic and 
intracerebroventricular infusion, we showed that administration of IGF-1 promoted the 
activation of Akt, indicative of increased IGF-1 signaling, in the injured brain. 
Intracerebroventricular infusion of IGF-1 attenuated motor and cognitive dysfunction 
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after brain injury. Elevated levels of IGF-1 in the brain resulted in significant increases in 
immature neuron density and enhanced the generation of newborn neurons in the 
injured hippocampus. We demonstrated that the significant increase in immature neuron 
density was retained in a clinically relevant delayed treatment onset of 6 hr post-injury. 
Targeted astrocyte-specific overexpression of IGF-1 promoted the generation of 
newborn neurons in the injured hippocampus by promoting neuronal differentiation of 
newly proliferated cells. We showed that immature neurons exhibited reduced dendritic 
arbor complexity after brain injury, a previously unknown pathological consequence of 
brain injury. Targeted overexpression of IGF-1 in the brain promoted the restoration of 
dendritic arbor complexity to the morphology observed in uninjured mice. Taken 
together, we provide compelling evidence and important groundwork for pursuing a 
comprehensive preclinical evaluation of IGF-1 in an effort to create a solid foundation for 
future clinical trials evaluating the administration of IGF-1 in brain-injured patients.  
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Appendix 1: Long-term Cognitive Deficit following Severe Controlled Cortical 
Impact as Assessed by the Novel Object Recognition (NOR) Task 
Deficits in spatial learning and memory, as assessed by Morris Water Maze, 
have been reported for up to one year following CCI in rats (Dixon et al. 1999). The 
novel object recognition task was utilized to evaluate brain injury-induced memory 
deficits at 7 d post-injury in Chapter 4 of this dissertation. We sought to determine if the 
novel object recognition task is capable of detecting persistent cognitive dysfunction in 
mice subjected to severe 1 mm CCI. A cohort of 8 week old male C57/BL6 mice were 
subjected to sham injury (n= 7) or severe 1 mm CCI (n=12) and evaluated for cognitive 
dysfunction at 8 d, and 2, 4, and 6 weeks following injury. We demonstrate that mice 
subjected to severe CCI exhibit a sustained cognitive deficit for weeks at least 6 weeks 
post-injury. Analysis by a repeated measures one-way ANOVA revealed that mice 
subjected to 1 mm CCI exhibited significantly lower recognition indices, indicative of 
reduced recognition of the novel object, at 8 d, and 2, 4, and 6 weeks post-injury 
compared to sham-injured mice at each respective time point (*p<0.01, Newman-Keuls 
post-hoc t-test; Fig. A1.1). Brain-injured mice show no change in recognition indices over 
the 6 week period post-injury; however, sham-injured mice show significantly higher 
recognition indices compared to sham-injured mice at 8 d and 4 week post-injury 
(p<0.05, Newman-Keuls post-hoc t-test).  
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Figure A1.1: Severe controlled cortical impact (CCI) results in cognitive deficits 
that persist for up to 6 weeks post-injury. Brain-injured mice exhibited significant 
reductions in recognition indices at 8 d, 2, 4, and 6 weeks after brain injury, as compared 
to sham-injured mice at each respective time point (*p<0.01, Newman-Keuls post-hoc t-
test following a one-way repeated measures ANOVA). Brain-injured mice showed no 
change in recognition indices during the 6 weeks following CCI.  
 
 
 
 
 
 
 
 
 
 
 
Copyright © Shaun William Carlson 2013 
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Appendix 2: Formulation of Poly(lactic-co-glycolytic acid) (PLGA) Microspheres 
for the Development of a Subcutaneously-injected Sustained Release Delivery 
System for IGF-1 
 Poly(lactic-co-glycolytic acid) (PLGA) is an FDA-approved biodegradable 
polymer often utilized to produce microspheres for sustained delivery of therapeutic 
agents (Crotts and Park 1998). Due to the short plasma half of IGF-1, we postulated that 
subcutaneous injection of IGF-1-encapsulated microspheres would provide sustained 
delivery of IGF-1 into the systemic circulation after brain injury. The work described 
below was completed in collaboration with Heidi Mansour, Ph.D. in the College of 
Pharmacy at the University of Kentucky, and personnel in her lab, including Yun Seok 
Rhee, Ph.D., Minji Sohn and Jackie Ma. Previous studies demonstrated that IGF-1 is 
compatible with the microsphere encapsulation process (Meinel et al. 2001; Singh et al. 
2001; Carrascosa et al. 2004). We developed a protocol to target production of spherical 
microspheres (1-5 µm in diameter) with an IGF-1 encapsulation efficiency of 75% in 
order to deliver 4.5 mg/kg of IGF-1 for a duration of 2 weeks post-injury. These 
parameters were selected to mimic a previous study that demonstrated efficacy of IGF-1 
encapsulated microspheres to achieve sustained delivery of IGF-1 for 2 weeks and 
improve motor function in a mouse model of cerebellar ataxia (Carrascosa et al. 2004). 
A 1-5 µm diameter was selected to reduce microsphere degradation by host immune 
cells following subcutaneous injection. 
The morphology and size of the microspheres were evaluated by scanning 
electron microscopy (SEM) and particle size analyzer, respectively. Loading efficiencies 
of IGF-1 and insulin, a structural surrogate of IGF-1 utilized to reduce the expense of 
protein during developmental stages, were analyzed by high performance liquid 
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chromatography. The methods of solvent extraction and spray drying were utilized to 
produce IGF-1 or insulin encapsulated PLGA microspheres in this study.  
The solvent extraction protocol that was utilized to produce IGF-1 encapsulated 
PLGA microspheres is detailed in Fig. A2.1. A water/oil/water (W/O/W) emulsion was 
created by the sequential addition of IGF-1 diluted in sodium succinate buffer to create 
the first aqueous phase, and PLGA dissolved in methylene chloride to create the primary 
water and oil emulsion (W/O). Addition of polyvinyl alcohol (PVA) and an initial 
homogenization of the solution resulted in the generation of the W/O/W emulsion. This 
was followed by sustained agitation to initiate microsphere formation. After a 16 hr 
period of continued agitation, the solution was centrifuged for washing and collection of 
the microspheres.  
 Several iterations were completed to generate microspheres of the target 
spherical shape (Fig. A2.2A) and size (Fig. A2.2B), but a loading efficiency of less than 
1% was achieved. Subsequent iterations to alter concentrations of PLGA and PVA did 
not improve the efficiency of IGF-1 encapsulation. In light of the low IGF-1 encapsulation 
efficiency, additional studies pursued the production of microspheres by the spray drying 
method, as IGF-1 had been shown to be compatible with the spray drying procedure 
(Lam et al. 2000). The previous morphology, size, and IGF-1 loading efficiency remained 
the target parameters for subsequent experiments.  
 The spray drying method atomizes a primary PLGA and IGF-1 solution into small 
droplets that are rapidly dried at elevated temperatures while being ejected from a small 
nozzle of the apparatus (Vehring 2008). The dried microspheres were collected and 
remained lyophilized until reconstituted for analysis. One disadvantage of the spray 
drying method is the need for high drying temperatures, which despite the brief exposure 
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to temperatures exceeding 60°C, could promote the denaturation of IGF-1. Conversely, 
a great advantage of the spray drying method is increased yield as the lyophilization 
process facilitates improved collection of the microspheres.  
 In an effort to reduce potential IGF-1 denaturation, we reduced the drying 
temperatures below 60°C. Insulin was also utilized to evaluate drug loading efficiency. 
Several iterations evaluating the concentrations of PLGA and insulin resulted in an 
approximate 50% improvement in yield and produced insulin encapsulated microspheres 
that exhibited the desired morphology (Fig. A2.3A), with a 75% loading efficiency of 
insulin. Analysis of the insulin release kinetics in vitro revealed a rapid release of 
approximately 40% of encapsulated insulin within 8 hr of reconstitution, followed by a 
sustained release of insulin for up to 7 d following reconstitution (Fig. A2.3C). Additional 
work is needed to determine if the in vitro release kinetics detailed in Fig. A2.3C is 
reproducible in vivo after subcutaneous injection. Subsequent studies evaluating the 
IGF-1 encapsulation efficiency and release profiles were not completed. It was 
suggested that increased loading efficiency and sustained release patterns for delivery 
of IGF-1 for 2 weeks would require higher drying temperatures that would likely lead to 
protein denaturation. While this study did not achieve the desired sustained release of 
IGF-1 for a period of 2 weeks, this work may be continued to evaluate if sustained 
release of IGF-1 for 1 week post-injury is a viable subcutaneous continuous delivery 
system for the administration of IGF-1 after TBI.  
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Figure A2.1: Protocol for the development of insulin-like growth factor-1 (IGF-1) 
encapsulated poly(lactic-co-glycolytic acid) (PLGA) microspheres by solvent 
extraction. IGF-1 is initially dissolved in sodium succinate buffer and mixed with PLGA 
polymer to create the primary water/oil (W/O) emulsion. Addition of polyvinyl alcohol 
(PVA) to the solution produced the W/O/W emulsion after homogenization. Prolonged 
stirring results in the formation of IGF-1 encapsulated PLGA microspheres. 
Centrifugation is utilized to rinse and collect the microspheres. This experiment 
schematic was prepared by Dr. Yun Seok Rhee.  
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Figure A2.2: Morphology and size of poly(lactic-co-glycolytic acid) (PLGA) 
microspheres generated by solvent extraction. (A) Spherical microspheres were 
observed by SEM that (B) ranged in size from 1 µm to greater than 10 µm, with a 
median diameter of 5 µm.  
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 37    0.179  0.000   0.000
 38    0.146   0.000   0.000
 39    0.119   0.000   0.000
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 41    0.079   0.000   0.000
 42    0.064   0.000   0.000
 43    0.052   0.000   0.000
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 45    0.034   0.000   0.000
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Figure A2.3: Morphology, size and release kinetics of insulin encapsulated 
poly(lactic-co-glycolytic acid) (PLGA) microspheres generated by spray drying. (A) 
Spherical microspheres were observed by SEM that (B) ranged in size from the targeted 
1 to 5 µm. Release kinetics demonstrate an initial burst release of insulin in the initial 12 
hr followed by sustained delivery for up to 7 d after microsphere reconstitution. 
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